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Abstract 
Abnormal scarring is a type of benign fibrosis of the skin that can restrict mobility, dexterity 
and quality of life. There are few, if any, truly effective treatment options for these 
conditions. Hypertrophic scarring is a common form of abnormal scarring characterized by 
increased fibroblast proliferation and differentiation of apoptosis-resistant and hyper-
contractile myofibroblasts that promote excessive deposition and contracture of the 
extracellular matrix (ECM). Periostin, a secreted ECM protein, is transiently expressed 
during normal cutaneous wound repair, but is abnormally abundant and persistent in 
abnormal scars and other benign fibroses that display enhanced fibroblast proliferation and 
myofibroblast differentiation. The objectives of this study were to elucidate the effects of 
periostin on fibroblast proliferation, myofibroblast differentiation and myofibroblast 
persistence in an in vitro human fibroblast model of hypertrophic scarring. Primary 
fibroblasts derived from patients with hypertrophic scars (HTS) or normal skin (NS) were 
cultured in two- and three-dimensional collagen cultures to more closely mimic their in vivo 
microenvironment. A series of in vitro techniques, including adenoviral transduction, WST-1 
assays, stressed fibroblast populated collagen lattices (sFPCLs), western immunoblotting and 
immunofluorescence confocal microscopy were employed to assess periostin effects on 
fibroblast proliferation and myofibroblast differentiation under these culture conditions. 
Periostin treatment was shown to enhance HTS fibroblast proliferation in compliant 2D 
collagen cultures through Akt and Rho kinase dependent pathways. When subjected to 
isometric tension in sFPCLs, periostin enhanced myofibroblast differentiation, as evidenced 
by increases in collagen contraction, alpha smooth muscle actin (αSMA) and the formation 
of supermature focal adhesions. In contrast, no discernible effects of periostin treatment were 
evident in NS fibroblasts. Periostin signalling maintained αSMA levels in HTS fibroblasts in 
an environment of decreasing ECM tension, and this was correlated with changes in focal 
adhesion kinase, cofilin and myosin light chain activities. These studies are the first to 
identify periostin as a mediator of excessive proliferation, myofibroblast differentiation and 
persistence in human fibroblasts derived from hypertrophic scars. The findings reported here 
suggest that novel therapeutic interventions designed to deplete periostin levels in the dermis 
of hypertrophic scars may have utility for attenuating fibroblast proliferation and depleting 
myofibroblast populations, and thereby enhance scar resolution. 
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Chapter 1  
1 Introduction 
1.1 The integumentary system  
The integumentary system, which is comprised of the skin and its appendages, is the 
largest organ in the body and accounts for up to 15% of the total adult body weight (1, 2).  
The main function of the skin is to provide a physical, chemical, and adaptive barrier to 
protect the body from external damage (1, 3, 4). The skin also plays important roles in 
hydration, sensation, thermoregulation, vitamin D synthesis, immune function and 
ultraviolet radiation protection (2, 5). This unique tissue is composed of two 
morphologically and functionally distinct layers: the epidermis and the dermis (1, 6). 
1.1.1 The epidermis 
The superficial protective layer known as the epidermis is largely composed of stratified 
epithelium that continuously renews itself (1).  The epidermis is mostly comprised of 
keratinocytes (90-95%) that originate from progenitor cells adjacent to the dermis. These 
cells undergo progressive differentiation resulting in flattened, anucleated, keratin-rich 
cells that form the physical barrier of the skin (1, 5). The epidermis also contains 
Langerhan’s cells, melanocytes, Merkel cells, and lymphocytes (1, 2).  Immune function 
in the epidermis is maintained by lymphocytes and Langerhan’s cells, which are dendritic 
cells that process and present antigens to T-cells (1, 2). Melanocytes produce the protein 
melanin, which is responsible for skin colour and protection from ultraviolet radiation (1, 
2). Lastly, Merkel cells are mechanoreceptors that make contact with sensory neurons 
and are involved with the sensation of touch (1, 2). 
The epidermis is typically composed of four, and in some cases five, continuous layers 
known as stratum. From lower to upper epidermis, they are the stratum basale (the only 
layer capable of cell division), stratum spinosum, stratum granulosum, stratum luciderm 
(a layer only found in the palms and soles) and the stratum corneum (1, 2, 6).  Since the 
epidermis is avascular, it relies on the vasculature in the adjacent dermis to provide 
nutrients. Therefore, as keratinocytes divide and move up through the epidermal layers 
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and away from the dermis, they receive fewer nutrients, undergo terminal differentiation 
and are ultimately shed by abrasion (1, 2). The epidermis is connected to the underlying 
dermis by the dermal-epidermal junction that facilitates the exchange of metabolic 
products between the stratum basale and the dermis (1, 2).  
1.1.2 The dermis 
The primary role of the dermis is to provide structure and tensile strength to the skin (1, 
2, 6). The dermis is divided into 2 layers, the papillary and reticular dermis (1, 2, 6). The 
papillary region is adjacent to the epidermis and contains the vasculature that allows for 
the exchange of metabolic products between the epidermis and dermis (1, 2, 6). The 
papillary dermis is also rich in nerves and nerve endings, both of which are responsible 
for transmitting the sensation of heat and touch (1, 6). The deeper reticular dermis is 
composed of fibroblasts, blood vessels, lympathic vessels and extracellular matrix (ECM) 
proteins including collagens and elastins (1, 6). Fibroblasts are the heterogeneous 
population of cells of mesenchymal origin that synthesize and secrete collagens, 
proteoglycans, fibronectin, matrix metalloproteinases (MMPs) and other ECM proteins 
that make up the papillary and reticular dermal layers (7). The organization of these ECM 
proteins provides tensile strength and structure to the skin (2). The reticular dermis also 
supports the skin’s appendages including hair follicles and various glands, including 
sweat glands (1, 2, 6). 
Below the dermis is a layer known as the hypodermis that primarily consists of 
subcutaneous fat. Although not technically part of the skin, the hypodermis functions to 
anchor the skin to the underlying muscle and bone, and supplies the dermis with blood 
vessels and nerves (1, 6). Other than adipocytes, the hypodermis is also home to mast 
cells, lymphocytes, and fibroblasts, and contributes to thermoregulation, energy storage, 
immune response, and protection from mechanical injuries (1, 6). 
Since the skin acts as a physical, chemical, and adaptive barrier to external insults, 
damage to the skin can leave an individual susceptible to a number of pathological 
conditions (8). Upon injury, the body needs to rapidly and effectively repair the wound to 
prevent infection and restore integrity to the skin (8).    
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1.2 Normal cutaneous wound repair 
Integumental injuries are defined as any insult or disruption to the normal structure and 
function of the skin (9, 10). These injuries can range from a small break that disrupts 
epithelial integrity to injuries extending deep into the dermis and subcutaneous tissue (11, 
12). The complex process required to repair injury, wound repair, is divided into 3 
overlapping phases: the inflammatory, proliferation and remodelling phases (Figure 1.1, 
(10)). In each phase, several important molecular, humoral and cellular events occur in 
order to regenerate the protective barrier of the skin (10). The important features of each 
phase of normal cutaneous wound repair are described in the following sections. 
1.2.1 Hemostasis and the inflammatory phase 
Immediately after insult to the dermis, the inflammatory phase begins with a process 
known as hemostasis, characterized by the formation of a blood clot and cessation of 
bleeding (8). Fibrin, platelets and disrupted blood vessels play an important role in 
mediating this process. Minutes after injury, a clot is formed comprised mainly of fibrin 
and platelets (8). The formation of the clot not only prevents blood flow, it also acts as a 
provisional matrix for inflammatory cells and fibroblasts to infiltrate the wound (12). 
This provisional matrix is also a repository for growth factors and cytokines (12). During 
hemostasis, activated platelets in the provisional matrix excrete the growth factors and 
cytokines in their granules. One of these cytokines is transforming growth factor (TGF)β, 
a molecule that is utilized by numerous cell types in all phases of wound healing (8, 13, 
14). In addition to the formation of a fibrin clot, vasoconstriction occurs at the site of 
injury, thereby preventing blood flow and contributing to hemostasis (8). 
Vasoconstriction lasts upwards of 15 minutes and is mediated by the release of 
vasoactive amines from injured cells (15, 16). Local vasoconstriction, in concert with 
activated platelets, allows for the accumulation of growth factors and cytokines in the 
provisional matrix and promotes the recruitment of inflammatory cells and fibroblasts to 
the wound (10).  
Once hemostasis is achieved, vascular changes occur that result in vasodilation and 
increased capillary permeability (8). The increased blood flow into the wound facilitates  
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Figure 1.1 Schematic representation of the phases of cutaneous wound repair. 
Normal cutaneous wound repair progresses through three overlapping phases following 
insult to the dermis. (a) The inflammatory phase is characterized by clot formation, 
vascular changes and recruitment of inflammatory cells, including macrophages, to the 
wound. Inflammatory cells are a major source of growth factors and cytokines that 
promote the proliferation phase. (b) The proliferation phase is marked by 
reepithelialization, angiogenesis, fibroblast migration and proliferation, collagen 
deposition and myofibroblast-mediated wound closure. (c) During the remodelling phase, 
collagen synthesis, degradation and ECM remodelling occur in order to restore strength 
to the wound. As the wound heals and the mechanical tension in the ECM is reduced, 
myofibroblasts and inflammatory cells undergo apoptosis. (d) The net result is a mature 
scar with high tensile strength. (e) When wound healing signals persist, excessive 
fibroblast proliferation and myofibroblast differentiation promote “overhealing” 
characterized by excessive ECM deposition and remodelling leading to the formation of 
abnormal scars. 
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the migration of inflammatory cells (8), such as polymorphonuclear cells (PMNs) and 
macrophages, that are  attracted to the wound by growth factors and cytokines such as 
TGFβ-1 (10, 12, 16, 17). PMNs and activated macrophages remove cellular debris, 
foreign particles and bacteria, and are a major source of the proinflammatory cytokines 
(13, 16, 18, 19) that regulate the inflammatory phase and initiate the proliferation phase 
(8, 13, 20, 21).  
1.2.2 The proliferation phase 
The proliferation phase is characterized by the formation of granulation tissue, dermal re-
vascularization and the re-establishment of the protective barrier of the skin. Fibroblasts 
play a vital role in the proliferation phase as they produce the ECM proteins, including 
collagens, that make up the granulation tissue (8). The provisional matrix is initially 
devoid of fibroblasts, therefore fibroblast migration, proliferation, and ECM deposition 
are vital for the regeneration of a functional dermis (8). Plasma-derived fibronectin (22) 
and TGFβ-1 are components of the provisional matrix that stimulate fibroblast migration 
to the wound (13, 23). Once within the wound, fibroblasts secrete components of the 
ECM, including collagens and fibronectin, and growth factors that regulate the function 
of other cells in the matrix (8). The ECM provides a scaffold for cell adhesion and 
regulates the growth, migration, and differentiation of the cells within it (24, 25). 
Collagen production begins approximately 3-5 days after injury and is stimulated by a 
number of cytokines including TGFβ-1 (13, 16). In normal skin and mature scars, dermal 
collagen is composed of 80-90% type I collagen and 10-20% type III collagen. In the 
early stages of wound healing, the proportion of type III collagen increases to 
approximately 30%  (8). Collagen deposition not only provides strength to the wound but 
also provides structural support for capillary formation and re-epithelialization (8) . 
The revascularization of the wound is a complex, but important, component of the 
proliferation phase. Cytokines, including TGFβ-1 (26), activate endothelial cells at the 
wound site, resulting in the release of proteolytic enzymes, such as MMPs, that dissolve 
the basal lamina (10). This allows the activated endothelial cells to proliferate and 
migrate within the wound. These newly built vessels interconnect with each other 
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forming a vessel loop (10). These new vessels differentiate into arteries and venules and 
restore blood flow to the newly formed granulation tissue (10).  
Re-epithelialization is another important process in the proliferation phase and is required 
to restore the protective barrier of the skin. Keratinocyte migration across the provisional 
matrix and newly formed granulation tissue is stimulated by a lack of contact inhibition 
and growth factor stimulation (8, 10). As migration proceeds, keratinocyte proliferation 
occurs at the wound edge to replace the cells and provide more cells for the migrating 
sheet (8, 10). Migration ceases when cells from opposing sides of the wound come in 
contact (8, 10). Once contact inhibition is established, the keratinocytes proliferate and 
differentiate to re-establish the stratified epithelium, thus restoring the skin’s protective 
barrier (8, 10).  
1.2.3 Myofibroblast differentiation 
A major event in the proliferation phase is the differentiation of fibroblasts into 
contractile myofibroblasts. Myofibroblasts are the primary ECM producing cells in 
normal cutaneous wound healing and are responsible for the contracture of the 
granulation tissue during repair (27, 28). The myofibroblast was first identified in 
granulation tissue over forty years ago as a fibroblastic cell with a prominent 
endoplasmic reticulum and contractile microfilament bundles (29). The primary 
distinguishing feature of myofibroblasts is the neo-expression of alpha smooth muscle 
actin (αSMA) in stress fibres, allowing these cells to exhibit a hyper-contractile 
phenotype (30). Myofibroblasts are generally negative for smooth muscle myosin heavy 
chain, desmin, h-caldesom, and smoothelin, thereby distinguishing myofibroblasts from 
smooth muscle cells (31). In addition to fibroblasts, pericytes, vascular smooth muscle 
cells, cells undergoing epithelial-mesenchymal transition (EMT) and fibrocytes have all 
been implicated as precursors for myofibroblasts (32-37). Myofibroblasts combine the 
contractile features of smooth muscle cells with the extensive ECM production of 
fibroblasts (29, 31) thus allowing for deposition, contraction, and remodelling of the 
granulation tissue. 
Fibroblasts in unwounded skin are stress shielded by the highly organized and cross-
linked ECM that surrounds them. Following insult to the dermis, the initial contraction of 
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the wound by the tractional forces imposed by migrating fibroblasts, increases the 
mechanical tension in the granulation tissue (29, 38). This increase in ECM tension 
promotes the differentiation of fibroblasts into “proto”-myofibroblasts, characterized by 
the formation of stress fibres containing β and γ actin, mature focal adhesion formation, 
and de novo expression of the fibronectin splice variant, ED-A fibronectin (38, 39). Stress 
fibres connect to the ECM through integrin-associated focal adhesion complexes, while 
cell-cell interactions occur through de novo N-cadherin expression. The net result is an 
environment under high mechanical tension that allows the fibroblasts to stabilize their 
proto-myofibroblast phenotype (37). 
Three events are required for the differentiation of proto-myofibroblasts into 
differentiated myofibroblasts characterized by the de novo expression of αSMA in their 
stress fibres (Figure 1.2, (30)). The first is the accumulation of cytokines such as active 
TGFβ-1, which induces αSMA expression (40, 41). Platelet granules, immune cells, and 
fibroblasts secrete TGFβ-1 in a latent form that is activated by increased mechanical 
tension within the ECM and by ECM-associated proteases (13, 42). Second, an 
accumulation of ED-A fibronectin in the ECM is required for myofibroblast 
differentiation (39). Lastly, the cells need to be stimulated by the increase in ECM 
tension generated by ECM remodelling (30). Specialized cell-ECM junctions termed 
fibronexus (in vivo) or “supermature” focal adhesions (in vitro) mediate this 
mechanoperception (43). The rigidity of the ECM determines the size of these cellular 
attachments to the ECM (43). αSMA can only become incorporated into pre-existing 
actin stress fibres once the ECM is stiff enough to allow the formation of supermature 
focal adhesions (suFAs, (43)). The formation of suFAs in combination with αSMA 
induction allows myofibroblasts to exert a 2-4 fold higher contractile stress on the ECM 
(43). A feedback loop between enhanced suFA formation and an ECM tension that is 
above threshold levels can maintain myofibroblasts in a differentiated state (43, 44).   
In addition to secreting ECM proteins into the granulation tissue, myofibroblasts utilize 
their contractile machinery to achieve wound closure. This contractile force is generated 
by contractile stress fibres composed of actin bundles, non-muscle myosin, and actin-
binding proteins, and is regulated by myosin light chain (MLC) phosphorylation  
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Figure 1.2 Schematic representation of the events required for myofibroblast 
differentiation. Fibroblasts in unwounded tissue are void of stress fibers and focal 
adhesions. Upon wounding, initial closure of the wound by migratory fibroblasts 
increases ECM tension leading to the formation of proto-myofibroblasts. Proto-
myofibroblasts are characterized by the formation of stress fibers, mature focal adhesions 
and de novo expression of the fibronectin splice variant, ED-A fibronectin. Contractile 
forces generated by proto-myofibroblasts increase the mechanical tension in the ECM 
resulting in the formation of supermature focal adhesions and increased levels of active 
TGFβ-1 and ED-A fibronectin. The presence of mechanical tension, TGFβ-1 and ED-A 
fibronectin leads to myofibroblast differentiation characterized by de novo expression and 
incorporation of alpha smooth muscle actin into their stress fibers, giving these cells a 
hypercontractile phenotype. Figure adapted with permission from the authors from 
Tomasek et al (30). 
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(30, 45-47). Myofibroblasts utilize two signalling pathways to regulate MLC 
phosphorylation, the calcium dependent MLC kinase pathway and the Rho kinase 
(ROCK) pathway. An increase in intracellular concentrations of calcium activates MLC 
kinase, which promotes myofibroblast contraction through direct phosphorylation of 
MLC (46, 48). Since increased calcium levels are often transient, this contraction is rapid 
and short-lived and is actively inhibited by the effects of  MLC phosphatase on MLC 
(30). In the ROCK pathway, guanosine-5’-triphosphate (GTP) bound RhoA activates 
ROCK (49, 50), which leads to increased MLC phosphorylation by two mechanisms. The 
first mechanism is by direct phosphorylation of MLC (51). The second mechanism is 
through MLC phosphatase inhibition (52, 53). Since MLC phosphatase activity is 
required for terminating myofibroblast contraction, its inhibition results in sustained 
contraction (30). Myofibroblast contractility in combination with ECM synthesis and 
degradation leads to connective tissue remodelling that includes the irreversible and long-
term contracture events that result in wound closure and increased wound strength. 
1.2.4 Remodelling phase  
The remodelling phase represents a balance between collagen synthesis, collagen 
degradation, and collagen remodelling (8, 12) with the net result of increasing the 
strength of the wound. Net collagen production by fibroblasts peaks around three weeks 
after wounding, after which collagen production decreases (8, 16). As collagen 
production decreases, collagen degradation increases and several remodelling processes 
are initiated to enhance the strength of the wounded skin. Type III collagen and 
proteoglycan levels decrease while fibroblasts secrete increasing amounts of type I 
collagen, which imposes greater mechanical strength (8, 10). In the early stages of wound 
repair, the collagen is arranged haphazardly, resulting in the visual appearance of a “scar” 
(8).  As the scar matures, wound strength increases as the collagen fibers become shorter, 
thicker, more organized and cross-linked due to contraction by myofibroblasts (8, 12). A 
mature scar has approximately 80% of the strength of unwounded skin (8, 12), indicating 
that wound repair falls short of true skin “regeneration”. As the wound heals and 
mechanical stress of the ECM is relieved, the number of myofibroblasts and macrophages 
is reduced via apoptosis (8, 12). Over time, capillary growth ceases and blood flow to the 
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wound site decreases, resulting in reduced metabolic activity within the wound site (12). 
The net result is a relatively acellular and avascular mature scar with high tensile strength 
that approaches, but does not achieve, that of unwounded skin. 
1.3 Abnormal cutaneous wound healing 
Potentially, non-healing chronic wounds or excessive cutaneous scarring can arise from 
any aberration of processes that contribute to normal cutaneous wound healing. 
Abnormalities in cell migration, proliferation, inflammation, ECM secretion, cytokine 
synthesis, and apoptosis can prevent normal wound repair (54) or conversely, contribute 
to excessive scar formation (55). Factors that promote excessive fibroblast proliferation 
and myofibroblast persistence leads to an “overhealing” phenomenon characterized by 
excessive collagen deposition at the site of injury, termed fibrosis (10), and contracture of 
the ECM (56, 57) that result in raised, collagenous scars.  The associated pathological 
contracture of the skin can cause major clinical problems, and there are few treatment 
options. Abnormal cutaneous scarring can be divided into two broad categories, 
hypertrophic scarring and keloid scarring.  The following sections will discuss the 
clinical, histological, and epidemiological characteristics of both hypertrophic and keloid 
scars and their treatment options. 
1.3.1 Clinical features of abnormal cutaneous wound healing 
Hypertrophic scars are clinically defined as raised collagenous scars that are confined to 
the borders of the initial wound (58). These scars occur 4-8 weeks following insult to the 
dermis, have a rapid growth phase of up to six months, then gradually regress over a 
period of years, eventually leading to a flat scar (59). In contrast, keloid scars extend 
beyond the borders of the initial wound, may develop several years after injury, or 
spontaneously, and do not regress over time (Figure 1.3, (58, 59)). Hypertrophic scars 
tend to occur at areas of high tension such as the shoulders, neck, pre-sternum, knees and 
ankles (59). In comparison, keloid scars tend to form on the shoulders, anterior chest, ear 
lobes, upper arms and the cheeks (59). Recurrence of hypertrophic scars following 
surgical incision is rare, however recurrence rates are high with keloid scars (59). Other 
than imposing a financial burden, these conditions impose morbidity that is difficult to  
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Figure 1.3 Clinical presentation of hypertrophic and keloid scars. (a) Clinical 
presentation of hypertrophic scarring following lymph node resection in the inguinal 
region. Hypertrophic scars present as raised collagenous scars that are confined to the 
borders of the initial wound. (b) Clinical presentation of keloid scarring on the anterior 
chest and the neck. In contrast to hypertrophic scars, keloid scars are able to extend 
beyond the borders of the initial wound. Photographs c/o Roth|McFarlane Hand and 
Upper Limb Centre. 
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quantify, including pain and loss of mobility, especially if the scar is associated with a 
joint (60). Furthermore, these scars are disfiguring and can adversely affect a patient’s 
quality of life both physically and psychologically (60, 61). 
1.3.2 Histological features of abnormal cutaneous wound healing 
Histologically, both hypertrophic and keloid scars contain excessive amounts of collagen 
(59). Hypertrophic scars contain primarily type III collagen fibres arranged in a wavy 
pattern parallel to the epidermal surface (58). These scars also contain abundant nodules 
of myofibroblasts, small blood vessels, and large extracellular collagen filaments (58, 
59). In contrast, keloid scars are composed of disorganized type I and III collagen fibres 
randomly oriented to the epidermal surface (59). These scars have poor vasculature, 
contain hypocellular collagen bundles and lack the excessive numbers of myofibroblasts 
evident in hypertrophic scars (59). Proliferating cell nuclear antigen, p53 and adenosine-
5’-triphosphate (ATP) levels are elevated in keloid scars, suggesting that they are 
primarily the result of excessive fibro-proliferation and potentially explaining why they 
grow beyond the site of the original injury (62, 63). Both hypertrophic and keloid scars 
display increased immune cell infiltration, increased  levels of TGFβ-1 and myofibroblast 
persistence, however these features decline over time in hypertrophic scars and may 
explain why hypertrophic scars regress (58, 59, 62). 
1.3.3 Epidemiological features of abnormal cutaneous wound 
healing 
Hypertrophic and keloid scars have equal sex distribution and have the highest incidence 
rates in the second and third decade of life (59). Hormones may affect hypertrophic and 
keloid scar formation, as these scars tend to occur during puberty and pregnancy and the 
scars can decrease in size following menopause (59, 64, 65). The incidence of 
hypertrophic scars is probably higher than keloid scars, however there is currently 
insufficient data available to make robust comparisons (62). Incidence rates for 
hypertrophic scars vary from 40-70% following surgical incision and up to 91% 
following burns (66, 67). With the exception of albino individuals, keloid scars can 
develop in people of any skin color, however, dark skinned individuals are more 
susceptible with incidence rates as high as 16% in African populations (59). The 
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formation of hypertrophic scars does not appear to have any association with skin 
pigmentation (68). The notion of genetic predisposition has been suggested, as patients 
with keloid scars report a positive family history that is strongly associated with keloid 
formation at multiple anatomical sites (59, 69). In contrast, patients with hypertrophic 
scars typically report no family history of scar development (59).  
1.3.4 Treatments 
Increased tension at wound margins has been implicated in the development of 
hypertrophic scars, and several prophylactic approaches have been implemented on this 
basis to reduce hypertrophic scar development (59). Pressure therapy and silicone gel 
sheeting have been used to apply continuous pressure to the scar during wound repair. 
These approaches have shown little success and cause discomfort leading to reduced 
patient compliance (70). TGFβ-3, which has been shown to reduce connective tissue 
deposition and is induced during the late stages of wound healing (71-73), has been used 
as a prophylactic approach to prevent scar formation. While initial studies showed 
evidence for the benefits of recombinant TGFβ-3, further independent studies revealed 
that this treatment was unsuccessful in improving scar resolution (74). Current treatment 
strategies include corticosteroid injections, cryotherapy, surgical resection, radiotherapy, 
and laser therapy. These treatment strategies have varied success rates in the resolution of 
hypertrophic and keloid scars and can be associated with painful and disfiguring side 
effects, risk of malignancy (in the case of radiotherapy), and high recurrence rates 
(surgical and laser therapy) (59, 70) . Emerging treatment strategies include interferon 
injections, which reduces collagen synthesis, and 5’-fluorouracil treatment to increase 
fibroblast apoptosis. These treatments have also demonstrated varied success rates and 
can present painful and harmful side effects (59, 70). 
Although some treatments have been shown to be effective in reducing hypertrophic and 
keloid scar formation in individuals, few of these studies have been supported by well-
designed studies with adequate control groups (59). Despite numerous studies, both in 
vitro and in vivo, there is limited information available regarding the cellular mechanisms 
that induce hypertrophic and keloid scar formation (59). One reason for our lack of 
knowledge of the cellular and molecular mechanisms involved in the development of 
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abnormal scars is a lack of representative and physiologically relevant  animal models of  
hypertrophic scar formation (59). Therefore, gaining a better understanding of the 
biochemical processes involved in abnormal wound healing is crucial if we hope to 
achieve normal skin repair or, optimally, true skin regeneration in patients prone to 
abnormal scarring.  
1.4 TGFβ-1 is a difficult therapeutic target 
As highlighted in the previous sections, TGFβ-1 plays essential roles in normal cutaneous 
wound healing.  In addition to these roles, excessive signalling by this cytokine has been 
implicated in hypertrophic and keloid scar formation (58, 59, 62). TGFβ-1 has proven to 
be a difficult therapeutic target in many disease processes including abnormal scar 
formation, as it can exert pleiotropic effects on different cell types that can be diverse 
and, in some cases, seemingly paradoxical (75, 76).  While TGFβ-1 is one of several 
cytokines that attract PMNs and macrophages to the wound (10, 12, 16, 17), depletion of 
TGFβ-1 in Tgfb null mouse models results in a lethal and widespread inflammatory 
response, revealing an essential anti-inflammatory role for this cytokine (77, 78). 
Knockdown of TGFβ-1, its receptor, or signalling components in mouse models inhibits 
normal repair in the dermis (79-82), whereas TGFβ-1 promotes matrix formation for 
keratinocyte migration while inhibiting keratinocyte proliferation (83, 84). In vitro 
studies demonstrate that TGFβ-1 can promote fibroblast proliferation without affecting 
myofibroblast differentiation or myofibroblast differentiation without affecting 
proliferation, in the same cell line (75). These apparently paradoxical outcomes are likely 
to be the result of concurrent activation of other signalling pathways that modify and 
supplement the downstream effects of TGFβ-1 signalling intermediates. For this reason, 
the identification of TGFβ-1-inducible proteins that supplement, enhance or modify 
TGFβ-1 signalling to promote pathological, rather than normal, fibroblast proliferation 
and/or myofibroblast differentiation may have greater utility as therapeutic targets than 
TGFβ-1 itself. 
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1.5 Identification of TGFβ-1-inducible proteins in abnormal 
wound healing 
During cutaneous wound healing, TGFβ-1 is released into the ECM by platelet granules, 
inflammatory cells and fibroblasts (13, 83) in an inactive form in association with 
latency-associated peptide (LAP) and latent TGFβ-1 binding protein-1 (LTBP-1) (31). 
Extracellular matrix proteins associate with LTBP-1 creating a reservoir of latent TGFβ-1 
(85-87). Latent TGFβ-1 bound in the ECM can interact with cells through integrin 
binding sites located in the LAP (85, 88). Stress applied to these integrins, either by 
stretching the ECM or by inducing cellular contraction, results in a conformational 
change in the large latent complex allowing the release of TGFβ-1 in an active form (42). 
Mechanical activation of TGFβ-1 enhances tissue remodelling by translating the level of 
ECM stiffness into pro-fibrotic signals (31). Therefore, the ECM is an important 
regulator of TGFβ-1 activation in both normal and abnormal wound healing.  
 
The ECM is comprised of both structural and non-structural proteins (89, 90). Structural 
proteins, such as collagens and fibronectin, provide strength to the dermis and act as 
scaffolds for migrating cells and as reservoirs for growth factors (8). Non-structural 
proteins within the ECM include cytokines like TGFβ-1 and the family of “matricellular” 
proteins that modify cell signalling in response to extracellular stimuli, such as changes in 
mechanical tension of the ECM (40, 42, 90).  Given the well-established roles of the 
ECM in scar formation, studies were focused on the roles of non-structural proteins in the 
ECM that might be activated by and/or act in combination with TGFβ-1 to promote 
excessive scarring. 
 
Initial studies in our laboratory showed increased expression of genes encoding ECM 
proteins in Dupuytren’s Disease, a fibro-contractile disease of the palmar fascia that has 
many similarities to abnormal scarring.  Microarray analyses of tissues derived from 
patients with or without Dupuytren’s disease identified POSTN, encoding the 
matricellular protein periostin, as a very highly upregulated transcript (91). Subsequent in 
vitro experiments demonstrated that periostin induced fibroblast survival and 
myofibroblast differentiation in primary fibroblasts derived from Dupuytren’s disease 
16 
 
tissue and induced proliferation of fibroblasts derived from “pre-diseased” palmar fascia 
(91).  As excessive fibroblast proliferation and increased myofibroblast differentiation 
and persistence are also characteristics of hypertrophic scarring (56, 57, 92-94), further 
studies were performed to investigate whether periostin expression was abundant in 
hypertrophic scar tissue.  Western immunoblotting, immunohistochemistry and in-situ 
hybridization data performed by our laboratory (95, 96) and reports by other groups (97-
99) demonstrated that POSTN  expression was upregulated in the basal stratum of 
hypertrophic and keloid scar tissue relative to mature normal scar tissue. Levels of the 
translated product of POSTN mRNA, periostin, were also upregulated in the dermis (but 
not the basal stratum) of hypertrophic and keloid scar tissue relative to normal mature 
scars.  Based on these studies, it was proposed that periostin might contribute to 
excessive fibroblast proliferation and myofibroblast differentiation in hypertrophic 
scarring.  
 
1.6 Periostin 
1.6.1 Gene and protein structure 
Periostin was originally identified as osteoblast-specific factor 2, a novel cell-adhesion 
molecule, in a mouse osteoblastic cell line (100, 101). Using murine cDNAs as probes, 
human homologs encoding a protein with a molecular weight of up to 93 kDa were 
subsequently identified in placental and osteosarcoma cDNA libraries (100, 102). 
Osteoblast-specific factor 2 was later renamed periostin due to its preferential expression 
in cells of mesenchymal origin located in the collagen rich ECM surrounding the 
periosteum and periodontal ligament (101). The murine periostin gene, Postn, located on 
chromosome three and the human gene, POSTN, located on chromosome 13, are highly 
homologous. Amino acid identity between the two species is 89.2% for the entire protein 
and 90.1% for the mature processed forms (100). POSTN encodes 23 protein-coding 
exons over a genetic footprint of 36 kilobases (102). POSTN expression is upregulated by 
a number of factors involved in wound healing including TGFβ-1, interleukins, platelet-
derived growth factor and fibroblast growth factor (101, 103, 104). 
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The N-terminal signal sequence of periostin consists of 23 amino acids and lacks a 
transmembrane domain, suggesting that periostin is a secreted protein (100). This is 
consistent with pronounced immunoreactivity to periostin in the ECM surrounding the 
periosteum and periodontal ligaments (101). Following the signal sequence is a cysteine-
rich Emilin-like (EMI) domain encoded by exons two and three (100, 102). EMI domains 
are typically involved in protein-protein interactions (105) and protein multimerization, 
and periostin dimers have been reported in some studies (106). Adjacent to the EMI 
domain are four repeated regions of 150 amino acids encoded by exons 3-14 (100, 102). 
These repeats share homology with the insect axon guidance protein fasciclin 1 (FAS1), 
an adhesion module (100, 107). Since periostin contains FAS1 domains, it has been 
assigned to the fasciclin family of proteins that includes stabilin 1 and 2, and TGFβ-
induced gene clone 3 (βig-h3) (108). Each FAS1 domain contains two conserved regions 
of 13-14 amino acids that have high sequence similarity. However, the conserved repeats 
between the FAS1 domains have relatively low sequence homology (100). Each FAS1 
domain contains glutamate residues and contains N-terminal recognition sites for γ-
glutamylcarboxylase, an enzyme responsible for posttranslational modification of 
glutamate residues (109). The FAS1 domains are believed to be involved in cell adhesion 
and protein-protein interactions, as bone morphogenic protein-1, tenascin C, and integrins 
have been suggested to bind this region of periostin (110-112). Interestingly, periostin 
does not contain any canonical Arg-Gly-Asp (RGD) integrin binding motifs, suggesting 
that integrin binding by periostin is independent of these motifs (102). βig-h3, which has 
a domain structure similar to periostin (102), has been demonstrated to bind α3β1 
integrins at sites that are independent of the RGD motif (112). This interaction occurs by 
two pentapeptides containing a central Asp-Ile (DI) dimer located in the second and 
fourth FAS1 domain (112). The DI dimer has a similar conformation to the RGD binding 
motif (113) and suggests a mechanism for periostin-integrin interactions (102). 
 
Lastly, exons 16-23, accounting for 182 amino acids, make up the hydrophilic or C-
terminal domain (102). This region is devoid of known domains, contains few known 
sequence motifs and contains a C-terminal nuclear localization signal at exon 22-23 
(102), suggesting that periostin may also have intracellular functions (114). Exons 17-21  
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Figure 1.4 Schematic representation of the human POSTN gene and domain 
structures. The human POSTN gene contains 23 protein-coding exons. Exon 1 encodes a 
signal sequence (SS), characteristic of secreted proteins. Exons 2-3 encode for the 
Emilin-like (EMI) domain involved in protein-protein interactions and protein 
multimerization. Exons 3-14 encode four repeated fasciclin 1 (FAS1) domains involved 
in cellular adhesion and protein-protein interactions. Purple arrows represent recognition 
sites for γ-glutamylcarboxylase and vertical black bars represent proposed integrin 
binding sites in FAS1 repeats 2 and 4. Exons 17-21 present themselves as exon cassettes 
that can be present or deleted in mature mRNA through alternative splicing events. Exons 
22-23 encode a C-terminal nuclear localization signal (NLS). Red oval represents heparin 
binding site in exon 23. 
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can be considered as “exon cassettes” that can be included or deleted in mature mRNA in 
various combinations through alternative splicing events (100-102). This results in 
several periostin isoforms ranging in size from 83-93 kDa (115) . The number of 
nucleotide residues in each exon cassette is a multiple of three, and therefore deletion or 
inclusion of any of these cassettes in the mature mRNA does not result in frameshift 
mutations (100). Initial studies identified four periostin isoforms in mouse and five 
isoforms in human tissues (100, 101), with additional studies expanding the latter to eight 
isoforms (116, 117). These isoforms appear to be differentially expressed during 
development and injury and appear to be tissue, developmental stage or disease specific 
(114, 118-121).  However, the function(s) of each individual isoform remain unclear. 
Secondary structure predictions demonstrate consecutive beta strands as the predominant 
structure in the C-terminal domain (102). βig-h3, which lacks this domain, has not been 
reported to interact with collagen or fibronectin. Therefore it has been proposed that the 
C-terminal domain’s beta strand structure may facilitate periostin binding to collagen and 
fibronectin (102). Periostin contains similar repeats to those found in various bacteria that 
are able to bind fibronectin through an extended beta zipper (102, 122). Therefore, the 
strength of periostin’s interaction with the ECM would be influenced by the number of 
beta strands present in the mature protein determined by alternative splicing (102). 
Lastly, the C-terminal domain contains a heparin binding site in exon 23, creating a 
potential binding site for glycoproteins and proteoglycans (Figure 1.4, (101)). 
 
1.6.2 Classification as a matricellular protein 
Periostin has been classified as a matricellular protein (123), i.e. one of a family of 
structurally unrelated ECM proteins that do not serve a structural role in the ECM but 
instead serve as a link between the ECM and cells and modify cell behavior in response 
to external stimuli (90, 124). Originally, this family of proteins consisted of 
thrombospondin, tenascin-C and SPARC but recent studies have classified osteopontin, 
periostin and members of the CCN family, including CCN2, as matricellular proteins 
(125). Several characteristics have been identified for the classification of matricellular 
proteins. 1) Matricellular proteins interact with structural components of the ECM, 
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receptors, growth factors and proteases thereby allowing these proteins to regulate 
cellular signalling cascades (125). 2) Matricellular proteins promote an intermediate 
cellular adhesive state (126) that activates survival signals and increases expression of 
genes associated with adaptation and repair (125). 3) In normal adult tissue, expression of 
matricellular proteins is low, but is upregulated in response to injury or during 
development (125). 4) Mice with targeted disruption in matricellular genes have subtle 
abnormalities in the absence of injury. However, loss of these proteins results in a wide 
range of alterations in injured and remodelled tissue (125). 
 
The first characteristic of matricellular proteins is their ability to bind ECM proteins, 
proteases and growth factors and to transmit external signals to the cell to modulate 
cellular phenotypes through receptor-mediated activation. Periostin has been 
demonstrated to bind several structural ECM proteins including type I and V collagen 
and fibronectin as well as other matricellular proteins including tenascin-C (104, 106). 
Bone morphogenic protein-1, a metalloproteinase, interacts with periostin inducing the 
cleavage and activation of lysyl oxidase required for collagen cross linking (127). 
Periostin has been shown to bind integrins αvβ3, αvβ5, α5β1, β1 and α6β4 in various systems 
(127-135), presumably through its FAS1 domains. Integrins mediate cell-ECM 
interactions and transmit signals from the ECM to modulate cell behavior (136, 137). 
Periostin signalling through αvβ3 and α6β4 has been shown to promote tumour cell 
survival through PI3K/Akt in human colon cancer cells and pancreatic ductal 
adenocarcinoma cells cultured on tissue culture plastic (129, 130). Periostin signalling 
through αvβ3 and αvβ5 can promote the migration of human ovarian epithelial cells, 
pancreatic ductal adenocarcinoma cells and mouse smooth muscle cells through Akt and 
FAK dependent pathways (128, 130, 134). Additionally, periostin has been shown to 
signal through αvβ3, αvβ5 and β1 integrins to induce the proliferation of rat 
cardiomyocytes (132).  It should be noted, however, that very few of these signalling 
intermediates and pathways were assessed on physiologically relevant culture substrates 
or within an ECM, where periostin could act as a matricellular molecule. 
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The second characteristic of matricellular proteins is their ability to promote cellular de-
adhesion that activates survival signals and induces expression of genes associated with 
repair. Periostin has been implicated in promoting a “de-adhesive” state in the stroma of 
cancers and its presence is correlated with malignant tumor invasion and metastasis (128, 
129, 138-141). In the presence of periostin, tumour cells enhance their invasive activity 
by forming fewer stress fibres and increasing motility (128). Periostin transfected cancer 
cells demonstrate morphological changes and increased mesenchymal cell markers 
suggesting that periostin may induce cancer cell invasion through EMT (142). Periostin 
has also been shown to promote survival through ECM-receptor activation in cancers, 
bone and periodontal ligaments.  Enhanced survival induced by periostin in cancers is 
mediated through PI3K and Akt activation (129, 130). In the periosteum and periodontal 
ligament, periostin-null mice have reduced expression of Notch 1 and its downstream 
effector Bcl-xL (143, 144). Notch proteins are transmembrane receptors that play an 
important role in cell survival under mechanical stress (145). Periostin binding to notch 
under stressed conditions increases expression of Bcl-xL leading to inhibition of 
apoptosis (121). Periostin expression has also been correlated with proteins associated 
with repair. Studies utilizing periostin-null mice have demonstrated reduced collagen 
fibrillogenesis and aSMA levels in cardiac repair and normal cutaneous wound healing 
(106, 120, 133). Collagen remodelling and myofibroblast differentiation are important 
processes in normal wound repair.  
 
The expression of matricellular proteins is usually low in most normal adult tissues but is 
upregulated during embryonic development and in response to injury. Periostin is highly 
expressed by fibroblasts in the embryonic myocardium and developing neonatal heart. In 
adult hearts, periostin expression is decreased and is primarily localized to the supporting 
structures of the heart valves that are subjected to mechanical tension. (123, 146, 147). In 
mouse skin, periostin is highly expressed during embryonic development in 
keratinocytes, at the basement membrane and in the dermis, however expression 
significantly decreases in adult mice (97). Unlike most matricellular proteins that are 
expressed at low levels in adult tissue, periostin expression in adult tissue is high in 
collagen-rich tissues under mechanical stress such as the periosteum, periodontal 
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ligaments, tendons, cardiac valves, and the skin (98, 101, 106, 123). A marked increase in 
periostin is seen in patients with myocardium infarction, advanced heart failure, and 
atherosclerotic and rheumatic value disease (120, 148, 149). Up-regulation of periostin in 
myocardium infarction plays an important role in early scar formation by promoting 
migration, myofibroblast differentiation and collagen deposition thereby preventing 
cardiac rupture (120, 150). Periostin expression is also upregulated during cutaneous 
wound healing (98, 151, 152) and its roles in this process will be discussed in more detail 
in the following section. 
 
The final unifying characteristic of matricellular proteins is that their deletion in mouse 
models generally results in subtle abnormalities in the absence of injury, but much more 
obvious abnormalities following injury. Despite high levels of periostin during 
embryonic development in the periosteum, periodontal ligament and heart valves, 
periostin-null mice are not embryonic-lethal and appear grossly normal at birth (150, 
153). Three to four weeks after birth, periostin-null mice display growth retardation and 
dental defects (153). Approximately 15% of periostin-null mice die in the first three 
weeks due to cardiac defects (153, 154). Alterations in repair are evident following injury 
in periostin-null mice. Following myocardium infarction, periostin-null mice have 
increased rates of cardiac rupture resulting from impaired collagen fibrillogenesis and 
myofibroblast differentiation (120, 150). Defects in collagen fibrillogenesis and 
osteoclast inactivation are evident in the periosteum resulting in decreased bone 
formation and mass (121, 155). In normal cutaneous wound healing, periostin-null mice 
displayed delayed wound healing caused by defective re-epithelialization and decreased 
myofibroblast populations (133, 151, 152). These studies suggest that periostin fulfills the 
requirements of a matricellular protein and has roles in tissue repair.   
 
1.7 Periostin in normal cutaneous wound healing 
Several groups have assessed the expression of POSTN and periostin during normal 
cutaneous wound repair using murine excisional wound healing models. POSTN 
expression is detectible in the wound at Day 1 after injury, with peak expression at Day 7 
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with an ongoing decrease thereafter approaching baseline levels by Day 18 (152). 
Periostin expression is evident in the granulation tissue and in migrating keratinocytes as 
early as three days post wounding (98, 151).  As increased periostin expression correlates 
with increased αSMA levels in the granulation tissue at Day 7 post wounding, some 
authors have suggested that periostin may contribute to normal myofibroblast 
differentiation (98). By Day 21, periostin expression is absent in keratinocytes and is only 
evident in the remodeled ECM (98, 152) and levels return to baseline by Day 28 (98). 
The expression pattern of POSTN and periostin over time are currently unclear in human 
cutaneous wound healing, due to obvious ethical restrictions in using humans as in vivo 
wound healing models.   
 
Only three groups have utilized periostin-null mice in excisional wounding studies to 
investigate the roles of periostin during cutaneous wound repair. Periostin-null mice 
display delayed wound closure (133, 151, 152) suggesting that periostin may have a role 
in re-epithelialization or granulation tissue formation. As periostin-null mice displayed 
decreased re-epithelialization despite evidence that periostin does not affect keratinocyte 
proliferation or migration (151), it is likely that loss of periostin impairs re-
epithelialization through an indirect mechanism.  
 
Of the three groups to report excisional wound healing studies in periostin-null mice, 
only one has investigated the effects of periostin in the dermis (133). This group 
demonstrated that the granulation tissue in periostin-null mice displayed decreased 
expression of αSMA and its gene, Acta2, at Day 7 post wounding relative to wild type 
controls (133). Similar results were identified in vitro, with decreased αSMA levels 
observed in periostin-null fibroblasts cultured in anchored collagen lattices, which 
resembles the matrix stiffness of granulation tissue (133, 156). The decrease in 
myofibroblast populations in the granulation tissue in these in vivo studies was not due to 
impaired fibroblast migration or proliferation (133). However, in vitro studies using 
embryonic mouse fibroblasts provided conflicting data, as periostin-null fibroblast 
exhibited decreased proliferation, while over expression of periostin induced their 
proliferation (152).  It is difficult to draw conclusions from these studies as they lacked 
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parallel in vivo experiments and utilized embryonic fibroblasts that may have 
characteristics that are distinct from adult murine fibroblasts (157). In vitro and in vivo 
experiments demonstrated that periostin-null dermal fibroblasts were significantly less 
contractile than wild type fibroblasts and that the addition of recombinant periostin was 
able to rescue this effect (133). This effect was blocked in the presence of inhibitors 
against integrin β1 and FAK and addition of periostin induced FAK phosphorylation 
(133, 152). These studies suggest that periostin contributes to normal murine cutaneous 
wound healing by facilitating myofibroblast differentiation and contraction through an 
integrin-focal adhesion dependent pathway (133). 
  
While these studies suggest that periostin can facilitate myofibroblast differentiation in 
murine wound healing models, the substantial differences between mouse and human 
skin make it unclear if these findings can be translated to normal human cutaneous 
wound healing. Mouse skin is covered in dense hair, lacks rete ridges and adipose sweat 
glands, has a thinner epidermis and dermis, has a faster keratinocyte turnover rate and is 
significantly more compliant than human skin (158, 159). In contrast, human skin has a 
thicker epidermis and dermis, less hair follicles, is relatively stiffer and is adherent to the 
underlying subcutaneous tissue (158-161). Mice and humans also heal cutaneous wounds 
by different mechanisms. Mice have a muscle layer below the hypodermis in the flanks, 
known as the panniculus carnosus, that is absent in most areas of human skin (158). This 
muscle layer allows mice to rapidly contract wounds following injury and enhances skin 
regeneration with minimal scarring. In contrast, human cutaneous wounds lacking a 
similar muscle layer heal through the formation of granulation tissue and re-
epithelialization, typically leading to the formation of a scar (158, 160, 162). These 
profound differences in wound healing mechanisms between mice and humans make it 
unclear if the roles of periostin in murine excisional wound healing can be translated to 
normal, or particularly abnormal, cutaneous repair in humans. 
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1.8 Periostin in abnormal wound healing 
Currently, there are no studies in the literature investigating the roles of periostin in the 
development of hypertrophic scars in humans. The molecular mechanisms implicated in 
the development of excessive scarring remain poorly understood. One reason for this is a 
lack of truly representative and physiological relevant animal models of human 
hypertrophic scar formation (59). Hypertrophic scarring does not normally occur in 
animals (163), and our current understanding of the mechanisms that promote excessive 
scarring are largely based on studies of chemically and/or genetically manipulated mice 
(164-166). These models can be very useful for investigating the cell types and molecules 
involved in scar formation at specific time points. More recently, animals with skin that 
more closely resembles human skin, such as the red Duroc pig (167), have been used as 
models with and without chemical or other treatments to induce scarring. While more 
physiologically relevant than mice, they cannot capture the multifactorial influences, such 
as age, sex, wound site and genetic predisposition that promote abnormal scarring in 
human patients. Since using humans as wound healing models is not ethically feasible, 
the next best option is analyze human scar tissue from patients undergoing surgical 
resections. By utilizing primary samples derived from human normal and abnormal scar 
tissue, we are able to perform a “top down” approach to identify factors that are elevated 
during abnormal scar formation relative to normal skin. Upon identification of such 
factors, in vitro studies can be performed on primary human fibroblasts that exhibit many 
clinically relevant features of both normal and abnormal scarring. As an in vitro model, 
these cells have the disadvantage of being obtained after scar formation has occurred, and 
are therefore unlikely to be informative of the initial stages of scar development, such as 
those induced by inflammation (59). However, primary fibroblasts derived from 
surgically resected hypertrophic tissue can provide clinically relevant models of the 
cellular processes that cause the abnormal persistence of scars for months or years, 
compared to normal skin wounds that typically heal in weeks.  
 
In situ hybridization studies performed by our lab demonstrated that POSTN expression 
was upregulated and persistent in the basal epithelium of human hypertrophic scar 
(Figure 1.5a) and keloid scar tissue relative to normal mature scars (96), consistent with 
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previous reports (99). Immunohistochemistry studies performed by our laboratory (95, 
96) and other groups (97, 98) have shown that periostin levels are abnormally abundant 
and localized to dermis in hypertrophic scars (Figure 1.5b and c) and keloid scars. 
Periostin is absent in the epidermis, despite clear evidence of POSTN expression, 
suggesting that the epidermis may be an additional source of dermal periostin in 
abnormal scarring conditions. Based on these findings, we hypothesize that the increased 
and persistent levels of periostin in the dermis of hypertrophic and keloid scars may 
contribute to excessive fibroblast proliferation and myofibroblast differentiation and 
persistence in these fibrotic conditions. 
 
1.9 Assessing the function of periostin in hypertrophic scar 
formation in an in vitro model system 
In order to assess the role(s) of a matricellular molecule like periostin in abnormal scar 
formation in vitro, studies must be performed in a model system that closely resembles 
the granulation tissue during wound healing in vivo. Excisional wound healing models 
and in vitro studies have been utilized to measure the stiffness of the ECM during wound 
healing. Matrix stiffness can be represented by Young’s modulus, which is the ratio of 
stress to strain of an elastic substrate. The Young’s modulus of the provisional matrix is 
10-1000 Pascals (Pa), indicating that it is very compliant (31). The proto-myofibroblast 
phenotype is only evident when matrix stiffness reaches 3000 Pa (168). The stiffness of 
granulation tissue in seven day old rat granulation tissue is approximately 18 000 Pa, 
consistent with αSMA being incorporated into stress fibers at a Young’s modulus of 16 
000 - 20 000 Pa (31). Fibrotic tissue and contracting granulation tissues can exhibit a 
matrix stiffness of 25 000 – 50 000 Pa (169). Tissue-culture plates provide an extremely 
stiff substrate (~3 gPa, or 3 000 000 000 Pa (170)). A culture substrate of this stiffness 
inevitably induces robust and non-physiological influences on myofibroblast 
differentiation (31) that has the potential to overshadow any other effects of potential 
inducers of myofibroblast formation (133). Despite its routine use for culturing 
fibroblasts, tissue culture plastic is a very non-physiological model system in which to 
assess cellular processes that are sensitive to matrix tension. To address this issue, our  
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Figure 1.5 POSTN expression and periostin levels are increased in hypertrophic 
scars. (a) In situ hybridization studies were performed using S
35 
labeled sense and 
antisense transcripts derived from a 391-bp fragment from the 5’ end of a POSTN cDNA.  
Paraffin-embedded mixed scar derived from a patient with a phenotypically normal scar 
at one edge transitioning to a hypertrophic scar at the opposite edge was exposed to 
antisense POSTN mRNA probe to compare POSTN expression across the normal-
abnormal scarring transition zone (indicated with an arrow). Silver grains deposited due 
to exposure to S
35 
labeled transcripts are evident as white specks under dark field 
microscopy. As shown, POSTN expression is much more abundant in the basal 
epithelium along the hypertrophic scar section of the mixed scar relative to the normal 
scar area. Immunohistochemistry of paraffin-embedded (b) hypertrophic scar and (c) 
normal scar tissue with a periostin polyclonal antibody. Periostin immunoreactivity is 
evident as brown staining from di-amino precipitation. Periostin is more abundant in 
hypertrophic scars relative to normal scars and expression extends deep into the dermis. 
Images c/o Cell and Molecular Biology Laboratory, Roth|McFarlane Hand and Upper 
Limb Centre. 
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laboratory takes the approach of routinely culturing primary fibroblasts on type I collagen 
substrates. Type I collagen is the most abundant collagen in the skin and mature scars (8) 
and our laboratory has demonstrated that the change in substrate stiffness induced by 
culture on collagen substrates can modify gene expression and protein levels in primary 
fibroblasts relative to the same cells cultured on stiff tissue culture plastic (91, 171). 
Based on these observations, the effects of periostin on fibroblast proliferation and 
myofibroblast differentiation were assessed in two- (2D) and three-dimensional (3D) 
collagen-based cultures in this thesis to more closely mimic the ECM and substrate 
stiffness experienced by these fibroblasts in vivo.  
 
Currently, three dimensional collagen lattices are utilized for examining in vitro the 
mechanical interactions that occur between cells and the ECM and how these interactions 
induce myofibroblast differentiation (47, 156). When cultured within a collagen lattice, 
fibroblasts experience a more complex environment and geometry compared to cells 
cultured on plastic (172). Fibroblast attachment, spreading, and migration through the 
collagen lattice generate mechanical signals that can modulate cellular phenotype. If the 
collagen lattice is mechanically restrained, such as in stressed Fibroblast Populated 
Collagen Lattices (sFPCLs) (47), tension develops as tractional forces compact the 
collagen fibers (30, 172). As the mechanical tension progressively increases in the 
collagen lattice, the fibroblasts will form stress fibers and focal adhesions associated with 
proto-myofibroblast and myofibroblast differentiation (156) similar to ECM remodelling 
in vivo (30). This tension is sustained in the lattice until it is released from its points of 
attachment (30). Newly polymerized 2D and 3D collagen gels have a matrix stiffness of 
300-400 Pa (173), which is similar to that seen in the provisional fibrin matrix (31). The 
Young’s modulus has not been reported for sFPCLs; however, it is believed to closely 
mimic the mechanical environment of the granulation tissue in Day 7 rat wounds, i.e. 
approximately 18 000 Pa (31, 44, 156). Using collagen substrates, periostin can be 
incorporated into collagenous ECM matrices to mimic its localization in vivo and provide 
a reproducible culture system to investigate periostin effect(s) on fibroblast proliferation 
and myofibroblast differentiation and persistence under physiological relevant conditions.  
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1.10 Hypothesis and objectives 
When wound healing signals become abnormal, excessive fibroblast proliferation and 
myofibroblast persistence can be induced, resulting in excessive ECM deposition and 
remodelling and hypertrophic scarring (56, 57, 92-94). TGFβ-1 is a potent inducer of 
myofibroblast differentiation in this context, however it is also implicated in regulating 
many of the processes that are essential for normal wound healing (13, 41, 174-177), 
making this cytokine a difficult therapeutic target. Therefore, TGFβ-1-inducible proteins 
that act in combination with and/or sequentially to TGFβ-1 signalling to promote 
pathological, rather than normal, fibroblast proliferation and/or myofibroblast 
differentiation may have greater utility as therapeutic targets. Periostin is a novel 
matricellular protein that is upregulated in the ECM of hypertrophic scars and may have 
potential as such a target. Although several studies have demonstrated that periostin 
regulates fibroblast proliferation and myofibroblast differentiation in other systems (91, 
132, 133, 152, 178-180), the roles of periostin in hypertrophic scar formation in human 
fibroblasts has not been assessed. Therefore, this thesis focuses on identifying the role(s) 
of periostin on hypertrophic scar fibroblast proliferation and myofibroblast differentiation 
and persistence in 2D and 3D collagen cultures. 
The central hypothesis of this thesis is that ECM-associated periostin contributes to 
hypertrophic scar formation by promoting excessive fibroblast proliferation and 
myofibroblast differentiation and by maintaining myofibroblasts in a differentiated 
state. 
The following objectives were designed to test this hypothesis: 
Objective 1: To assess the effects of periostin on the proliferation of normal skin and 
hypertrophic scar derived fibroblasts 
Objective 2: To assess the effects of periostin on the differentiation of fibroblasts 
derived from normal skin and hypertrophic scar tissues 
Objective 3: To identify the mechanism(s) utilized by periostin to induce and maintain 
hypertrophic scar myofibroblasts in a differentiated state  
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Chapter 2  
2 Materials and Methods 
2.1 Materials 
2.1.1 Biochemicals 
 Bovine serum albumin (BSA)  Sigma-Aldrich, St. Louis, MO 
Glycine     Fisher Scientific, Hampton, NH 
Sodium hydroxide    Sigma-Aldrich, St. Louis, MO 
Hydrochloric acid    Merck KGaA, Darmstadt, GER 
Sodium dodecyl sulfate (SDS)  Sigma-Aldrich, St. Louis, MO 
Tris Base     Fisher Scientific, Hampton, NH 
Sodium chloride (NaCl)   Fisher Scientific, Hampton, NH 
Glacial acetic Acid    Fisher Scientific, Hampton, NH 
Potassium chloride (KCl)   Fisher Scientific, Hampton, NH 
Potassium phosphate (KH2PO4)  Fisher Scientific, Hampton, NH 
Sodium phosphate, monobasic (NaH2PO4) Fisher Scientific, Hampton, NH 
Sodium phosphate, dibasic (Na2HPO4) Fisher Scientific, Hampton, NH 
Imidazole     Sigma-Aldrich, St. Louis, MO 
Glycerol     Fisher Scientific, Hampton, NH 
Bromophenol blue    Fisher Scientific, Hampton, NH 
2.1.2 Cell culture 
100 mm and 24-well tissue culture plates Becton Dickinson, Franklin Lakes, NJ 
Alpha Modified Eagle’s medium (αMEM) Life Technologies, Carlsbad, CA 
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Dulbecco’s modified Eagle’s medium  Life Technologies, Carlsbad, CA 
(DMEM) 
 
100x L-glutamine    Life Technologies, Carlsbad, CA 
100x antibiotic-antimycotic   Life Technologies, Carlsbad, CA 
Fetal bovine serum (FBS)   Life Technologies, Carlsbad, CA 
Tryspin-EDTA    Life Technologies, Carlsbad, CA 
Type I rat tail collagen   Made in our laboratory 
Waymouth medium    Sigma-Aldrich, St. Louis, MO 
Dimethyl sulfoxide (DMSO)   Sigma-Aldrich, St. Louis, MO 
Recombinant human periostin  R&D systems, Minneapolis, MN 
Recombinant human TGFβ-1   R&D systems, Minneapolis, MN 
Hank’s balanced salt solution   Sigma-Aldrich, St. Louis, MO 
Collagenase     Sigma-Aldrich, St. Louis, MO 
Nalgene® cryogenic vials   Thermo Scientific, Waltham, MA 
Sircol collagen quantification assay  Biocolor Ltd., Carrickfergus, UK 
 
Table 2.1 Buffers and medium for cell culture 
Buffer/medium Application Composition 
Phosphate buffered saline 
(PBS) 
Wash buffer 8 g NaCl, 0.2 g KCl, 1.44 g 
Na2HPO4, 0.24 g KH2PO4, reverse 
osmosis (R.O) H2O up to 1 L, pH 7.4 
Freezing Medium Primary cell storage 50% FBS, 35% αMEM, 15% DMSO  
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2.1.3 Cell proliferation assay 
Cell Proliferation Reagent WST-1  Roche Diagnostics, Mannheim, GER 
96-well tissue culture plates   Becton Dickinson, Franklin Lakes, NJ 
 
Table 2.2 Inhibitors for cell proliferation assays 
Inhibitor Mode of Action Concentration Vehicle Supplier 
PI3K inhibitor, 
LY294002 
Inhibition is 
competitive with 
respect to ATP 
binding site 
10 μM DMSO Cell Signaling 
Technologies, 
Danvers, MA 
AKT inhibitor 
VIII 
Binds pleckstrin 
homology 
domain and 
prevents 
activation by 
PI3K 
0.5 μM DMSO Merck KGaA, 
Darmstadt, 
GER 
GSK3β 
inhibitor VIII 
Inhibition is 
competitive with 
respect to ATP 
binding site 
1 μM DMSO Merck KGaA, 
Darmstadt, 
GER 
Rho Kinase 
inhibitor, 
Y27632 
Inhibition is 
competitive with 
respect to ATP 
binding site 
10 μM H2O Sigma Aldrich, 
St. Louis, MO 
ERK 1/2 
inhibitor, 
PD98059 
Binds to ERK 
specific MAP 
kinase, MEK, 
preventing 
activation of 
ERK 1/2 by 
MEK 
20 μM DMSO Sigma Aldrich, 
St. Louis, MO 
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2.1.4 Protein chemistry 
RIPA lysis buffer    Teknova Inc., Hollister, CA 
Proteinase inhibitor cocktail    Sigma-Aldrich, St. Louis, MO 
Phenylmethanesulfonyfluoride (PMSF) Sigma-Aldrich, St. Louis, MO 
Sodium fluoride (NaF)   Sigma-Aldrich, St. Louis, MO 
Sodium orthovanadate (Na3VO4)  Sigma-Aldrich, St. Louis, MO 
Pierce® BCA protein assay kit  Thermo Scientific, Waltham, MA 
30% Acrylamide/Bis solution (29:1)  BioRad, Hercules, CA 
Ammonium persulphate   BioRad, Hercules, CA 
N,N,N’,N’-tetramethylethylenediamine BioRad, Hercules, CA 
(TEMED) 
Dithiotreitol (DTT)    Sigma-Aldrich, St. Louis, MO 
polyvinylidene difuoride (PVDF) – plus,  Santa Cruz Biotechnology, Santa Cruz, CA 
0.45 micron transfer membranes  
Tween®20     Merck KGaA, Darmstadt, GER 
Novex sharp molecular weight markers Life Technologies, Carlsbad, CA 
Immobilon™ western chemiluminescent  Millipore Corporation, Billerica, MA 
HRP substrate 
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Table 2.3 Buffers for protein analysis 
Buffer Application Composition 
RIPA lysis buffer Cell lysis 150 mM NaCl, 1% Triton X-
100, 1% sodium deoxycholate, 
0.1% SDS, 50 mM Tris-HCl 
(pH 7.5), 2 mM EDTA (pH 8.0) 
SDS gel-loading buffer SDS-PAGE R.O. H2O  with 50 mM Tris-HCl 
(pH 6.8), 100 mM DTT, 2% 
SDS, 0.1% bromophenol blue, 
10% glycerol  
1.0 M Tris SDS-PAGE stacking gel 121.0 g Tris base dissolved in 
R.O. H2O to 1 L, pH 6.8 
1.5 M Tris SDS-PAGE resolving gel 181.65 g Tris base dissolved in 
R.O. H2O to 1 L, pH 8.8 
5x electrophoresis 
running buffer 
SDS-PAGE 15.1 g Tris Base, 94.0 g glycine, 
25 ml 20% (w/v) SDS, R.O. 
H2O  up to 1 L 
10x electrophoresis 
transfer buffer 
SDS-PAGE 30.3 g Tris base, 144.4 g 
glycine, R.O. H2O up to 1 L 
1x electrophoresis 
transfer buffer 
SDS-PAGE 1 part 10x electrophoresis 
transfer buffer, 2 parts methanol, 
7 parts R.O. H2O 
10x Tris buffered saline 
(TBS) 
Western immunoblotting 80.8g NaCl, 60.6 g Tris Base, 
R.O. H2O up to 1 L, pH 7.4 
TBS/tween20 Western immunoblotting 1x TBS with 0.1% Tween®20 
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Table 2.4 Primary antisera for western immunoblotting 
Antibody Description Antibody dilution 
(western blotting) 
Supplier 
Phospho-Akt Rabbit anti-
phospho-Akt (ser 
473), polyclonal 
1:1000 in 5% BSA, 
TBS/tween20 
Cell Signaling 
Technology, 
Danvers, MA 
Total Akt Rabbit anti-Akt, 
polyclonal 
1:1000 in 5% BSA, 
TBS/tween20 
Cell Signaling 
Technology, 
Danvers, MA 
Phospho-GSK-3β Rabbit anti-
phospho-GSK-3β 
(ser 9), polyclonal 
1:1000 in 5% BSA, 
TBS/tween20 
Cell Signaling 
Technology, 
Danvers, MA 
Total GSK-3β Mouse anti-GSK-
3β, clone 7/GSK-
3b, monoclonal 
1:1000 in 5% non-
fat milk, 
TBS/tween20 
BD Biosciences 
Canada, 
Mississauga, ON 
β-catenin Rabbit anti-β-
catenin, polyclonal 
1:1000 in 5% non-
fat milk, 
TBS/tween20 
Millipore 
Corporation, 
Billerica, MA 
Phospho-ERK 1/2 Rabbit anti-
phospho-p44/42 
MAPK (Thr 202, 
Tyr 204) 
1:1000 in 5% BSA, 
TBS/tween20 
Cell Signaling 
Technology, 
Danvers, MA 
Total ERK 1/2 mouse anti-p44/42 
MAPK (ERK1/2), 
clone L34F12, 
monoclonal 
1:1000 in 5% non-
fat milk, 
TBS/tween20 
Cell Signaling 
Technology, 
Danvers, MA 
Alpha smooth 
muscle actin 
(αSMA) 
Mouse anti-αSMA, 
monoclonal 
1:1000 in 5% non-
fat milk, 
TBS/tween20 
Sigma-Aldrich, St. 
Louis, MO 
OB cadherin Mouse anti-
Cadherin 11, clone 
5B2H5, monoclonal 
1:1000 in 5% non-
fat milk, 
TBS/tween20 
Life Technologies, 
Carlsbad, CA 
Periostin Rabbit  anti-
periostin, clone H-
300, polyclonal 
1:1000 in 5% non-
fat milk, 
TBS/tween20 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA 
36 
 
Phospho-Focal 
adhesion Kinase 
(FAK) 
Rabbit anti-
phospho-FAK (Tyr 
397), polyclonal 
1:500 in 5% BSA, 
TBS/tween20 
Cell Signaling 
Technology, 
Danvers, MA 
Total FAK Rabbit anti-FAK, 
polyclonal 
1:500 in 5% BSA, 
TBS/tween20 
Cell Signaling 
Technology, 
Danvers, MA 
Phospho-myosin 
light chain (MLC) 
Rabbit anti-
phospho-MLC 2 
(ser 19), polyclonal 
1:500 in 5% BSA, 
TBS/tween20 
Thermo Scientific, 
Rockford, IL 
Total MLC Rabbit anti-MLC 2, 
polyclonal 
1:500 in 5% BSA, 
TBS/tween20 
Thermo Scientific, 
Rockford, IL 
Phospho-cofilin Rabbit anti-
phospho-cofilin (Ser 
3), clone 77G2, 
monoclonal 
1:500 in 5% BSA, 
TBS/tween20 
Cell Signaling 
Technology, 
Danvers, MA 
Total cofilin Rabbit anti-cofilin, 
clone D3F9, 
monoclonal 
1:500 in 5% non-fat 
milk, TBS/tween20 
Cell Signaling 
Technology, 
Danvers, MA 
Alpha V integrin 
(αV) 
 
Rabbit anti-αV, 
clone Q-20, 
polyclonal 
1:1000 in 5% non-
fat milk, 
TBS/tween20 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA 
Alpha 5 integrin 
(α5) 
Rabbit anti-α5, 
polyclonal 
1:1000 in 5% non-
fat milk, 
TBS/tween20 
Cell Signaling 
Technology, 
Danvers, MA 
β-actin Mouse anti-β-actin, 
HRP-linked, clone 
C4, monoclonal 
1:2500 in 5% non-
fat milk, 
TBS/tween20 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA 
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Table 2.5 Secondary antisera for western immunoblotting 
Antibody Description Antibody dilution 
(western blotting) 
Supplier 
Mouse secondary Horse anti-mouse 
IgG, HRP-linked 
1:1000 in 5% non-
fat milk, 
TBS/tween20 
Cell Signaling 
Technology, 
Danvers, MA 
Rabbit Secondary Goat anti-rabbit 
IgG, HRP-linked 
1:1000 in 5% non-
fat milk, 
TBS/tween20 
Cell Signaling 
Technology, 
Danvers, MA 
 
2.1.5 Polymerase Chain Reaction (PCR) 
RNeasy mini kit     Qiagen, Venlo, Netherlands 
High-capacity cDNA archive kit   Life Technologies, Carlsbad, CA 
10X PCR buffer, minus Mg   Life Technologies, Carlsbad, CA 
50 mM Magnesium chloride   Life Technologies, Carlsbad, CA 
Custom primers    Sigma Aldrich, St. Louis, MO 
Platinum® Taq DNA polymerase  Life Technologies, Carlsbad, CA 
100 mM dNTP set, PCR grade  Life Technologies, Carlsbad, CA  
UltraPure™ Agarose    Life Technologies, Carlsbad, CA 
QIAEX® II Gel extraction kit  Qiagen, Venlo, Netherlands 
MicroAmp Optical 384-well reaction plate  Life Technologies, Carlsbad, CA 
TaqMan universal PCR master mix   Life Technologies, Carlsbad, CA 
TaqMan gene expression assay primers  Life Technologies, Carlsbad, CA 
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Table 2.6 TaqMan gene expression assay primers 
Primer Protein Encoded Assay ID 
POSTN Periostin Hs00170815_m1 
CCND1 Cyclin D1 Hs00765553_m1 
BCL2 Bcl2 Hs00608023_m1 
BAX Bax Hs00180269_m1 
GAPDH GAPDH Hs99999905_m1 
ACTB β-actin Hs99999903_m1 
 
2.1.6  Flow cytometry 
Guava ViaCount® reagent   Millipore, Billerica, MA 
MCDB 105 medium    Sigma-Aldrich, St. Louis, MO 
 
2.1.7 Immunoprecipitation 
Protein A/G magnetic beads   Thermo Scientific, Waltham, MA 
Coomassie brilliant blue R-250  Fisher Scientific, Hampton, NH 
Amicon® Ultra centrifugal 10 kDa filters Millipore Corporation, Billerica, MA 
Table 2.7 Antisera for immunoprecipitation 
Antibody Description Antibody 
Concentration 
Suppliers 
Periostin Rabbit  anti-
periostin, clone H-
300, polyclonal 
2 μg / 500 μg total 
cell lysate 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA 
IgG Rabbit anti-human 
IgG3, clone H-270, 
polyclonal 
2 μg / 500 μg total 
cell lysate 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA 
IgG Anti-human IgG 
from rabbit serum 
2 μg / 500 μg total 
cell lysate 
Sigma-Aldrich, St. 
Louis, MO 
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Table 2.8 Buffers and solutions for immunoprecipitation 
Buffer Application Composition 
Lysis buffer Cell lysis R.O. H2O  with 20 mM 
Tris-HCl (pH 8.0), 137 mM 
NaCl, 1% Triton® X-100, 2 
mM EDTA 
Wash buffer Wash buffer TBS with 0.05% 
Tween®20 and 0.5 M NaCl 
Elution buffer Protein elution 4 parts lysis buffer, 1 part 
SDS gel-loading buffer 
Gel fixation solution Fixing polyacrylamide gels 50% methanol, 10% acetic 
acid, 40% R.O. H2O 
Coomassie brilliant blue 
concentrated stain solution 
Protein staining 12.0 g coomassie brilliant 
blue, 300 ml methanol, 60 
ml acetic acid 
Coomasie brilliant blue 
staining solution 
Protein staining 500 ml methanol, 30 ml 
coomassie brilliant blue 
concentrated stain solution, 
400 ml R.O H2O, 100 ml 
acetic acid, filtered using 
0.22 μm filter 
Destaining solution Wash solution 45% methanol, 10% acetic 
acid, 45% R.O. H2O 
Gel storage solution Polyacrylamide gel storage R.O. H2O  with 5% acetic 
acid 
 
2.1.8 Nickel magnetic bead precipitation 
37% formaldehyde    Merck KGaA, Darmstadt, GER 
10x glycine solution    Cell Signaling Technology, Danvers, MA 
Nonidet P40 (NP-40)    Merck KGaA, Darmstadt, GER 
PureProteome™ nickel magnetic beads  Millipore, Billerica, MA 
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Table 2.9 Buffers for Nickel Magnetic Bead precipitation 
Buffer Application Composition 
Lysis buffer Cell lysis R.O. H2O  with 50 mM 
NaH2PO4, 300 mM NaCl, 10 
mM imidazole (pH 8), 0.1% 
NP-40 
Wash buffer Wash buffer R.O. H2O  with 50 mM 
NaH2PO4, 300 mM NaCl, 20 
mM imidazole (pH 8), 0.1% 
NP-40 
Elution Buffer Protein elution R.O. H2O  with 50 mM 
NaH2PO4, 300 mM NaCl, 300 
mM imidazole (pH 8) 
 
2.1.9 Loss-of-function studies 
Table 2.10 Adenoviral shRNA constructs 
Construct Promoter Targeting sequence Multiplictiy of 
infection (MOI) 
Supplier 
Ad-GFP-
U6-h-
POSTN-
shRNA 
U6 CGGTGACAGTATA
ACAGTAA 
25 Vector Biolabs, 
Philadelphia, 
PA 
Ad-U6-
RNAi-GFP 
U6 GACACGCGACTTG
TACCACT 
25 Vector Biolabs, 
Philadelphia, 
PA 
 
2.1.10 Immunofluorescence confocal microscopy 
35 mm, poly-D-lysine coated glass bottom MatTek Corporation, Ashland, MA 
tissue culture plates (No. 1.5 coverslip,  
10 mm glass diameter) 
 
Paraformaldehyde 16% solution  Electron Microscopy Sciences, Hatfield, PA 
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Background Sniper    Biocare Medical, Concord, Ca 
Dako antibody diluent    Dako Canada Inc., Burlington, ON 
Negative control mouse IgG1   Dako Canada Inc., Burlington, ON 
Hoeschst 33342     Life Technologies, Carlsbad, CA 
 
ProLong® Gold antifade reagent  Life Technologies, Carlsbad, CA 
18 x 18 mm, No.1 coverslips   Fisher Scientific, Hampton, NH 
 
Table 2.11 Buffers for immunofluorescence confocal microscopy 
Buffer Application Composition 
Immunofluorescence 
phosphate buffered solution 
(IF-PBS) 
Wash buffer 0.2 g NaH2PO4, 1.375 g 
Na2HPO4, 8.8 g NaCl, 
R.O. H2O up to 1 L 
Cell permeabilization 
solution 
Cell permeabilization PBS with 0.1% Triton® X-
100 
  
 
Table 2.12 Antisera for immunofluorescence confocal microscopy 
Antibody Description Dilution Supplier 
Vinculin Mouse anti-
vinculin, clone 
VIN-11-5, 
monoclonal 
1:200 in Dako 
antibody diluent 
Sigma-Aldrich, St. 
Louis, MO 
Negative control 
mouse IgG1 
Mouse anti- 
Aspergillus niger 
glucose oxidase, 
clone DAK-GO1, 
monoclonal 
 
4 μg/ml in Dako 
antibody diluent 
Dako Canada Inc., 
Burlington, ON 
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Table 2.13 Spectral properties of molecular probes and LSM 510 Duo Vario 
confocal microscope 
Molecular 
Probe 
Dilution LSM Laser 
Lines for 
Excitation 
LSM Emission 
Filters 
Supplier 
αSMA-cy3 1:100 in 
Dako 
antibody 
diluent 
30 mW 514 nm 
Argon/2 Ion 
laser 
BP 560-615 IR Sigma-Aldrich, 
St. Louis, MO 
Alexa Fluor 647 1:100 in 
Dako 
antibody 
diluent 
5 mW 633 nm 
HeNe 
LP 650 Life 
Technologies, 
Carlsbad, CA 
Alexa Fluor 594 1:100 in 
Dako 
antibody 
diluent 
30 mW 514 nm 
Argon/2 Ion 
laser 
BP 560-615 IR Life 
Technologies, 
Carlsbad, CA 
Hoechst 1:10 000 in 
PBS 
50 mW 405-50 
nm Diode 
BP 420-480 Life 
Technologies, 
Carlsbad, CA 
 
2.2 Methods 
2.2.1 Clinical specimen collection 
Surgically resected normal skin, hypertrophic scar and keloid scar tissue samples were 
collected from patients in the clinics of the Roth|McFarlane Hand and Upper Limb Centre 
or in the operating rooms of St. Joseph’s Hospital, London, Ontario. All subjects 
provided written informed consent and specimens were collected with the approval of 
Western University Research Ethics Board for Health Sciences Research involving 
Human Subjects (HSREB protocol # 08222E).  
2.2.2 Primary cell culture 
Primary cells were harvested from surgically resected hypertrophic scar, keloid scar and 
normal skin tissue as previously described (181). A total of eight patient-derived 
hypertrophic scar samples, three keloid scar samples and six normal skin samples were 
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used to derive primary fibroblasts for analyses in this thesis. In brief, tissue samples were 
finely minced, adhered to the bottom of 100 mm dishes and cultured in αMEM 
supplemented with 10% fetal bovine serum (FBS), 1x L-glutamine and 1x antibiotic-
antimycotic solution at 37˚C in 5% CO2. Explant cultures (passage 0) were incubated for 
2-4 weeks allowing for the migration, and subsequent proliferation, of fibroblasts from 
the tissue to the 100 mm dish. Upon reaching 50% confluency, primary cultures were 
sub-cultured using 0.05% Trypsin-EDTA. Primary fibroblast cultures at passage 1 were 
frozen down in freezing medium (Table 2.1) in Nalgene® cryogenic vials at -80°C 
overnight then stored in liquid nitrogen. All primary cell lines were used up and until a 
maximum of four passages, during which no changes in cell behavior or morphology 
attributable to serial passage were evident.  
2.2.3 Preparation of rat tail type I collagen 
Frozen rat tails were obtained from the laboratories of Drs. Ruud Veldhuizen and Ting-
Yim Lee (Western University, London, ON). Frozen rat tails were thawed in 70% ethanol 
for one hour. Rat tails were skinned and collagen fibers were mechanical extracted from 
rat tail tendons. Collagen fibers were soaked in 70% ethanol for 30 minutes then placed 
under ultraviolet light overnight in a tissue culture cabinet. Under sterile conditions, 
collagen fibers were incubated in sterile 0.017M acetic acid with mechanical stirring for 
seven days at 4°C. Undissolved collagen fibers were removed from the solution by 
centrifugation at 18 000 x g at 4°C overnight. The supernatant was collected into sterile 
bottles and stored at 4°C. Collagen concentration was determined using the Sircol 
collagen quantification assay (Biocolor Ltd., Carrickfergus, UK) in accordance with the 
manufacturer’s instructions.  
2.2.4 WST-1 cell proliferation assay 
The WST-1 proliferation assay was utilized to measure the proliferation of hypertrophic 
scar and normal skin fibroblasts grown in collagen cultures. Collagen lattices were cast in 
96-well tissue culture trays. For each well, 48 μl of type I rat tail collagen (final 
concentration of 1.8 mg/ml) was quickly mixed with 12 μl of neutralization solution (3 
parts Waymouth media: 2 parts 0.34 M NaOH), and 2 μg/ml human recombinant 
periostin or vehicle (0.1% BSA-PBS). Collagen lattices were incubated at 37°C in 5% 
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CO2 for 20 minutes to allow for collagen polymerization. 1x10
3
 cells in 100 μl of 2% 
FBS-αMEM ± inhibitors (Table 2.2) were seeded onto the collagen lattices and incubated 
at 37°C in 5% CO2. 10 μl of WST-1 reagent was added at days 1, 3, 5 and 7 post seeding 
and incubated for 2 hours at 37˚C to allow for the cleavage of tetrazolium salt to 
formazan by the succinate-tetrazolium reductase system. Equal volumes of media (90 µl) 
were transferred to an additional 96-well tissue culture tray and absorbencies were 
measured at 450 and 650 nm (reference wavelength) using an iMARK Microplate Reader 
(Bio-Rad, Hercules, CA). Difference scores were calculated relative to day 1 absorbance 
readings.  
2.2.5 Fibroblast Populated Collagen Lattices (FPCLs) 
Collagen contraction assays were carried out using primary normal skin, hypertrophic 
scar and keloid scar fibroblasts based on Tomasek and Rayan (182).  Collagen lattices 
were cast in 24-well tissue culture trays. For each well, 1x10
5
 cells were quickly mixed 
with 400 μl of type I rat tail collagen (final concentration of 1.8 mg/ml), 100 μl of 
neutralization solution and 2 μg/ml human recombinant periostin or vehicle. In a subset 
of experiments, normal skin fibroblasts were primed with 5 ng/ml recombinant TGFβ-1 
or vehicle (PBS with 1% BSA and 4 mM HCl) in 2% FBS-αMEM for 72 hours prior to 
sFPCL setup. Collagen lattices were incubated at 37°C in 5% CO2 for 45 minutes to 
allow for collagen polymerization. Wells were then flooded with 1 ml of 2% FBS-
αMEM. In a subset of experiments, wells were flooded with fibroblast-conditioned media 
(section 2.2.9.2). For stressed FPCLs (sFPCLs), collagen cultures were maintained for 72 
hours. During this time, the primary fibroblasts in three-dimensional cultures respond to 
stress within the tethered, polymerized collagen lattice and differentiate into contractile 
myofibroblasts (183). After three days in culture, collagen lattices were simultaneously 
released from the wells using a metal spatula, thereby allowing the differentiated 
myofibroblasts to contract the untethered lattice. Floating lattices were digitally scanned 
within two minutes (designated time 0), 0.5, 2, 6, and 24 hours after release and the area 
of each lattice was determined using the freehand tool in ImageJ software (National 
Institutes of Health, Bethesda, MD). Sequential area calculations were normalized to the 
area of the well prior to release.  
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For relaxed FPCLs (rFPCLs), lattices were cultured for one hour prior to being 
mechanical released from the wells. Fibroblasts cultured in rFPCLs are not subjected to 
mechanical tension and do not differentiate into myofibroblasts. Therefore, rFPCLs 
undergo gradual lattice contraction over a 24 hour period due to fibroblast attachment, 
spreading and migration (183). Floating lattices for rFPCLs were digitally scanned at 24 
hours after release. 
2.2.6 Western immunoblotting 
2.2.6.1  Protein extraction 
For total protein extraction from fibroblasts cultured on collagen substrates, cultures were 
washed in PBS and incubated with 1 ml collagenase solution (final concentration of 0.25 
mg/ml) for 30 minutes with gentle rocking at 37˚C using a thermal rocker, in order to 
detach the fibroblasts from the collagen substrates. The collagenase solution was 
collected from each well and centrifuged at 600 x g for 4 minutes to pellet the cells. Cell 
pellets were washed with PBS and centrifuged at 16 000 x g for 1 minute. Cell pellets 
were resuspended in 100 μl of ice cold RIPA lysis buffer supplemented with proteinase 
inhibitor cocktail, 0.1M sodium fluoride (NaF), 10 mM phenylmethanesulfonyfluoride 
(PMSF) and 10 mM sodium orthovanadate (Na3VO4). Cell pellets were incubated on ice 
for 30 minutes then subjected to needle aspiration. Cell lysates were centrifuged at 16 
000 x g for 10 minutes and the supernatant was stored at -80°C. 
For total protein extraction from sFPCLs, lattices were collected immediately prior to 
collagen lattice release (after 72 hours in culture), 24 and 48 hours after collagen lattice 
release and transferred to a 2 ml microcentrifuge tube containing 100 – 400 μl of ice cold 
RIPA lysis buffer supplemented with proteinase inhibitor, NaF, PMSF and NA3VO4. 
Collagen lattices were homogenized using an Ultra-Turrax T25 tissue homogenizer 
(IKA® Works Inc., Wilmington, NC) at 16 000 x g for 30 seconds. Cell extracts were 
incubated on ice for 30 minutes then subjected to needle aspiration. Cell extracts were 
centrifuged at 16 000 x g for 10 minutes to remove insoluble material and the supernatant 
was stored at -80°C.  
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2.2.6.2 Bicinchoninic acid (BCA) total protein assay 
Bovine serum albumin (BSA) standards were prepared by serial dilution with RIPA lysis 
buffer to concentrations of 2000, 1000, 500, 250, 125, 62.5, 31.25 and 0 μg/ml. Total cell 
lysates were prepared in a 1/5 and 1/10 dilution in RIPA lysis buffer and 10 μl of each 
dilution and standard was added in triplicate to 96-well tissue culture trays. 200 μl of 
Pierce® BCA protein assay reagent A:B (49:1) was added to each well and samples were 
incubated for 30 minutes at 37°C in 5% CO2. The colourimetric reaction was analyzed at 
595 nm using an iMARK Microplate Reader. The data was used to construct a standard 
curve and protein concentrations were calculated from the obtained absorbance values to 
ensure equal loading into polyacrylamide gels. We were unable to perform BCA analyses 
on sFPCL lysates due to the high collagen concentration in the lysates and phenol red in 
the media. Therefore, 40 μl of total cell lysate was used for western immunoblotting and 
densitometry was performed to correct for unequal loading. 
2.2.6.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
8-10% polyacrylamide resolving gels were made with a 5% stacking gel and set up in the 
Bio-Rad Mini Protean III apparatus (Biorad, Hercules, CA). 8% polyacrylamide 
resolving gels were used for the analysis of αSMA, OB cadherin, periostin, integrins, β-
catenin, FAK, Akt, ERK1/2 and GSK-3β. 10% polyacrylamide resolving gels were used 
for the analysis of myosin light chain and cofilin levels. Samples were diluted to load 
either 25 µg of total protein or 40 μl of sFPCL lysate per well and SDS gel-loading buffer 
(Table 2.3) was added to each sample at a 1:4 (v/v) ratio. Samples were  boiled at 95
o
C 
for 5-10 minutes, placed on ice for 2 minutes and centrifuged at 16 000 x g for 1 minute. 
Samples were loaded into 1.5 mm wells and subjected to SDS-PAGE in 1x 
electrophoresis running buffer (Table 2.3) using a PowerPac 3000 (Bio-Rad, Hercules, 
CA) set to 80 V though the stacking gel and 120 V through the resolving gel.  
2.2.6.4 Transfer, blocking, incubation, detection and densitometry 
Proteins were transferred to polyvinylidene difluoride (PVDF) – plus, 0.45 micron 
transfer membranes in ice cold 1x electrophoresis transfer buffer (Table 2.3) on ice at 225 
mA for two hours.  The PVDF membranes were blocked for one hour in 5% non-fat milk 
(w/v) or 5% BSA (w/v) in TBS-0.1% Tween®20 (TBS/tween, Table 2.3) depending on 
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the primary antibody (Table 2.4). Membranes were washed with TBS/tween (3 x 5 
minutes) and incubated with primary antibody overnight at 4°C with gentle rotation. 
Membranes were washed with TBS/tween (3 x 5 minutes) and probed with the 
corresponding horseradish peroxidase (HRP)–conjugated secondary antibody (Table 2.5) 
for 90 minutes at room temperature with gentle rotation. Membranes were washed with 
TBS/tween (3 x 5 minutes) and incubated with 1 ml Immobilon™ western 
chemiluminescent HRP substrate (1:1 ratio of luminal to HRP solution) and imaged using 
the ChemiGenius
2
 Bio Imaging System (Syngene, Frederick, MD). Images were captured 
using Gene Snap (Syngene, Frederick, MD) and densitometry analysis was performed 
using the manual band quantification analysis function in Gene Tools (Syngene, 
Frederick, MD).  
2.2.7 PCR 
2.2.7.1 RNA extraction and cDNA synthesis 
Cell pellets were collected from sFPCLs or two-dimensional collagen substrates using 
collagenase treatment (2.2.6.1). Cell pellets were lysed and total RNA was extracted 
using the RNeasy mini kit in accordance with the manufacturer’s instructions. Total RNA 
was eluted in 50 μl of RNase-free water. Total RNA concentration and quality was 
assessed using the NanoDrop-1000 spectrophotometer (Thermo Scientific, Waltham, 
MA). 2 μg of high quality total RNA was reversed transcribed into cDNA first strand 
using the High-Capacity cDNA archive kit in accordance with the manufacturer’s 
instructions.  
2.2.7.2 Real time PCR 
cDNA samples were diluted to a final concentration of 10 ng/μl in RNase/DNase free 
water and 20 ng of cDNA was loaded in triplicate into MicroAmp Optical 384-well 
reaction plates.  TaqMan gene expression assays were used to measure POSTN, CCND1, 
BAX and BCL2 expression in accordance with the manufacturer’s instructions (Table 2.6 
for primers). POSTN and BAX expression was measured relative to GAPDH endogenous 
control and CCND1 and BCL2 expression was measured relative to ACTB using the 
ΔΔCt method (relative quantification, RQ) after confirmation of parallel PCR 
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amplification efficiencies using the 7900HT Sequence Detection System (Life 
Technologies, Carlsbad, CA). PCR reactions were carried out under the following 
conditions: Initial denaturation at 95°C for 5 minutes followed by cycles of denaturation 
(95°C for 15 seconds), primer annealing (60°C for 1 minute) and transcript extension 
(50°C for 2 minutes) for 40 cycles. The relative quantification for each gene normalized 
to vehicle controls was analyzed using RQ Manager 1.2.1 software (Life Technologies, 
Carlsbad, CA).  
2.2.7.3 Reverse-transcription PCR 
20 ng of cDNA was subjected to PCR analysis with Platinum®Taq DNA polymerase in 
accordance with the manufacturer’s instructions. PCR reactions were carried out under 
the following conditions: initial denaturation at 95°C for 3 minutes, followed by cycles of 
denaturation (95°C for 30 seconds), primer annealing (58°C for 30 seconds) and 
transcript extension (72°C for 2 minutes) for 40 cycles, with a final extension at 72C for 
7 minutes. The primers (Forward 5’- ACAACGGGCAAATACTGGAA-3’, Reverse 5’- 
AACTTCCTCACGGGTGTGTCA-3’) were designed to have 100% sequence identity 
with four POSTN mRNA isoforms originally reported ((101), NCBI Reference 
Sequences: NM_006475.2, NM_001135934.1, NM_001135935.1 and 
NM_001135936.1).  PCR products were visualized by agarose gel electrophoresis, 
amplicons were isolated using the QIAEX® II Gel extraction kit and sequenced at the 
Robarts Research Institute DNA sequencing facility (Western University, London, ON).  
2.2.8 Flow Cytometry 
Cell viability was assessed using the Guava ViaCount® assay that distinguishes between 
viable and non-viable cells based on the differential permeability of DNA-binding dyes in 
the ViaCount® reagent. Primary fibroblasts were cultured in sFPCLs treated with 2 
μg/ml human recombinant periostin or vehicle for 72 hours. Cells were extracted from 
sFPCLs using collagenase (2.2.6.1). Cell pellets were resuspended in 1 ml of MCDB 
medium and cell number was assessed using a hemocytometer. Accurate cell counting on 
the Guava system occurs at a cell concentration of 1x10
4 
- 5x10
5
 cells/ml. Cell 
suspensions of appropriate concentrations were diluted to 300 μl in MCDB media and 
incubated with 100 μl of Guava ViaCount reagent for 5 minutes. Flow cytometry analysis 
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was performed using the Guava EasyCyte Mini (Millipore, Billerica, MA). Using a 
stained cell sample, threshold levels were set to separate nucleated cells from debris and 
viable cells from non-viable cells using CytoSoft 4.2.1 software (Millipore, Billerica, 
MA). Once threshold levels were set, samples were analyzed in triplicate for 1000 
cellular events. Viability data was exported to FlowJo 7.6.5 (Tree Star Inc, Ashland, OR) 
and plotted with cell viability on the y-axis and forward scatter on the x-axis to separate 
collagen debris from the viable and non-viable cell populations. Manual gates were set 
and applied to all the samples within the experiment. Viability was assessed by 
calculating the percentage of viable versus non-viable cells from the total cell population.  
2.2.9 Immunoprecipitation (IP)  
2.2.9.1 Fixation 
Primary hypertrophic scar fibroblasts were cultured on 100 mm tissue culture plates in 
10% FBS-αMEM. When 85% confluency was achieved, fibroblasts were fixed with 
formaldehyde (final concentration of 1%) for 10 minutes at room temperature. 25 mM 
glycine solution (final concentration of 2.5 mM) was added to each plate and incubated 
for an additional five minutes at room temperature to quench the formaldehyde. Plates 
were washed with ice-cold PBS (5 x 1 minute), incubated with 100 µl non-denaturing 
lysis buffer (Table 2.8) and cells were lysed using a cell scraper. Total protein extracts 
were collected in a 1.5 ml microcentrifuge tube, incubated on ice for 30 minutes and 
subjected to needle aspiration. Cell extracts were centrifuged at 16 000 x g for 10 minutes 
and the supernatant was stored at -80˚C.  
2.2.9.2 Generation of conditioned media 
Primary hypertrophic scar or normal skin fibroblasts were cultured on 100 mm tissue 
culture plates in 10% FBS-αMEM until the cells achieved 80% confluency. Cells were 
washed overnight in serum free αMEM then cultured in 5 ml fresh serum-free αMEM for 
96 hours. Conditioned media was collected, supplemented with proteinase inhibitor 
cocktail and stored at -80°C. For immunoprecipitation studies, fresh conditioned media 
was concentrated 50x using 10 kDa Amicon® Ultra centrifugal filters and the 
concentration was assessed by BCA assay (2.2.6.2). 
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2.2.9.3  Immunoprecipitation  
1 mg of hypertrophic scar-conditioned media or total cell lysate (2.2.9.1), in a final 
volume of 1 ml, was incubated with 4 μg of periostin-specific antibody or IgG control 
(Table 2.7) overnight at 4˚C with gentle rotation. Protein A/G magnetic beads were 
washed twice with wash buffer (175 µl and 1 ml for 1 minute each, Table 2.8), and 
incubated with the antigen/antibody mixture for 1 hour at room temperature with gentle 
rotation. Magnetic beads were washed with 500 μl wash buffer (3 x 5 minutes) and 500 
μl purified water (1 x 2 minutes). Magnetic beads were resuspended in 80 μl lysis buffer 
(Table 2.8) and 20 μl SDS gel-loading buffer (Table 2.3) and boiled at 95°C for 5 
minutes (conditioned media samples) or 70°C for 45 minutes to reverse formaldehyde 
crosslinks (total cell lysate samples). The supernatant was collected and 50 µl was loaded 
into 1.5 mm wells and subjected to SDS-PAGE. PVDF membranes were probed with 
antibodies against periostin and integrins αV and α5 (Table 2.4). 50 μg of total cell lysate 
or conditioned media (input samples) was analyzed to confirm the presence of periostin 
and integrins αV and α5 in the pre-immunoprecipitated sample. 
2.2.9.4 Gel fixation and coomassie brilliant blue staining  
Immunoprecipitated samples were subjected to SDS-PAGE and stained with coomassie 
brilliant blue for liquid chromatography tandem mass spectrometry analysis. 
Polyacrylamide gels were fixed for 30 minutes at room temperature with gentle rocking 
in gel fixation solution (Table 2.8). Gels were stained with coomassie brilliant blue 
staining solution (Table 2.8) for 30 minutes at room temperature with gentle rocking. 
Gels were then destained in destaining solution (Table 2.8) for 2-3 hours at room 
temperature with gentle rocking. Destaining solution was replaced every 45 minutes. 
Gels were imaged using the ChemiGenius
2
 Bio Imaging System and images were 
captured using Gene Snap. Gels were stored at 4°C in 5% acetic acid.  
2.2.9.5 Spot picking, in-gel digestion and mass spectrometry 
Differential protein bands in periostin immunoprecipitated samples relative to IgG 
controls were isolated using the Ettan spot picker (GE Healthcare, Little Chalfont, UK) at 
the Functional Proteonomic Facility (FPF) at Western University (London, ON). Isolated 
samples were stored in R.O H2O with 45% methanol and 5% acetic acid and submitted to 
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the FPF for in-gel digestion. In-gel digestion was performed using a MassPREP 
automated digester station (PerkinElmer, Waltham, MA). In brief, gel pieces were 
coomassie brilliant blue destained using 50 mM ammonium bicarbonate and 50% 
acetonitrile. Proteins were reduced using 10 mM DTT, followed by alkylation using 55 
mM iodoacetamide and tryptic digestion. Peptides were extracted using a solution of 1% 
formic acid and 2% acetonitrile and lyophilized.  
Lyophilized samples were submitted to the Biological Mass Spectrometry Laboratory 
(Western University, London, ON) for quadrupole time-of-flight (Q-TOF) liquid 
chromatography tandem mass spectrometry (LC-MS/MS) analysis.  In brief, lyophilized 
fractions were reconstituted in 0.1% formic acid prior to injection. For gel-enhanced 
analysis, excised band samples were identified as having low, medium, or high 
complexity based on clear, light, or dark coomasie staining, respectively. Depending 
upon the anticipated complexity of the sample, ∼1/2, 1/5, or 1/8 of each fraction was 
analyzed using a 60-, 90-, or 150-min LC method, respectively. Separation using LC (5–
40% acetonitrile, 0.1% formic acid gradient) was performed on a NanoAcquity Ultra 
Performance Liquid Chromatography (UPLC, Waters Corporation, Milford, MA) with a 
25 cm x 75 μm C18 reverse phase column. Peptide ions were detected in data-dependent 
acquisition mode by tandem MS using a Q-ToF Ultima-Global mass spectrometer 
(Waters Corporation, Milford, MA). Raw data was refined, deNovo sequenced and 
searched using Peaks 6.0 (Bioinformatics Solutions Inc., Waterloo, ON) against NCBInr 
– human database. Results were filtered using a false discovery rate of 1% and a 
minimum of two unique peptides were required for positive protein identification. 
2.2.10 Nickel magnetic bead precipitation 
Primary hypertrophic scar fibroblasts were cultured on 100 mm tissue culture plates in 
10% FBS-αMEM until 80% confluency was achieved. Cultures were then treated with 2 
µg/ml human recombinant periostin or vehicle in 2%FBS-αMEM overnight. Samples 
were fixed and lysed as described 2.2.9.1. PureProteome™ Nickel Magnetic Beads 
(Millipore, Billerica, MA) were used to precipitate the histidine-tagged human 
recombinant periostin from total cell lysates. Nickel magnetic beads were placed in a 
magnetic stand to remove the storage buffer and washed for 1 minute with gentle rotation 
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with 500 µl lysis buffer (Table 2.9). 1 mg of total cell lysate, in a final volume of 1 ml, 
was added to the magnetic beads and incubated at room temperature with gentle rotation 
for 2 hours. Magnetic beads were washed for 10 minutes with sterile water, 2.5 hours 
with wash buffer (Table 2.9), twice for 10 minutes with wash buffer then quickly in 
sterile water. Magnetic beads were incubated with 100 µl elution buffer (Table 2.9) for 5 
minutes at room temperature with gentle rotation. 25 μl of SDS gel-loading buffer (Table 
2.3) and 1 μl proteinase inhibitor cocktail was added to the supernatant and samples were 
incubated at 70°C for 45 minutes to reverse the formaldehyde crosslinks. 50 µl of the 
supernatant was loaded into 1.5 mm wells and subjected to SDS-PAGE. PVDF 
membranes were probed with antibodies against periostin and integrins αV and α5 (Table 
2.4). 50 μg of total cell lysate (input sample) was analyzed to confirm the presence of 
periostin and integrins αV and α5 in the pre-precipitated samples. 
2.2.11 Loss-of-function studies 
Adenoviral shRNA constructs were purchased from Vector Biolabs (Philadephia, PA). 
Both POSTN shRNA and scrambled control vectors have an adenoviral-type 5 (dE1/E3) 
backbone, are regulated by the U6 promoter and co-express green fluorescent protein 
(GFP), allowing for visualization of transduction efficiency by epifluorescent 
microscopy. POSTN and scrambled shRNA sequences (Table 2.10) were analyzed by 
BLAST to confirm that the POSTN shRNA sequence was present in all POSTN variants 
and that the scrambled shRNA sequence was not directed against any known human 
target.  
2.2.11.1 Amplification of adenoviral shRNA constructs 
Adenoviral POSTN and scrambled shRNA vectors were amplified using HEK 293 cells 
(Gift from Dr. Lina Dagnino, Western University, London, ON). HEK 293 cells were 
cultured in 100 mm tissue culture plates to confluency in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 4% FBS. Adenovirus, at a multiplicity of infection 
(MOI) of 2, was added to fresh 4% FBS-DMEM and HEK 293 cells were incubated in 
this inoculum for 4-5 days. When 70% of the cells floated off the plate, cells were 
harvested by rinsing the plate with media. Cells were pelleted by centrifugation at 1300 x 
g for 5 minutes. The media was aspirated and cell pellets were resuspended in 1 ml sterile 
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10% glycerol-PBS. Cell pellets were subjected to four rounds of freeze/thaw cycles using 
liquid nitrogen and a warm water bath. Cell pellets were vortexed gently after each thaw. 
Cellular debris was removed from the samples by centrifugation at 16 000 x g for 10 
minutes and the supernatant containing the virus was stored at -80°C.  
2.2.11.2 GFP adenovirus titering 
Primary hypertrophic scar fibroblasts were seeded in 10% FBS-αMEM in 24-well trays at 
a cell concentration of 100 000 cells/well and cultured overnight at 37°C in 5% CO2. 
Viral dilutions of the amplified stocks were prepared by serially diluting virus in αMEM 
supplemented with 2% FBS. Viral dilutions were added to each well at 300 μl/well in 
triplicate and incubated for 48 hours. After 48 hours, non-transduced cells were collected 
following trypsin digestion and counted using a hemocytometer to obtain a total cell 
count per well. The cells transduced with virus were fixed in 4% paraformaldehyde for 
10 minutes at room temperature. Wells were washed with PBS (3 x 5 minutes) and 
stained with Hoescht for 5 minutes. Wells were then washed in PBS (2 x 5 minutes) and 
imaged using the Olympus IX81 deconvolution microscope (Olympus Corporation, 
Tokyo, Japan). Cell numbers per field were assessed by counting the number of Hoescht 
positive cells. The number of GFP positive-viral transduced cells were counted in the 
same field. The percentage of virus transduced cells was calculated in the lowest viral 
dilution where at least 70% of the cells were transduced. The percentage of viral 
transduced cells per field was multiplied by the total number of cells present in the well 
to determine the total number of cells transduced per well. Using the dilution factor and 
the number of transduced cells, the concentration of the virus was determined. 
2.2.11.3 Multiplicity of infection (MOI) optimization studies 
Primary hypertrophic scar fibroblasts were cultured on 100 mm tissue culture plates in 
10% FBS-αMEM until the cells reached 60% confluence. The media was replaced with 
2% FBS –αMEM containing adenoviral POSTN or scrambled shRNA constructs at an 
MOI of 0, 10, 25, 50 and 100. Cells were cultured for 72 hours at 37°C in 5% CO2. After 
72 hours, cell pellets were collected following digestion with trypsin (5 minutes at 37˚C). 
Total protein and RNA was extracted from cells using methods described in 2.2.6 and 
2.2.7. POSTN expression and periostin levels were assessed in POSTN shRNA treated 
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fibroblasts relative to scrambled shRNA controls using real time PCR and western 
immunoblotting, respectively.  
2.2.11.4 Viral transduction 
Primary fibroblasts were cultured in 10% FBS-αMEM on 100 mm tissue culture plates. 
When 60% confluency was achieved, fibroblasts were transduced with adenovirus 
constructs expressing shRNAs against POSTN or scrambled shRNA controls at an MOI 
of 25 in 2% FBS-αMEM. After 72 hours in culture, fibroblasts were assessed for GFP 
expression using an Olympus IX81 deconvolution microscope to determine transduction 
efficiency. If transduction efficiency was greater than 90%, the cells were collected by 
trypsin digestion and seeded into sFPCLs. 
2.2.12 Immunofluorescence (IF) confocal microscopy 
2.2.12.1 sFPCL setup for immunofluorescence confocal microscopy 
Miniature collagen lattices were cast in 35 mm, poly-D-lysine coated glass bottom tissue 
culture plates with a No.1.5 cover slip with a glass diameter of 10 mm. For each glass 
bottom plate, 1 x10
4
 cells were quickly mixed with 40 μl of type I rat tail collagen (final 
collagen concentration of 1.8 mg/ml), 10 μl of neutralization solution and 2 μg/ml human 
recombinant periostin or vehicle. Collagen lattices were incubated at 37°C in 5% CO2 for 
45 minutes to allow for collagen polymerization. Wells were then flooded with 1 ml 2% 
FBS-αMEM and incubated for 72 hours to achieve a stressed collagen matrix. After 72 
hours, the media was aspirated and lattices were fixed with 4% paraformaldehyde for 10 
minutes at room temperature. Plates were washed with PBS (3 x 5 minutes) and stored in 
70% ethanol at 4°C. 
2.2.12.2 Immunofluorescence staining with two primary antibodies 
from the same host species 
Glass bottom plates were washed with IF-PBS (Table 2.11, 5 x 5 minutes) to remove the 
ethanol. Cell membranes were permeabilized (5 minutes, Table 2.11), washed with IF-
PBS (3 x 5 minutes) and blocked with Background Sniper for 5-10 minutes. Incubation 
with Background Sniper for longer than 10 minutes resulted in loss of signal. Samples 
were washed briefly with IF-PBS and incubated with a primary vinculin antibody (Table 
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2.12) for 1 hour at room temperature in a covered humidity chamber. Samples were 
washed with IF-PBS (3 x 5 minutes) then incubated with an Alexa Fluor 647 conjugated 
secondary antibody (Table 2.13) for 1 hour at room temperature in a covered humidity 
chamber in the dark. Samples were washed with IF-PBS (3 x 5 minutes) then blocked 
with negative control mouse IgG1 (Table 2.12) for 45 minutes at room temperature in a 
covered humidity chamber in the dark. Samples were washed with IF-PBS (3 x 5 
minutes) and incubated with a primary αSMA antibody conjugated to cy3 (Table 2.13) 
for 1 hour at room temperature in a covered humidity chamber in the dark. Samples were 
washed with IF-PBS (3 x 5 minutes), incubated with Hoechst (Table 2.13) for 5 minutes 
in the dark then washed with IF-PBS(2 x 5 minutes). Prolong Gold anti-fade reagent was 
added to the samples and a cover slip was applied over top. Samples were incubated 
overnight at 4° C then coverslips were sealed with nail polish. Samples were stored at 
4°C in the dark.  
2.2.12.3 Imaging and data analysis 
Triple immunofluorescence-labelled cells were observed with a Zeiss LSM 510 Duo 
Vario confocal microscope (Zeiss Canada Inc., Toronto, ON) equipped with three lasers 
used simultaneously; an Argon/2 ion laser, a HeNe laser and a Diode laser (Table 2.13 
for LSM laser lines for excitation and emission filters). All images were captured using a 
40x/1.3 Oil Plan Apochromat objective lens. The pinhole was set to match 1 AU (airy 
unit) to ensure the best signal to noise ratio. Each channel was adjusted for gain and 
digital offset to achieve optimal fluorescent signal using Zen 2009 Software (Zeiss 
Canada Inc., Toronto, ON). Serial optical sections of individual cells were taken in a total 
depth of 3-6 μm with an optimal z-step of 0.38 μm determined by Zen 2009 Software. A 
minimum of 30 images from three different experiments (10 images per experiment) 
were captured per treatment. Images were exported as TIFFs using Zen Software and 
extended depth of field composite images of maximum intensity were generated for 
vinculin stained images using Image-Pro Plus 7.0 (Media Cybernetics, Inc., Rockville, 
MD). Length of focal adhesions (FA), determined by vinculin staining, was manually 
measured using the straight line tool in Image J. The length of vinculin-stained FAs were 
defined by their longest axis regardless of orientation. Total FA numbers, average FA 
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length and the classification of FAs were calculated using Excel. Focal adhesions were 
arbitrarily classified into three categories: immature FAs (≤ 2 μm), mature FAs (2-6 μm) 
and supermature FAs (> 6 μm, (184)). 
2.2.13 Statistical analyses 
Statistics were calculated using SPSS Statistics 17.0 software (IBM Corporation, 
Armonk, NY) and Microsoft Excel 2007 (Microsoft, Redmond, WA). All data sets 
consist of data obtained from a minimum of three patients from three independent 
experiments assessed in triplicate unless otherwise stated. ANOVA of repeated measures 
were used to assess significant treatment effects and significant treatment/time 
interactions to distinguish between overall treatment-induced effects from treatment-
induced effects that become significant over time. When a significant treatment/time 
interaction was observed, simple main effects analyses were further performed to 
determine at which time point treatment had a significant effect. Significant treatment 
effects at individual time points were assessed by paired t-tests. Results were deemed 
significant when p<0.05. 
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Chapter 3  
3 In vitro analysis of the effects of periostin on fibroblast 
proliferation in hypertrophic scarring 
3.1 Rationale 
Excessive fibroblast proliferation is one of the hallmarks of “overhealing” conditions like 
hypertrophic scarring (55, 185, 186).  Periostin has been demonstrated to induce 
proliferation in several cell types including human dermal fibroblasts (152), mouse 
embryonic fibroblasts (152), phenotypically normal palmar fascia fibroblasts from 
patients with Dupuytren’s disease (91), human periodontal ligament fibroblasts (178), 
mouse mesenchymal cells (179), colorectal cancer cells (180), human retinal pigment 
epithelial cells (187) and rat cardiomyocytes (132). Of these previous in vitro studies, 
only two groups (132, 187) have investigated the signalling pathways utilized by 
periostin to induce cellular proliferation. These studies have demonstrated that periostin-
induced human retinal pigment epithelial cell and rat cardiomyocyte proliferation was 
dependent on phosphatidylinositide 3-kinases (PI3K)/Akt activation. However, there 
have been no studies in the literature investigating the effects of periostin on hypertrophic 
scar-derived fibroblast proliferation or the signalling intermediates activated by it, nor 
have these pathways been assessed in fibroblasts grown on physiologically relevant 
culture substrates. Since periostin has been demonstrated to induce proliferation in other 
cell types, it was hypothesized that periostin contributes to the excessive fibroblast 
proliferation characteristically observed in hypertrophic scarring. 
The aim of this chapter is to describe the effects of periostin on hypertrophic scar (HTS)- 
and normal skin (NS)-derived fibroblast proliferation and to identify potential signalling 
pathways utilized by periostin to elicit these effects.  
3.2 Assessment of POSTN expression and periostin levels 
in fibroblasts derived from hypertrophic scar tissue 
Previous in situ hybridization studies performed in our laboratory demonstrated that 
POSTN expression was upregulated and persistent in keratinocytes in the basal stratum 
58 
 
and in dermal fibroblasts in hypertrophic scar tissue relative to normal scar tissue (96), 
consistent with a previous report (99). To confirm the increased expression of POSTN in 
primary HTS-derived fibroblasts relative to fibroblasts derived from NS, real time PCR 
for POSTN expression was performed as described in 2.2.7.2. POSTN expression was 
increased approximately six fold in primary fibroblasts derived from HTS tissue relative 
to NS tissue (Figure 3.1a, N=1 patient, n=1). These findings were consistent with our 
previous in vivo studies (96) and previously published data (99). 
In parallel, western immunoblotting studies were performed to assess the levels of 
periostin in primary fibroblasts derived from HTS and NS tissue. Alternative splicing in 
the C-terminal region of POSTN results in periostin isoforms that range in size from 83-
93 kDa (115). Western immunoblotting of total cell lysates with a periostin-specific 
antibody revealed two bands approximately 85 and 90 kDa in size. Densitometry analysis 
of both bands revealed that periostin levels were increased approximately five fold in 
primary fibroblasts derived from HTS tissue relative to NS tissue (Figure 3.1b, N=2 
patient, n=1). These findings are consistent with previous immunohistochemistry studies 
performed by our group (95, 96) and others (97) that demonstrated that periostin was 
abnormally abundant in the dermis of hypertrophic and keloid scar tissue.  
3.3 Identification of POSTN variants in fibroblasts derived 
from hypertrophic scar tissue 
Up to eight human POSTN variants have been reported in various systems to date (101, 
102, 116, 117, 188-190). To determine which POSTN variants were present in abnormal 
scar tissue, total RNA was extracted from HTS fibroblasts and amplified by reverse-
transcription PCR. Forward and reverse primers designed to anneal to regions outside of 
the variable region in the C-terminal domain, as described in 2.2.7.3 (Figure 3.2a), 
revealed four amplicons (variants 1-4) representing four human POSTN variants 
originally reported by Horiuchi et al., (101) in human placental and osteosarcoma cDNA 
libraries (Figure 3.2b, N=2 patients, n=1). The predicted amplicon sizes were 1120 base 
pairs (bp) for variant 1, 946 bp for variant 2, 955 bp for variant 3 and 865 bp for variant 
4. The identity of each POSTN variant was confirmed by DNA sequencing. Although not  
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Figure 3.1 POSTN expression and periostin levels are abundant in primary 
fibroblasts derived from hypertrophic scar tissue.  Primary hypertrophic scar (HTS)- 
and normal skin (NS)-derived fibroblasts were cultured on two-dimensional collagen 
substrates for 72 hours in 10% FBS-αMEM. (a) POSTN expression was assessed in total 
RNA by real time PCR as described in 2.2.7.2. As shown, POSTN expression was 
increased approximately five to six fold in HTS fibroblasts relative to NS fibroblasts. 
Expression data are normalized to NS (N=1 patient, n=1). (b) Periostin levels were 
assessed in total cell lysates by western immunoblotting and densitometry as described in 
2.2.6. Periostin levels were increased five to six fold in HTS fibroblasts relative to NS 
fibroblasts. Values were normalized to NS patient 11 (N=2 patients, n=1). β-actin 
immunoreactivity was assessed to ensure equal protein loading. Human recombinant 
periostin (1 µg/ml, hrPN) was used as a positive control. Data are represented by mean 
values and SEM. RQ= relative quantification, AU= arbitrary units. 
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Figure 3.2 POSTN variant 1 is the most abundant transcript in hypertrophic scar 
fibroblasts. (a) Schematic representation of POSTN variants 1-4 and location of PCR 
primers within the cDNA (red arrows). Breaks in black bars represent deleted exon 
cassettes through alternative splicing. (b) Primary hypertrophic scar (HTS)-derived 
fibroblasts were cultured on two-dimensional collagen substrates for 72 hours in 10% 
FBS-αMEM. POSTN variants were assessed by reverse-transcription PCR of total RNA 
using primers designed to amplify the alternatively spliced C-terminal region. The 
identity of the largest MW amplicon was confirmed as isoform 1 by DNA sequencing 
(N=2 patients, n=1). MW= molecular weight ladder, bp= base pairs. 
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quantitative, these PCR analyses were performed using a single primer set and the 
relative intensity of each amplicon was predicted to approximate the amount of each 
variant in the sample. Based on this assumption, POSTN variant 1 was identified as the 
most abundant POSTN variant in hypertrophic scars. Western immunoblotting studies 
confirmed the most abundant periostin isoform in HTS cells was the same molecular 
weight as human recombinant periostin variant 1 (Figure 3.1b, N=2 patients, n=1).  
3.4 Assessment of the basal proliferation rates of 
hypertrophic scar- and normal skin-derived fibroblasts 
in 2D collagen cultures 
The “basal” (unstimulated) proliferation rates of primary fibroblasts derived from HTS 
and NS tissue were assessed on type I collagen substrates using the water soluble 
tetrazolium-1 (WST-1) proliferation assay as described in 2.2.4. Primary fibroblasts were 
seeded onto a thin two-dimensional (2D) type I collagen substrate in 2% FBS-αMEM and 
proliferation was assessed over a seven day period.  As shown in Figure 3.3a, no 
significant differences between the basal proliferation rates of HTS and NS fibroblasts 
were observed over the course of the assay (N=3 patients, n=3).  
3.5 Assessment of the effects of periostin on hypertrophic 
scar and normal skin fibroblast proliferation in 2D 
collagen cultures 
To determine the effects of periostin on fibroblast proliferation, primary HTS and NS 
fibroblasts were seeded onto a type I collagen substrate containing 2 μg/ml human 
recombinant periostin or vehicle (PBS with 0.1% BSA) and proliferation was assessed 
over a seven day period using the WST-1 proliferation assay (2.2.4). A significant 
interaction between periostin treatment and time was observed (p<0.05) and the presence 
of periostin in the culture substrate enhanced HTS fibroblast proliferation over a seven 
day period relative to vehicle controls with significant differences evident at day five and 
seven (Figure 3.3b, p<0.05, N=3 patients, n=3). In contrast, exogenous periostin 
treatment had no discernible effect on the proliferation of normal skin fibroblasts under 
identical culture conditions (Figure 3.3c, N=3 patients, n=3).  
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Figure 3.3 Periostin enhances the proliferation of hypertrophic scar-derived 
fibroblasts. Primary hypertrophic scar (HTS)- and normal skin (NS)-derived fibroblast 
proliferation was assessed using the WST-1 proliferation assay described in 2.2.4. 
Primary fibroblasts were seeded onto a two-dimensional type 1 collagen substrate 
containing periostin (PN, 2µg/ml) or vehicle (veh, 0.1% BSA in PBS) and proliferation 
was assessed over seven days. (a) No significant differences between the basal 
proliferation rates of HTS and NS fibroblasts were observed (N=3 patients each, n=3). (b) 
Incorporation of exogenous periostin into two-dimensional collagen lattices significantly 
enhanced HTS fibroblast proliferation relative to vehicle controls over a seven day period 
(N=3 patients, n=3). (c) Exogenous periostin treatment had no discernible effect on NS 
fibroblast proliferation under identical culture conditions (N=3 patients, n=3). Significant 
treatment/time interactions are denoted by #p<0.05 (ANOVA of repeated measures). 
Significant treatment effects at individual time points are denoted as *p<0.05 (simple 
main effects analyses). Data are presented by mean difference scores relative to day one 
absorbance readings and SEM.  
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3.6 Identification of the signalling pathway(s) utilized by 
periostin to induce hypertrophic scar fibroblast 
proliferation in 2D collagen cultures 
A central aim of this chapter was to identify the signalling intermediates utilized by 
periostin to induce the proliferation of HTS fibroblasts. To achieve this, a series of 
pharmacological inhibitors were assessed. These inhibitors were targeted against 
signalling intermediates previously shown to be activated by periostin or other mitogens.  
3.6.1 Assessment of PI3K inhibition effects on periostin-induced 
HTS fibroblast proliferation.  
LY294002 is a small molecule inhibitor that competes with the ATP binding site in the 
catalytic domain of PI3K. To determine if periostin signalling required PI3K activity to 
enhance proliferation, LY294002 and periostin (2 µg/ml) were included in a subset of 
cultures of HTS fibroblasts and proliferation was assessed using WST-1 assays. 10 µM 
LY294002 was used in these experiments as this concentration has been demonstrated to 
inhibit human fibroblast proliferation in other systems (191-193). LY294002 has modest 
off-target effects at this concentration (194). As shown in Figure 3.4a, a significant 
interaction between LY294002 treatment and time was observed (p<0.05) and PI3K 
inhibition attenuated periostin-induced HTS fibroblast proliferation over seven days 
relative to vehicle controls with significant differences evident at day three and seven 
(p<0.01, N=3 patients, n=3). Similarly, a significant LY294002 treatment and time 
interaction was observed (p<0.05) and LY294002 treatment was found to attenuate basal 
HTS fibroblast proliferation over the course of the assay relative to vehicle controls with 
significant effects observed at day five and seven (Figure 3.4b, p<0.05, N=3 patients, 
n=3). 
3.6.2 Assessment of Akt inhibition effects on periostin-induced 
HTS fibroblast proliferation 
Akt inhibitor VIII is a small molecule inhibitor that binds to the pleckstrin homology 
domain of Akt and prevents activation by PI3K. To determine if periostin signalling 
required Akt activity to enhance HTS fibroblast proliferation, Akt inhibitor VIII and  
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Figure 3.4 Inhibition of phosphatidylinositide 3-kinases attenuates periostin-induced 
and basal hypertrophic scar fibroblast proliferation. Primary hypertrophic scar 
(HTS)-derived fibroblasts were cultured onto two-dimensional collagen substrates 
containing periostin (PN, 2 µg/ml) or vehicle (veh). Culture medium was supplemented 
with 10 µM LY294002 (PI3Ki) or DMSO control and proliferation was assessed in 
WST-1 assays. As shown in (a), PI3K inhibition significantly attenuated PN-induced 
HTS fibroblast proliferation relative to vehicle controls (N=3 patients, n=3). (b) PI3K 
inhibition significantly attenuated basal proliferation over a seven day period relative to 
vehicle controls (N=3 patients, n=3). Significant treatment/time interactions are denoted 
by #p<0.05 (ANOVA of repeated measures). Significant treatment effects at individual 
time points are denoted by *p<0.05, **p<0.01 and ***p<0.001 (simple main effects 
analyses). Data are presented by mean difference scores relative to day one absorbance 
readings and SEM. 
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Figure 3.5 Inhibition of Akt attenuates periostin-induced hypertrophic scar 
fibroblast proliferation. Primary hypertrophic scar (HTS)-derived fibroblasts were 
cultured on two-dimensional collagen substrates containing periostin (PN, 2 µg/ml) or 
vehicle (veh). Culture medium was supplemented with 0.5 µM Akt inhibitor VIII (Akti) 
or DMSO and proliferation was assessed in WST-1 assays. (a) Akt inhibition 
significantly attenuated PN-induced HTS fibroblast proliferation over seven days relative 
to vehicle controls (N=3 patients, n=3). (b) Akt inhibition had no discernible effects on 
basal HTS fibroblast proliferation over seven days relative to vehicle controls (N=3 
patients, n=3). Significant treatment/time interactions are denoted by #p<0.05 (ANOVA 
of repeated measures). Significant treatment effects at individual time points are denoted 
by *p<0.05 (simple main effects analyses). Data are presented by mean difference scores 
relative to day one absorbance readings and SEM. (c) Primary HTS fibroblasts were 
cultured on two-dimensional collagen cultures for 72 hours, washed overnight in serum-
free medium and treated with 2 µg/ml PN or vehicle for 60 minutes in serum-free 
medium. Total cell lysates were assessed for phosphorylated (ser 473) and total Akt 
immunoreactivity by western immunoblotting as described in 2.2.6. Exogenous PN 
treatment had no effect on Akt activation (N=1 patient, n=3). β-actin immunoreactivity 
was assessed to ensure equal protein loading. Representative immunoblots are shown. 
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periostin (2 µg/ml) were included in a subset of cultures of HTS fibroblasts and 
proliferation was assessed using WST-1 assays. 0.5 µM Akt inhibitor VIII was used in 
these experiments based on previous studies investigating the effect of Akt inhibition on 
B-cell proliferation (195). At 1 µM, Akt inhibitor VIII does not significantly inhibit other 
kinases (194). A significant interaction between Akt inhibitor VIII treatment and time 
was observed (p<0.05) and Akt inhibition attenuated periostin-induced HTS fibroblast 
proliferation over the course of the assay relative to vehicle controls with significant 
differences evident at day seven (Figure 3.5a, p<0.05, N=3 patients, n=3). In contrast, 
Akt inhibition had no discernible effects on the proliferation of untreated HTS fibroblasts 
(Figure 3.5b, N=3 patients, n=3). In addition to WST-1 proliferation assays, western 
immunoblotting was performed to determine if exogenous periostin treatment induced the 
phosphorylation of Akt at serine 473. As shown in Figure 3.5c, addition of periostin had 
no discernible effects on the phosphorylation of serine 473 in HTS fibroblasts after 
treatment with periostin in media for 60 minutes relative to vehicle controls (N=1 patient, 
n=3).  
3.6.3 Assessment of Glycogen synthase kinase - 3 beta (GSK-3β) 
inhibition effects on periostin-induced HTS fibroblast 
proliferation 
GSK-3β inhibitor VIII is a small molecule inhibitor that competes with the ATP binding 
site in the catalytic domain of GSK-3β. To determine if periostin signalling required 
GSK-3β activity to promote HTS fibroblast proliferation, GSK-3β inhibitor VIII and 
periostin (2 µg/ml) were included in a subset of cultures of HTS fibroblasts and 
proliferation was assessed using WST-1 assays. 1 µM GSK-3β inhibitor VIII was used in 
these experiments as this concentration has been demonstrated to enhance prostate cancer 
cell proliferation (196). GSK-3β inhibitor VIII has no discernible off-target effects at 
concentrations up to 10 µM (194). GSK-3β inhibition had no discernible effects on 
periostin-induced or basal HTS fibroblasts proliferation relative to vehicle controls 
(Figure 3.6a and b, N=3 patients, n=3). In addition to WST-1 proliferation assays, 
western immunoblotting studies were performed to determine if exogenous periostin 
treatment increased β-catenin levels or the phosphorylation of GSK-3β at serine 9. As 
shown in Figure 3.6c, addition of periostin did not enhance β-catenin levels or induce  
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Figure 3.6 Glycogen synthase kinase–3 beta inhibition had no effect on hypertrophic 
scar fibroblast proliferation. Primary hypertrophic scar (HTS)-derived fibroblasts were 
cultured onto two-dimensional collagen substrates containing periostin (PN, 2 µg/ml) or 
vehicle (veh). Culture medium was supplemented with 1 µM GSK-3β inhibitor VIII 
(GSK-3βi) or DMSO and proliferation was assessed in WST-1 assays. GSK-3β inhibition 
had no discernible effect on (a) PN-induced or (b) basal HTS fibroblast proliferation 
relative to vehicle controls (N=3 patients, n=3). Data are presented by mean difference 
scores relative to day one absorbance readings and SEM. (c) Primary HTS fibroblasts 
were cultured on two- dimensional collagen cultures for 72 hours, washed overnight in 
serum-free medium and treated with 2 µg/ml PN or vehicle for 60 minutes in serum-free 
medium. Total cell lysates were extracted and assessed for β-catenin and total and 
phosphorylated (ser 9) GSK-3β immunoreactivity by western immunoblotting as 
described in 2.2.6. Exogenous PN treatment did not affect β-catenin levels or induce 
GSK-3β phosphorylation relative to vehicle controls (N=1 patient, n=3). (d) Positive 
control demonstrating that 1 µM GSK-3β inhibitor VIII was effective in inhibiting GSK-
3β activity by increasing β-catenin levels. β-actin immunoreactivity was assessed to 
ensure equal protein loading. Representation immunoblots are shown. 
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GSK-3β phosphorylation at serine 9 in HTS fibroblasts after exposure to periostin in 
media for 60 minutes relative to vehicle controls (N=1 patient, n=3).  
3.6.4 Assessment of Rho kinase (ROCK) inhibition effects on 
periostin-induced HTS fibroblast proliferation. 
Y27632 is a small molecule inhibitor that competes with the ATP binding site in the 
catalytic domain of ROCK. To determine if periostin signalling required ROCK activity 
to enhance HTS fibroblast proliferation, Y27632 and periostin (2 µg/ml) were included in 
a subset of cultures of HTS fibroblasts and proliferation was assessed using WST-1 
assays. 10 µM Y27632 was used in these experiments which has been demonstrated to 
inhibit NIH 3T3 and human gingival fibroblast proliferation (197, 198). Y27632 has 
modest off-target effects at this concentration (194). A significant interaction between 
Y27632 treatment and time was observed (p<0.05) and ROCK inhibition significantly 
attenuated periostin-induced HTS fibroblast proliferation over seven days relative to 
vehicle controls with a strong trend (p=0.051) towards decreased proliferation evident at 
day seven (Figure 3.7a, N=3 patients, n=3). In contrast, ROCK inhibition had no 
discernible effects on the basal proliferation of HTS fibroblasts cultured under identical 
conditions (Figure 3.7b, N=3 patients, n=3). In parallel, western immunoblotting was 
performed to determine if exogenous periostin treatment induced the phosphorylation of 
myosin light chain (MLC), an established downstream target of ROCK. MLC 
phosphorylation at serine 19 was not detected under these culture conditions (data not 
shown).  
3.6.5 Extracellular signal-regulated kinase (ERK) inhibition effects 
on periostin-induced HTS fibroblast proliferation 
ROCK has previously been shown to enhance proliferation through ERK (197-201). 
Therefore, the effects of ERK inhibition were assessed on periostin-induced HTS 
fibroblast proliferation. PD98059 is a small molecule inhibitor that prevents binding and 
activation of ERK1/2 by the ERK specific mitogen-activated protein kinase, MEK. To 
determine if periostin signalling required ERK1/2 activity to promote HTS fibroblast 
proliferation, PD98059 and periostin (2 µg/ml) were included in a subset of cultures of  
69 
 
 
Figure 3.7 Rho kinase inhibition attenuates periostin-induced hypertrophic scar 
fibroblast proliferation. Primary hypertrophic scar (HTS)-derived fibroblasts were 
cultured onto two-dimensional collagen substrates containing periostin (PN, 2 µg/ml) or 
vehicle (veh). Culture medium was supplemented with 10 µM Y27632 (ROCKi) or 
vehicle and proliferation was assessed in WST-1 assays. (a) ROCK inhibition 
significantly attenuated PN-induced HTS fibroblast proliferation relative to vehicle 
controls over the course of the assay (N=3 patients, n=3). (b) In contrast, ROCK 
inhibition had no discernible effect on basal HTS fibroblast proliferation (N=3 patients, 
n=3). Significant treatment/time interactions are denoted by #p<0.05 (ANOVA of 
repeated measures). Data are presented by mean difference scores relative to day one 
absorbance readings and SEM.  
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Figure 3.8 Extracellular signal-regulated kinase inhibition had no effect on basal or 
periostin-induced hypertrophic scar fibroblast proliferation. Primary hypertrophic 
scar (HTS)-derived fibroblasts were cultured on two-dimensional collagen substrates 
containing periostin (PN, 2 µg/ml) or vehicle (veh). Culture medium was supplemented 
with 20 µM PD98059 (ERKi) or DMSO and proliferation was assessed in WST-1 assays. 
ERK inhibition had no discernible effect on (a) PN-induced or (b) basal HTS fibroblast 
proliferation over the course of the assay relative to vehicle controls (N=3 patients, n=3). 
Data are presented by mean difference scores relative to day one absorbance readings and 
SEM. (c) Primary HTS fibroblasts were cultured on two-dimensional collagen cultures 
for 72 hours, washed overnight in serum-free medium and treated with 2 µg/ml PN or 
vehicle for 60 minutes in serum-free medium. Total cell lysates were assessed for total 
and phosphorylated (thr 202/tyr 204, thr185/tyr187) ERK immunoreactivity by western 
immunoblotting as described in 2.2.6. Exogenous PN treatment did not enhance ERK 
phosphorylation relative to vehicle controls (N=1 patient, n=3). (d) Positive control 
demonstrating that 20 µM ERK inhibitor, PD98059, was effective at inhibiting TGFβ-1-
induced ERK1/2 phosphorylation. β-actin immunoreactivity was assessed to ensure equal 
protein loading. Representative immunoblots are shown. 
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HTS fibroblasts and proliferation was assessed using WST-1 assays. 20 µM PD98059 
was used in these experiments based on previous studies investigating the effects of ERK 
inhibition on human cardiac and dermal fibroblast proliferation (195). At 50 µM, 
PD98059 has no discernible off-target effects (202).  Inhibition of ERK activity had no 
discernible effects on periostin-induced or basal HTS fibroblast proliferation relative to 
vehicle controls (Figure 3.8a and b, N=3 patients, n=3). In parallel, western 
immunoblotting studies were performed to determine if exogenous periostin treatment 
induced the phosphorylation of ERK1/2. As shown in Figure 3.8c, periostin treatment did 
not increase ERK1/2 phosphorylation relative to vehicle controls after exposure to 
periostin in media for 60 minutes (N=1 patient, n=3). 
3.7 Discussion 
A central hypothesis of this thesis was that periostin contributes to excessive fibroblast 
proliferation in hypertrophic scarring. The in vitro studies presented in this chapter 
demonstrate that exogenous periostin treatment was able to enhance the proliferation of 
fibroblasts derived from abnormal scar tissue, supporting the central hypothesis. Periostin 
appears to elicit this effect in HTS fibroblasts through Akt and ROCK dependent 
pathways.  In contrast, exogenous periostin had no discernible effects on the proliferation 
of NS fibroblasts cultured under identical conditions on type I collagen substrates.  
One of the molecular features of hypertrophic scarring is the increased expression of 
POSTN and the abnormal abundance and persistence of its protein product, periostin.  
Real time PCR and western immunoblotting studies indicated that POSTN expression and 
periostin levels were increased in primary fibroblasts derived from HTS tissue relative to 
NS tissue in in vitro cultures. These data are consistent with previous in vivo studies 
performed by our laboratory (95, 96) and by other groups (97, 99) which demonstrated 
that POSTN expression is markedly increased in the basal epithelium and in dermal 
fibroblasts, and that periostin is abnormally abundant in the dermis of hypertrophic scar 
tissue relative to normal scar tissue. These findings indicate that POSTN expression and 
periostin levels in primary fibroblasts derived from NS and HTS tissues reflect the tissues 
from whence they were derived and these cells are therefore likely to be representative in 
vitro models of scarring. 
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As discussed in section 1.6.1, POSTN is alternatively spliced and up to eight human 
POSTN variants have been reported (101, 102, 116, 117, 188-190). The expression and 
function of these variants is currently unclear and the identity of specific POSTN variants 
expressed in hypertrophic scarring has not been previously reported. With reverse-
transcription PCR, four amplicons were identified in total RNA extracted from HTS 
fibroblasts, and these amplicons corresponded to four of the POSTN variants previously 
identified (101). The largest and most abundant of these amplicons was identified as 
POSTN variant 1 by DNA sequencing. In addition, three additional splice variants (2, 3 
and 4) were detected in HTS fibroblasts and sequenced.  To our knowledge, this is the 
first study to identify different POSTN variants in hypertrophic scarring. Comparisons 
between the immunoreactivity of recombinant periostin and the endogenously produced 
periostin in human hypertrophic scar tissue lysates revealed that 2 µg/ml of recombinant 
periostin approximated the levels of periostin in hypertrophic scars in vivo (91, 96). 
Based on these findings, the effects of treating HTS and NS fibroblasts with recombinant 
periostin isoform 1 at 2 µg/ml were investigated in the remainder of the thesis. 
A small number of in vitro studies have assessed the effects of periostin on proliferation 
in cells cultured on substrates that mimic the microenvironment (91, 203). However, the 
majority of in vitro studies (132, 152, 178-180, 187) have assessed periostin effects on 
proliferation in cells cultured on rigid tissue culture plastic. Tissue culture plastic 
provides an extremely stiff substrate that greatly exceeds the stiffness of the ECM of 
contracting or fibrotic tissues in vivo (169, 170) and invariably leads to robust 
myofibroblast differentiation in fibroblast cultures (31). Therefore, culturing primary 
fibroblasts on plastic substrates may provide misleading information derived from the 
differences in fibroblast and myofibroblast sensitivities to treatments. For this reason, the 
effects of periostin on HTS fibroblast proliferation was assessed on type I collagen 
substrates, the most abundant collagen in normal skin and mature scar tissue (8). As a 
matricellular protein, periostin serves as a link between cells and their collagenous ECM, 
and it can modify cellular behavior in response to external stimuli, including changes in 
ECM stiffness (90). Using collagen substrates, periostin can be incorporated into a 
collagenous ECM matrix to mimic its localization in vivo and provide a model system to 
assess the effects of ECM-associated periostin on HTS fibroblast proliferation under 
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physiological relevant conditions. Compliant 2D collagen gels have a Young’s modulus 
of 300-400 Pa, which is equivalent to the ECM stiffness found in the provisional matrix 
in vivo (31, 173). Since fibroblasts are recruited to a similarly compliant provisional 
matrix during cutaneous wound healing (8), 2D collagen substrates provide a more 
physiologically representative in vitro model. 
Fibroblast proliferation was assessed using the WST-1 proliferation assay, which 
measures cellular mitochondrial activity as an indicator of net cellular proliferation (the 
combined effects of growth and apoptosis). While this approach provides an indirect 
measure of proliferation, it is an optimal approach in this context because it avoids the 
need to disrupt cellular interactions with periostin embedded into the collagen substrate. 
Optimization studies in our laboratory have demonstrated a linear correlation between 
manual cell counts and WST-1 absorbance over a range of 0.03 to 0.4 absorbance units at 
450 nm with every 0.038 nm correlating to approximately 1000 cells (data not shown). In 
addition, WST-1 absorbance values plateau in HTS fibroblasts cultured in the presence of 
mitomycin C, an established inhibitor of cellular proliferation (204), on 2D collagen 
substrates (data not shown). These findings indicate that this assay is a representative 
measure of cellular proliferation under these culture conditions. 
Periostin has been demonstrated to induce the proliferation of various cell types in other 
culture systems (91, 132, 152, 178-180, 187). The data presented in this chapter indicates 
that exogenous ECM-associated periostin significantly enhances HTS fibroblast 
proliferation on 2D compliant collagen cultures. Based on these findings and the 
accumulation of periostin in the dermis of excisional mouse wounds as early as three 
days post wounding (98, 151), periostin may act as a growth factor during the initial 
stages of wound healing to increase fibroblast numbers at the wound site. Fibroblast 
proliferation in the provisional matrix and newly formed granulation tissue is vital for the 
regeneration of a functional dermis (8). Therefore, the persistent and abundant levels of 
periostin observed in the dermis of hypertrophic scars may continue to promote excessive 
fibroblast proliferation after wound closure. Excessive fibroblast proliferation at the 
wound site would be predicted to enhance the dermal density of the wound to abnormal 
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levels and promote excessive myofibroblast differentiation, thereby enhancing 
hypertrophic scar formation.  
In contrast to HTS fibroblasts, exogenous periostin treatment had no effect on the 
proliferation of NS fibroblasts. The mechanisms that explain these differences in 
sensitivity to periostin between HTS and NS fibroblasts have yet to be elucidated. One 
possibility is that a combination of fibrosis-associated growth factors is required to 
“activate” NS fibroblasts to induce periostin sensitivity in these cells. This activation may 
include the expression of a receptor(s) or other interacting molecules not normally 
present in unwounded NS fibroblasts, or activation of a sequential or parallel pathway(s) 
required for periostin signalling. These possibilities are further addressed in Chapter 4.6. 
As NS fibroblasts appear relatively insensitive to ECM-associated periostin under these 
culture conditions, that may suggest that periostin promotes pathological, rather than 
normal, fibroblast proliferation. It remains unclear if periostin-induced fibroblast 
proliferation is a normal or abnormal component of cutaneous wound healing in humans, 
as normal scar tissue samples could not be obtained for primary cell derivation due to 
ethical constraints. Collectively, these studies indicate that periostin specifically enhances 
the growth of abnormal scar-derived fibroblasts cultured on 2D collagen substrates. 
Therefore, periostin may be an attractive therapeutic target for therapies designed to 
inhibit excessive fibroblast proliferation characteristically observed in hypertrophic 
scarring.  
The second component of this chapter was to identify the signalling intermediates utilized 
by periostin to promote HTS fibroblast proliferation on 2D collagen cultures. As periostin 
has been demonstrated to signal through the PI3K/Akt pathway to elicit tumour growth 
(129-131) and proliferation of several cell types in vitro (132, 187), initial studies focused 
on these intermediates.  PI3K inhibition was shown to significantly attenuate both basal 
and periostin-induced HTS fibroblast proliferation. These data were interpreted to 
indicate that PI3K inhibition attenuates multiple pathways involved in cellular 
proliferation and is therefore unlikely to be helpful for distinguishing the specific effects 
of periostin from other signalling pathways that also induce proliferation in a PI3K 
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dependent manner. Therefore, the effects of Akt inhibition, an established downstream 
target of PI3K (205), were assessed on periostin-induced HTS fibroblast proliferation. 
Akt inhibition significantly attenuated periostin-induced HTS fibroblast proliferation 
while having no discernible effects on basal proliferation. These data are consistent with 
previous reports demonstrating that periostin promoted the proliferation of rat 
cardiomyocytes and retinal pigment epithelial cells through a PI3K/Akt dependent 
pathway (132, 187). Although significant, the effects of Akt inhibition on periostin-
induced HTS fibroblast proliferation were quite modest and proliferation was attenuated 
by approximately 19% over seven days relative to vehicle controls. The modest 
cumulative reduction in proliferation across seven days led to the conclusion that Akt was 
not the major signalling pathway intermediate utilized for periostin-induced HTS 
fibroblast proliferation under these culture conditions.  
While Akt inhibition significantly attenuated periostin-induced HTS fibroblast 
proliferation using WST-1 assays, no evidence of periostin-induced Akt activation was 
observed by western immunoblotting. These findings are inconsistent with previous 
reports demonstrating that periostin enhanced Akt activation in other systems (130, 152, 
187). The contrasting findings between the WST-1 and western immunoblotting studies 
may be explained by the technical limitations of assessing matricellular interactions by 
western immunoblotting. Unlike the WST-1 assays, where periostin was incorporated 
into a collagen-rich matrix where it was constantly available to stimulate proliferation, it 
was necessary to add periostin directly to the culture medium to assay for rapid changes 
in Akt phosphorylation by western immunoblotting. Fibroblast attachment and spreading 
onto collagen substrates after seeding takes several hours. If periostin was incorporated 
into the collagen substrates prior to seeding, HTS fibroblasts would be exposed to 
periostin throughout the attachment and spreading process. Once these fibroblasts had 
achieved normal morphology, any effects of periostin on Akt activation may no longer be 
detectable, as Akt phosphorylation is typically rapid and transient. Therefore, periostin 
was added to the culture medium after the fibroblasts achieved normal morphology (130, 
152, 187) in order to assess its effects on Akt activation. As it is a matricellular protein, 
periostin interacts with cells while attached to the surrounding ECM and modifies cellular 
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signalling and phenotype in response to changes in the microenvironment (90). It is 
plausible that soluble periostin (added to the culture medium) is functionally distinct from 
ECM-associated periostin and this may explain why no changes in kinase 
phosphorylation were detected. 
To identify additional signalling pathway(s) utilized by periostin to induce HTS 
fibroblast proliferation, a series of pharmacological inhibitors targeted against GSK-3β, 
ROCK and ERK1/2, each of which are established signalling intermediates in cellular 
proliferation (201, 206, 207), were assessed. These studies demonstrated that inhibition 
of GSK-3β and ERK had no discernible effects on basal or periostin-induced HTS 
fibroblast proliferation in 2D collagen cultures, whereas ROCK inhibition significantly 
attenuated periostin-induced HTS fibroblast proliferation.   
In addition to its well established roles in mediating stress fiber formation, focal adhesion 
formation and contraction of myofibroblasts (49-53, 208, 209), ROCK has also been 
shown to mediate proliferation in corneal epithelial cells (200, 210), neuroblastoma cells 
(211), hepatic stellate cells (201) and NIH 3T3 mouse fibroblasts (197). The ROCK 
specific inhibitor, Y27632, used for the studies in Chapter 3 had no effect on basal levels 
of proliferation relative to vehicle treated HTS fibroblasts, consistent with previous 
reports in corneal epithelial cells and neuroblastoma cells (210, 211). These data 
demonstrate that ROCK signalling is not essential for basal HTS fibroblast proliferation. 
However, ROCK inhibition significantly attenuated periostin-induced HTS fibroblast 
proliferation and this effect was more pronounced than that observed with Akt inhibition 
(37% decrease vs 19% decrease in proliferation over seven days). These data indicate that 
periostin also promotes HTS fibroblast proliferation in 2D collagen cultures through a 
ROCK dependent pathway. To our knowledge, this is the first study to identify ROCK as 
a signalling intermediate in periostin-induced proliferation in any model system. 
Previous studies have demonstrated that ROCK induces the expression of cell cycle 
progression proteins, including cyclin D1, through a Ras/ERK mediated pathway (197-
201). However, ERK inhibition had no discernible effect on periostin-induced HTS 
fibroblast proliferation. Parallel studies of CCND1 expression, encoding cyclin D1, were 
77 
 
performed by culturing HTS fibroblasts in serum free media for 72 hours in order to 
synchronize the fibroblasts in G0 prior to stimulation with serum and soluble periostin. 
No effects on CCND1 expression were evident in periostin treated samples relative to 
serum controls after 3 hours (data not shown). As described for the western 
immunoblotting assays for Akt activity, periostin was not incorporated in the collagen 
substrates in these experiments, as it was necessary to synchronize the cells in G0 prior to 
periostin stimulation. HTS fibroblasts secrete high levels of endogenous periostin, so it is 
very likely that these cells were exposed to periostin during the synchronization process 
prior to treatment, making these experiments difficult to interpret. It is currently unclear 
if soluble and ECM-associated periostin have differential effects on the behavior of HTS 
fibroblasts. Exposure to periostin during the synchronization process and treatment with 
soluble periostin may explain why CCND1 expression was not altered in these 
experiments. The downstream mechanisms involved in ROCK-dependent periostin-
induced HTS fibroblast proliferation will be a focus of future studies.  
Previous studies have reported conflicting data in regards to the regulation of ROCK 
activity by PI3K activation (130, 212, 213), and this interaction may be dependent on 
particular cell type and/or specific treatment conditions (214). As PI3K inhibition 
significantly attenuated HTS fibroblast proliferation, it is conceivable that PI3K 
activation may be involved in periostin-induced ROCK activation in 2D collagen 
cultures. Future studies, outside the scope of this thesis, will investigate whether PI3K or 
a parallel pathway activates ROCK to promote periostin-induced HTS fibroblast 
proliferation in 2D collagen cultures.  
In summary, periostin enhances HTS fibroblast proliferation in 2D collagen cultures that 
mimic the mechanical tension of the provisional matrix in the early stages of cutaneous 
wound healing in vivo (31, 173). As a hallmark of abnormal scarring, excessive fibroblast 
proliferation increases cell density and ECM deposition in the wound thereby increasing 
the number of cells available for myofibroblast differentiation and promoting abnormal 
dermal density. These studies demonstrate that periostin promotes HTS fibroblast 
proliferation through an Akt dependent pathway, consistent with previous reports (132, 
187). Furthermore, periostin was shown for the first time to enhance HTS fibroblast 
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proliferation through a ROCK dependent pathway. As ROCK is better known as an 
essential component of myofibroblast differentiation and contraction (30), and since 
myofibroblasts are the cellular cause of excessive contraction and remodelling of the 
dermis during scar formation, the remainder of this thesis focuses on the roles of periostin 
on myofibroblast differentiation and persistence. 
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Chapter 4  
4 In vitro analysis of the effects of periostin on 
myofibroblast differentiation and persistence in 
hypertrophic scarring 
4.1 Rationale 
The myofibroblast is a major cellular contributor in both normal cutaneous wound 
healing and abnormal scar formation (27, 28, 56-58). Myofibroblasts combine the 
contractile features of smooth muscle cells with the extensive ECM production of 
fibroblasts, thereby allowing them to deposit, contract and remodel granulation tissue (29, 
31). In normal cutaneous wound healing, myofibroblast numbers increase during the 
proliferation phase and gradually undergo apoptosis in the remodelling phase. However, 
in abnormal scarring conditions, myofibroblast populations are maintained at high levels 
(56, 57, 92-94) due, at least in part, to a prolonged proliferation phase (59). An abnormal 
excess of myofibroblasts results in an “overhealing” phenomenon characterized by 
excessive collagen production and contracture of the ECM (56, 57, 92-94). The 
molecules that promote excessive myofibroblast differentiation and their persistence 
during hypertrophic scar formation are unclear. 
Previous studies have demonstrated that periostin induces myofibroblast differentiation in 
animal models of normal cutaneous wound repair (133) and in primary human palmar 
fascia fibroblasts (91). In addition, changes in periostin levels over time have been 
demonstrated to parallel αSMA levels in murine models of cutaneous wound healing (98) 
suggesting a role for periostin in myofibroblast differentiation. These studies led to the 
hypothesis that periostin promotes excessive myofibroblast differentiation and 
persistence in hypertrophic scars.  
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4.2 Assessment of the basal contractility of hypertrophic 
scar- and normal skin-derived fibroblasts in stressed 
fibroblast populated collagen lattices (sFPCL) 
 The basal contractility of primary fibroblasts derived from HTS and NS tissue was 
assessed and compared using sFPCL contraction assays as described in 2.2.5. In brief, 
primary fibroblasts were seeded into 3D collagen lattices and maintained in culture for 72 
hours in 2% FBS-αMEM to promote their tension-mediated differentiation into 
myofibroblasts, modelling their differentiation during wound closure in vivo (30, 183). 
After 72 hours, the collagen lattices were released from the surrounding well and lattice 
contraction was measured over a 24 hour period. As shown in Figure 4.1a, HTS 
fibroblasts were significantly more contractile than NS fibroblasts (p<0.01) with 
significant increases in contraction observed immediately after release (designated as 0 
hr), 6 hours and 24 hours after release (p<0.05, N=6 patients, n=3). Similarly, fibroblasts 
derived from keloid scar (KS) tissue, an abnormal scarring condition with similarities to 
hypertrophic scarring including increased periostin levels (58, 59, 62, 97, 215), displayed 
a non-significant trend (p=0.118) towards increased contractility relative to NS 
fibroblasts (Figure 4.1b, N=3 patients, n=3).  
4.3 Assessment of the effects of periostin on the 
contractility of HTS and NS fibroblasts in sFPCLs 
To assess the effects of increased periostin levels in the dermis of hypertrophic scar tissue 
on collagen lattice contraction, primary fibroblasts were seeded in sFPCLs with 2 μg/ml 
human recombinant periostin or vehicle incorporated into the collagen lattice. A 
significant interaction between periostin treatment and time was observed in HTS 
fibroblasts (p<0.01) and periostin enhanced HTS fibroblast contractility over 24 hours 
relative to vehicle controls with significant differences evident at all time points assessed 
(Figure 4.2a, p<0.05, N=8 patients, n=3). Periostin also significantly increased the 
contractility of KS fibroblasts above basal levels (p<0.05) with significant differences 
evident at lattice release (Figure 4.2b, p<0.05, N=3 patients, n=3). In contrast, a periostin-
enriched matrix had no discernible effects on the contractility of NS fibroblasts relative to 
basal levels (Figure 4.2c, N=6 patients, n=3). 
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Figure 4.1 Hypertrophic scar-derived fibroblasts have enhanced contractility 
relative to normal skin-derived fibroblasts. To assess the basal contractility of primary 
fibroblasts derived from hypertrophic scar (HTS), keloid scar (KS) and normal skin (NS) 
tissue, stressed fibroblast populated collagen lattices were used as described in 2.2.5. 
Primary fibroblasts were cultured within three-dimensional, tethered collagen lattices for 
72 hours to induce myofibroblast differentiation. After 72 hours, collagen lattices were 
mechanically released from the surrounding wells allowing for myofibroblast-mediated 
contraction of the free floating collagen lattices. Area measurements were taken over a 24 
hour period following release. (a) HTS fibroblasts significantly contracted collagen 
lattices to a greater extent than NS fibroblasts (N=6 patients, n=3). (b) A non-significant 
trend (p=0.118) towards enhanced collagen lattice contraction was observed in KS-
derived fibroblasts relative to NS fibroblasts (N=3 patients, n=3). Significant overall 
treatment effects are denoted by ^^p<0.01 (ANOVA of repeated measures). Significant 
treatment effects at individual time points are denoted by *p<0.05 and **p<0.01 (t-tests). 
Data are presented by mean values and SEM. 
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Figure 4.2 Periostin enhances collagen lattice contraction in abnormal scar-derived 
fibroblasts. To assess the effects of periostin (PN) on collagen lattice contraction, 
primary hypertrophic scar (HTS)-, keloid scar (KS)- and normal skin (NS)-derived 
fibroblasts were cultured in stressed fibroblast populated collagen lattices containing 2 
µg/ml PN or vehicle (veh, 0.1% BSA in PBS). (a) Exogenous PN treatment significantly 
enhanced HTS fibroblast collagen lattice contraction over 24 hours relative to vehicle 
controls (N=8 patients, n=3). (b) Exogenous PN treatment also significantly enhanced KS 
fibroblast collagen lattice contraction relative to vehicle controls (N=3 patients, n=3). (c) 
Exogenous PN treatment had no discernible effect on NS fibroblast collagen lattice 
contraction (N=6 patients, n=3). Significant overall treatment effects are denoted by 
^p<0.05 and significant treatment/time interactions are denoted by ##p<0.01 (ANOVA of 
repeated measures). Significant treatment effects at individual time points are denoted by 
*p<0.05 and **p<0.01 (t-tests and simple main effects analyses). Data are presented by 
mean values and SEM. 
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4.4 Identification of the mechanisms utilized by periostin to 
enhance HTS fibroblast contractility 
These findings suggested that, unlike NS fibroblasts, HTS fibroblasts were sensitive to 
periostin in their ECM and responded to its presence by increasing collagen lattice 
contraction.  Periostin could potentially induce collagen lattice contraction through 
several mechanisms. These include increasing fibroblast proliferation and/or viability in 
the collagen lattice, increasing fibroblast migration and adhesion within the lattice, or by 
enhancing myofibroblast differentiation. Each of these mechanisms was assessed in turn 
to identify the molecular mechanism(s) utilized by periostin to induce collagen lattice 
contraction. 
4.4.1 Assessment of the effects of periostin on cell viability in 
sFPCLs 
To determine the effects of periostin on HTS fibroblast viability in sFPCLs, cell 
membrane permeability and BCL2/BAX mRNA ratio, independent markers of cell 
viability, were independently assessed using flow cytometry (2.2.8) and real time PCR 
(2.2.7), respectively. Exogenous periostin treatment had no discernible effect on HTS 
fibroblast membrane permeability in sFPCLs after 72 hours in culture (Figure 4.3a, N=4 
patients, n=3) or BCL2/BAX ratio after 48 hours in sFPCL culture relative to vehicle 
controls (Figure 4.3b, N=3 patients, n=3). Similarly, exogenous periostin treatment had 
no discernible effect on the BCL2/BAX ratio in KS fibroblasts after 48 hours in sFPCL 
culture relative to vehicle controls (Figure 4.3c, N=3 patients, n=3). 
4.4.2 Assessment of the effects of periostin on proliferation in 
sFPCLs 
To determine if periostin induced HTS fibroblast proliferation in 3D cultures, CCND1 
expression was measured by real time PCR 48 hours after culture in a sFPCL, with or 
without periostin treatment.  In contrast to periostin-induced HTS fibroblast proliferation 
in compliant 2D cultures over a seven day period, periostin had no effect on CCND1 
expression in HTS fibroblasts cultured under mechanical tension (Figure 4.4a, N=3 
patients, n=3). Exogenous periostin treatment also had no discernible effect on CCND1  
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Figure 4.3 Periostin had no effect on hypertrophic scar fibroblast viability in 
stressed fibroblast populated collagen lattices. Primary hypertrophic scar (HTS) and 
keloid scar (KS) fibroblasts were cultured in stressed fibroblast populated collagen 
lattices (sFPCLs) containing periostin (PN, 2 µg/ml) or vehicle (veh). (a) The effects of 
PN on HTS fibroblast membrane permeability, an indicator of cellular viability, was 
assessed after 72 hours in sFPCL culture using flow cytometry as described in 2.2.8. PN 
had no discernible effect on HTS fibroblast viability relative to vehicle controls (N=4 
patients, n=3). (b and c) The effects of PN on BCL2/BAX expression, a marker of 
apoptosis, were assessed in HTS and KS fibroblasts cultured in sFPCLs for 48 hours by 
real time PCR (2.2.7). PN had no effect on the BCL2/BAX ratio in (b) HTS or (c) KS 
fibroblasts relative to vehicle controls when cultured under mechanical tension. Values 
were normalized to vehicle controls (N=3 patients, n=3). Ultraviolet (UV) irradiation of 
HTS cells for 60 minutes was utilized as a positive control to induce cell death. Data are 
presented by mean values and SEM. RQ=relative quantification. 
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Figure 4.4 Periostin had no effect on hypertrophic scar fibroblast proliferation in 
stressed fibroblast populated collagen lattices. Primary hypertrophic scar (HTS) and 
keloid scar (KS) fibroblasts were cultured in stressed fibroblast populated collagen 
lattices (sFPCLs) containing periostin (PN, 2 µg/ml) or vehicle (veh) for 48 hours. 
CCND1 expression, a marker of proliferation, was assessed in total RNA by real time 
PCR as described in 2.2.7. Exogenous periostin treatment did not affect CCND1 
expression in (a) HTS or (b) KS fibroblasts cultured under mechanical tension relative to 
vehicle controls. Values were normalized to vehicle controls (N=3 patients, n=3). 
Transforming growth factor (TGF)β-1 (5 ng/ml) was utilized as a control to inhibit 
CCND1 expression. Data are presented by mean values and SEM. RQ=relative 
quantification. 
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expression in KS fibroblasts cultured under identical conditions (Figure 4.4b, N=3 
patients, n=3). 
4.4.3 Assessment of the effects of periostin on adhesion and 3D 
migration in rFPCLs 
Relaxed FPCLs (rFPCLs), described in 2.2.5, were utilized to assess the effects of 
periostin on HTS fibroblast adhesion and migration in 3D collagen cultures. Fibroblasts 
cultured in rFPCLs are not subjected to mechanical tension and do not undergo culture-
induced myofibroblast differentiation (183).  Instead, lattice contraction is induced by 
tractional forces generated by cellular adhesion to the collagen and migration within the 
lattice (183, 216, 217). Periostin treatment had no discernible effect on HTS or KS 
fibroblast contractility in rFPCLs (Figure 4.5a and b, N=3 patients, n=3).  
4.4.4 Assessment of the effects of periostin on myofibroblast 
differentiation in sFPCLs 
To determine if periostin-induced HTS fibroblast contraction of sFPCLs was the result of 
enhanced myofibroblast differentiation, cell lysates were derived from sFPCLs 
immediately prior to collagen lattice release (after 72 hours of culture in the restrained 
lattice). αSMA and OB cadherin levels, established markers of myofibroblast 
differentiation (30, 218), were assessed by western immunoblotting and densitometry. 
Exogenous periostin treatment significantly increased αSMA levels in HTS fibroblasts 
relative to vehicle controls under identical culture conditions (Figure 4.6a, p<0.05, N=5 
patients, n=3). A non-significant trend (p=0.066) towards increased OB cadherin levels 
was observed in periostin treated HTS fibroblasts relative to vehicle controls (Figure 
4.6b, N=5 patients, n=3). Periostin had no discernible effects on αSMA or OB cadherin 
levels in KS fibroblasts relative to vehicle controls (Figure 4.6c and d, N=3 patients, 
n=3). 
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Figure 4.5 Periostin had no effect on hypertrophic scar fibroblast adhesion and 
migration in three dimensional collagen cultures. To assess the effects of exogenous 
periostin (PN) treatment on fibroblast adhesion and migration in three-dimensional (3D) 
collagen cultures, primary hypertrophic scar (HTS) and keloid scar (KS) fibroblasts were 
cultured in relaxed fibroblast populated collagen lattices containing PN (2 µg/ml) or 
vehicle (veh) as described in 2.2.5. Area measurements of the contracted collagen lattices 
were performed 24 hours after collagen lattice release. PN had no discernible effect on 
(a) HTS or (b) KS fibroblast migration in 3D collagen cultures (N=3 patients, n=3). 
Platelet-derived growth factor (PDGF) treatment (100 ng/ml) was utilized as a positive 
control to induce fibroblast migration based on previous studies (219). Data are presented 
by mean values and SEM. 
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Figure 4.6 Periostin enhances myofibroblast differentiation in hypertrophic scar-
derived fibroblasts. Primary hypertrophic scar (HTS) and keloid scar (KS) fibroblasts 
were cultured in stressed fibroblast populated collagen lattices containing periostin (PN, 
2µg/ml) or vehicle (veh) for 72 hours as described in 2.2.5. Total cell lysates were 
assessed for alpha smooth muscle actin (αSMA) and OB cadherin immunoreactivity, 
markers of myofibroblast differentiation, by western immunoblotting and densitometry, 
as described in 2.2.6. (a) Exogenous PN treatment significantly increased αSMA levels in 
HTS fibroblasts cultured in sFPCLs relative to vehicle controls (N=5 patients, n=3). (b) A 
non-significant trend (p=0.066) towards increased OB cadherin levels were observed in 
HTS fibroblast cultured in sFPCLs embedded with PN relative to vehicle controls (N=5 
patients, n=3 patients). Exogenous PN treatment had no discernible effects on (c) αSMA 
and (d) OB cadherin levels in KS fibroblasts relative to vehicle controls. Values were 
normalized to vehicle controls. β-actin immunoreactivity was assessed to ensure equal 
protein loading. Significant treatment effects are denoted by *p<0.05 (t-tests). Data are 
presented by mean values and SEM. Representative immunoblots of the mean 
densitometry data are shown. AU=arbitrary units.  
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4.5 Assessment of the effects of periostin-depletion of HTS 
myofibroblast differentiation in sFPCLs 
As shown in Figure 3.1b, HTS fibroblasts exhibit increased endogenous periostin levels 
relative to NS cells. The effects of exogenous periostin treatment on HTS fibroblasts 
described in the previous sections were therefore over and above the effects of 
endogenous periostin signalling. To obtain further support for the central hypothesis of 
this section, loss of function studies were performed in HTS fibroblasts by transducing 
them with an adenoviral vector containing a shRNA targeted against POSTN.  
4.5.1 Assessment of POSTN expression and periostin levels in 
HTS fibroblasts following adenoviral transduction with 
shRNAs against POSTN 
HTS fibroblasts were transduced with adenoviral vectors expressing either shRNAs 
against POSTN or scrambled control shRNAs. Transduction was at a multiplicity of 
infection (MOI) of 25 and the transduced fibroblasts were cultured on plastic tissue 
culture dishes for 72 hours in 2% FBS-αMEM. Transduction efficiency was then 
determined by assessing the percentage of cells expressing green fluorescent protein 
(GFP) by epifluorescence microscopy. As shown in Figure 4.7a and b, adenovirus 
transduction efficiency approximated 100% for all experiments assessed. Transduced 
HTS fibroblasts were then seeded into sFPCLs and POSTN and periostin levels were 
assessed after 72 hours in culture under 3D tension by real time PCR and western 
immunoblotting, respectively. As shown in Figure 4.7c and d, adenoviral transduction 
with shRNAs against POSTN significantly reduced POSTN expression by 92% and 
periostin levels by 60% relative to scrambled shRNA controls (p<0.001, N=4 patients, 
n=3). 
4.5.2 Assessment of the effects of periostin depletion on HTS 
myofibroblast differentiation in sFPCLs  
To assess the effects of periostin depletion on HTS myofibroblast differentiation in 
sFPCLs, HTS fibroblasts were transduced with adenovirus expressing shRNAs against 
POSTN or scrambled control shRNAs for 72 hours in 2% FBS-αMEM prior to seeding in 
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Figure 4.7 POSTN expression and periostin levels are significantly depleted in 
hypertrophic scar fibroblasts transduced with adenovirus expressing shRNAs 
against POSTN. Primary hypertrophic scar (HTS)-derived fibroblast were transduced 
with adenoviral vectors encoding shRNAs against POSTN or scrambled control shRNAs 
at a multiplicity of infection of 25. The adenoviral vector co-expresses green fluorescent 
protein, allowing transduction efficiency to be assessed by epifluorescence microscopy. 
(a) Comparisons of epifluorescence and (b) differential interference contrast microscopy 
indicate that transduction efficiency approximated 100% in all experiments. (c and d) 
Following adenoviral transduction, HTS fibroblasts were cultured in sFPCLs for 72 
hours. (c) POSTN expression was assessed in total RNA by real time PCR as described in 
2.2.7. Periostin depletion by shRNA treatment significantly decreased POSTN expression 
in HTS fibroblasts by 92% relative to scrambled controls (N=3 patients, n=3). (d) Total 
cell lysates were assessed for periostin immunoreactivity by western immunoblotting and 
densitometry as described in 2.2.6. Periostin depletion by shRNA treatment significantly 
decreased periostin levels by 60% relative to scrambled controls (N=4 patients, n=3). 
Values were normalized to scrambled shRNA controls. β-actin immunoreactivity was 
assessed to ensure equal protein loading. Significant treatment effects are denoted by 
***p<0.001 (t-tests). Data are presented by mean values and SEM. Representative 
immunoblots of the mean densitometry data are shown. RQ=relative quantification, 
AU=arbitrary units. 
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sFPCLs. No significant effects on the ability of HTS fibroblasts to contract sFPCLs were 
observed in periostin-depleted HTS or KS fibroblasts relative to scrambled controls 
(Figure 4.8a and b, N=3 patients, n=3 for each). Periostin depletion by shRNA treatment 
had no discernible effect on αSMA levels in HTS fibroblasts relative to scrambled 
shRNA controls (Figure 4.9a, N=4 patients, n=3). However, a significant decrease in 
αSMA levels was observed in periostin-depleted fibroblasts relative to scrambled shRNA 
controls in two of the four HTS patient fibroblast lines assessed (p<0.05, Figure 4.9b). 
Periostin depletion by shRNA treatment had no effect on OB cadherin levels in HTS 
fibroblasts relative to scrambled shRNA controls (Figure 4.9c, N=4 patients, n=3). 
Additionally, periostin depletion by shRNA treatment had no significant effect on αSMA 
or OB cadherin levels in KS fibroblasts relative to scrambled shRNA controls (Figure 
4.10a and b, N=3 patients, n=3). 
4.6 Assessment of NS fibroblast responses to periostin 
The contraction data presented in section 4.3 demonstrates that periostin induces collagen 
lattice contraction in HTS fibroblasts but not in NS fibroblasts. As NS fibroblasts are 
unlikely to be exposed to the growth factors and cytokines that promote abnormal wound 
healing, it was proposed that NS fibroblasts might need to be “activated” by fibrosis-
associated factors before they can respond to periostin treatment.  While not a major 
focus of this thesis, the following section describes pilot studies to identify some of the 
factors required for NS fibroblast “activation” in this model system. 
4.6.1 Assessment of the effects of TGFβ-1 priming on NS 
fibroblast contractility  
During cutaneous wound healing, TGFβ-1 is released following injury to the dermis and 
plays a critical role in many processes essential to normal wound repair (8, 13, 41, 174-
177, 220). With relevance to the roles of periostin described in the previous sections, 
TGFβ-1 signalling is required for myofibroblast differentiation (40, 41). Therefore, it was 
proposed that priming with TGFβ-1 might be required to sensitize NS fibroblasts to the 
presence of periostin.  To assess this, cultures were pretreated with 5 ng/ml human  
92 
 
 
Figure 4.8 Periostin depletion had no effect on collagen lattice contraction in 
hypertrophic scar-derived fibroblasts. Primary hypertrophic scar (HTS) and keloid 
scar (KS)-derived fibroblasts were transduced with adenoviral vectors expressing 
shRNAs targeted against POSTN or scrambled control shRNAs for 72 hours on tissue 
culture plastic. To assess the effects of periostin depletion on collagen lattice contraction, 
shRNA treated HTS and KS fibroblasts were cultured in stressed fibroblast populated 
collagen lattices described in 2.2.5. Collagen lattice contraction was assessed over a 24 
hour period. Periostin depletion by shRNA treatment had no effect on (a) HTS or (b) KS 
fibroblast collagen lattice contraction relative to scrambled shRNA controls (N=3 
patients, n=3). Data are presented by mean values and SEM. 
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Figure 4.9 Periostin depletion significantly decreases αSMA levels in fibroblasts 
derived from a subset of HTS patients. Primary hypertrophic scar (HTS)-derived 
fibroblasts were transduced with adenoviral vectors expressing shRNAs targeted against 
POSTN or scrambled control shRNAs for 72 hours and then seeded into stressed 
fibroblast populated collagen lattices. Total cell lysates were assessed for alpha smooth 
muscle actin (αSMA) and OB cadherin immunoreactivity, by western immunoblotting 
and densitometry, immediately prior to collagen lattice release. (a) Periostin-depletion 
had no significant effects on αSMA levels in HTS fibroblasts assessed as a group (N=4 
patients, n=3), (b) however, significant decreases in αSMA levels were observed 
following periostin depletion in a subset of individual patient-derived fibroblast cultures. 
Shown is a representative immunoblot and densitometry data for HTS patient #5. (c) No 
discernible effects on OB cadherin levels were observed in periostin-depleted HTS 
fibroblasts relative to scrambled shRNA controls (N=4 patients, n=3). Values were 
normalized to scrambled shRNA controls. β-actin immunoreactivity was assessed to 
ensure equal protein loading. Significant treatment effects are denoted by **p<0.01 (t-
tests). Data are presented by mean values and SEM. Representative immunoblots of the 
mean densitometry data are shown. AU=arbitrary units. 
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Figure 4.10 Periostin depletion had no significant effects on myofibroblast markers 
in keloid scar fibroblasts. Primary keloid scar (KS)-derived fibroblasts were transduced 
with adenoviral vectors expressing shRNAs targeted against POSTN or scrambled control 
shRNAs for 72 hours on tissue culture plastic then seeded into stressed fibroblast 
populated collagen lattices. Total cell lysates were assessed for alpha smooth muscle 
actin (αSMA) and OB cadherin immunoreactivity, by western immunoblotting and 
densitometry, immediately prior to collagen lattice release. Periostin-depletion had no 
significant effects on (a) αSMA or (b) OB cadherin levels in HTS fibroblasts relative to 
scrambled shRNA controls (N=3 patients, n=3). Values were normalized to scrambled 
shRNA controls. β-actin immunoreactivity was assessed to ensure equal protein loading. 
Data are presented by mean values and SEM. Representative immunoblots of the mean 
densitometry data are shown. AU=arbitrary units. 
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recombinant TGFβ-1 for 72 hours prior to being seeded into sFPCLs. As shown in Figure 
4.11a, a significant increase in sFPCL contraction was evident in TGFβ-1 primed NS 
fibroblasts in collagen lattices containing periostin (p<0.05) relative to TGFβ-1 primed 
NS fibroblasts in the absence of periostin. This effect was only evident at release and no 
significant effects were observed at any time point assessed after release (N=3 patients, 
n=3). 
4.6.2 Assessment of the effects of HTS-conditioned media on NS 
fibroblast contractility in sFPCLs 
TGFβ-1 is likely to be only one of many growth factors and cytokines secreted by HTS 
fibroblasts. To determine if additional fibrosis-associated signalling molecules were 
required to induce periostin sensitivity in NS fibroblasts, the effects of exposing NS 
fibroblasts to HTS fibroblast-conditioned culture media were assessed. HTS fibroblasts 
were grown to 80% confluency in serum-containing media, washed and cultured for 96 
hours in serum free media, after which the conditioned media was collected. NS 
fibroblasts were then cultured in sFPCLs in the presence of HTS-conditioned media for 
72 hours, with or without periostin addition to the collagen matrix. The addition of HTS-
conditioned media had no effects on NS fibroblast contraction relative to fibroblasts 
cultured in the presence of NS-conditioned media (Figure 4.11b, N=1 patient, n=5). 
However, a significant periostin treatment and time interaction (p<0.01) was observed 
and the presence of exogenous periostin significantly induced the contractility of NS 
fibroblasts cultured in HTS-conditioned media over 24 hours relative to vehicle controls. 
Significant increases in periostin-induced NS fibroblast contraction were observed at 
collagen lattice release, 0.5 and 2 hours after release (Figure 4.11c, p<0.05, N=1 patient, 
n=5).  
4.6.3 Identification of potential periostin interactors in HTS- 
conditioned media 
A combination of periostin and HTS-conditioned media was found to significantly induce 
NS fibroblast contractility, whereas neither of these treatments alone had discernible 
effects on the ability of NS fibroblasts to contract collagen lattices. These data were 
interpreted to suggest that periostin needed to interact with one or more molecules in 
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Figure 4.11 Fibrosis-associated growth factors are required to induce periostin 
sensitivity in normal skin fibroblasts. (a) Primary normal skin (NS) fibroblasts were 
cultured on tissue culture plastic for 72 hours in 10% FBS-αMEM supplemented with 5 
ng/ml transforming growth factor (TGF)β-1. TGFβ-1 primed NS fibroblasts were then 
seeded into stressed fibroblast populated collagen lattices (sFPCLs) containing 2 µg/ml 
periostin (PN) or vehicle (veh) and cultured for 72 hours. Collagen lattice contraction was 
assessed over 24 hours. PN significantly enhanced TGFβ-1-primed NS fibroblast 
contraction at collagen lattice release (N=3 patients, n=3). (b,c) Primary NS fibroblasts 
were seeded into sFPCLs embedded with PN or vehicle and cultured for 72 hours in 
hypertrophic scar (HTS)- or NS fibroblast-conditioned media (CM). (b) Culture in HTS 
CM had no effect on NS fibroblast collagen lattice contraction relative to NS fibroblasts 
cultured in NS CM (N=1 patient, n=3). (c) Exogenous periostin treatment significantly 
enhanced NS fibroblast contractility when cultured in HTS CM over 24 hours relative to 
vehicle controls (N=1 patient, n=5). Significant treatment/time interactions are denoted 
by ##p<0.01 (ANOVA of repeated measures). Significant treatment effects at individual 
time points are denoted by *p<0.05 and **p<0.01 (t-tests and simple main effects 
analyses). Data are presented by mean values and SEM.  
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HTS fibroblast-conditioned media to enhance the contraction of NS fibroblasts. In order 
to identify potential periostin interactors, immunoprecipitation experiments were 
performed on HTS-conditioned media. In brief, HTS-conditioned media, in the absence 
of exogenous periostin, was concentrated 50 times and 1 mg of total protein was 
incubated with an antibody specific to periostin and precipitated with protein A/G 
magnetic beads. Eluted samples were separated using SDS-PAGE and analyzed by 
coomassie staining and western immunoblotting. Coomassie staining identified bands at 
approximately 85 and 90 kDa in periostin immunoprecipitated samples (Figure 4.12a) 
and western immunoblotting confirmed the identity of these bands as endogenous 
periostin (Figure 4.12b). Two additional bands were evident in the periostin 
immunoprecipitated samples that were absent or extremely faint in the IgG control lane 
(Figure 4.12a). These bands were excised and analyzed by liquid chromatography tandem 
mass spectrometry (LC-MS/MS). They were identified as keratin-14 (user contamination) 
and fragments of IgG and periostin. Optimization experiments utilizing a variety of 
protocol modifications failed to identify potential periostin interactors in HTS-
conditioned media. 
4.7 Assessment of the effects of periostin on HTS 
myofibroblast persistence in sFPCLs 
Normally, as cutaneous wounds heal and ECM stress is relieved, the myofibroblasts that 
promote wound closure undergo apoptosis (8, 12). However, in abnormal scarring, 
myofibroblasts fail to undergo apoptosis and persist, resulting in excessive collagen 
production and contracture of the ECM (56, 57, 92-94) that promotes hypertrophic scar 
formation. When sFPCLs are released, a rapid contraction of the collagen lattices 
decreases the tension in the ECM. This release in ECM tension correlates with 
disassembly of stress fibers in myofibroblasts (47). To determine if periostin promotes 
myofibroblast persistence in HTS fibroblasts, αSMA levels were assessed in sFPCL 
cultures immediately prior to release (under mechanical tension for 72 hours) and up to 
48 hours after collagen lattice release (in the presence of decreased ECM tension) by 
western immunoblotting and densitometry. HTS fibroblasts with high levels of  
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Figure 4.12 Identification of potential periostin interactors in hypertrophic scar- 
conditioned media. Hypertrophic scar (HTS) conditioned media was generated (2.2.9.2) 
and concentrated 50 times. 1 mg of total protein was incubated with a periostin (PN)-
specific antibody and immunoprecipitated (IP) with protein A/G magnetic beads as 
described in 2.2.9.3. IP samples were separated using SDS-PAGE and samples were 
analyzed by (a) coomassie staining (2.2.9.4) and (b) western immunoblotting (2.2.6). (a) 
Coomassie staining identified 4 bands at molecular weights of 90 kDa, 85 kDa, 65 kDa 
and 60 kDa that were absent or extremely faint in IgG control samples. The 65 and 60 
kDa bands were identified as keratin-14 and fragments of IgG and PN by liquid 
chromatography tandem mass spectrometry (not shown). (b) The 90 and 85 kDa bands 
were identified as endogenous PN by western immunoblotting with a PN-specific 
antibody. Protein A/G magnetic beads (beads) and PN-specific antibody (ab) were used 
as controls. Bands at 55 kDa in both images correlate to the size of IgG heavy chain. 
Representative images are shown. MW= molecular weight ladder, WB= western 
immunoblot.  
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Figure 4.13 Periostin maintains myofibroblasts in a differentiated state under 
conditions of decreasing ECM tension. Primary hypertrophic scar (HTS) fibroblasts 
were cultured in stressed fibroblast populated collagen lattices (sFPCLs) and total cell 
lysates were derived immediately prior to collagen lattice release (after 72 hours of 
culture), 24 and 48 hours after collagen lattice release. The effects of periostin (PN) 
addition or depletion on alpha smooth muscle actin (αSMA) levels were assessed by 
western immunoblotting and densitometry. (a) HTS fibroblasts maintained αSMA levels 
following collagen lattice release in the presence of endogenous PN. αSMA levels were 
significantly increased in PN treated HTS fibroblasts relative to vehicle controls and 
αSMA levels were maintained for at least 48 hours after lattice release.Values were 
normalized to vehicle controls immediately prior to lattice release (N=5 patients, n=3). 
(b) Periostin depletion by shRNA treatment resulted in a significant and ongoing decrease 
in αSMA levels in HTS fibroblasts following collagen lattice release relative to 
scrambled shRNA controls. Values were normalized to scrambled controls immediately 
prior to lattice release (N=4 patients, n=3). β-actin immunoreactivity was assessed to 
ensure equal protein loading. Significant overall treatment effects are denoted by ^p<0.05 
(ANOVA of repeated measures). Significant treatment effects at individual time points 
are denoted by *p<0.05 and **p<0.01 (t-tests). Data are presented as mean values and 
SEM. Representative immunoblots of the mean densitometry data are shown. 
AU=arbitrary units. 
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endogenous periostin expression (vehicle treated fibroblasts) maintained αSMA levels 
following collagen lattice release. HTS fibroblasts treated with exogenous periostin had 
significantly higher αSMA levels (p<0.05) relative to vehicle treated fibroblasts cultured 
under mechanical tension and were able to maintain these high levels of αSMA following 
the release of ECM tension (Figure 4.13a, N=5 patients, n= 3). In contrast, periostin-
depleted HTS fibroblasts had significantly decreased αSMA levels (p<0.05) relative to 
scrambled shRNA controls with significant decreases observed at 24 and 48 hours after 
collagen lattice release (Figure 4.13b, p<0.05, N=4 patients, n=3). 
4.8 Discussion 
In order to assess periostin effects on myofibroblast differentiation and persistence, it was 
necessary to perform studies in a model system that mimicked in vivo conditions of 3D 
stress in a collagen-enriched environment. The stressed fibroblast populated collagen 
lattice (sFPCL) assay was chosen on this basis. When initially seeded into sFPCL, the 
fibroblasts experience an ECM environment similar to that of the provisional matrix in 
vivo (31, 173). During ECM remodelling, tractional forces generated by migrating 
fibroblasts increase the mechanical tension of the ECM thereby inducing proto-
myofibroblast and myofibroblast differentiation (30, 156). This mechanical tension is 
sustained until the collagen lattice is released from its points of attachment (30). Upon 
release, myofibroblast-mediated contraction rapidly contracts the collagen lattice.  
To investigate periostin effects on myofibroblast differentiation in HTS fibroblasts, three 
markers of myofibroblast differentiation were assessed: contractility, αSMA and OB 
cadherin levels. The neo-expression of αSMA in their stress fibres is a distinguishing 
feature of myofibroblasts and facilitates their hyper-contractile phenotype (30). 
Incorporation of αSMA into stress fibers is specific to differentiated myofibroblasts, as 
the stress fibers in proto-myofibroblast are composed solely of β- and γ-actins (38, 39). 
OB cadherin, a membrane protein involved in adherins junctions (221), also enhances 
collagen lattice contraction by myofibroblasts (218) and its expression is reported to be 
upregulated in differentiated myofibroblasts relative to proto-myofibroblasts (218).  
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The findings reported in this chapter indicate that periostin enhances myofibroblast 
differentiation in human dermal fibroblasts derived from hypertrophic scar tissue. The 
evidence supporting this conclusion includes significant increases in HTS fibroblast 
contractility and αSMA levels in the presence of exogenous periostin. In addition, a non-
significant trend towards increased OB cadherin levels in periostin treated HTS 
fibroblasts was noted. The absence of any discernible effects of periostin treatment on 
fibroblast proliferation, viability, adhesion or migration in 3D cultures suggests that they 
are unlikely to explain periostin-induced HTS collagen lattice contraction. Furthermore, 
periostin significantly enhanced KS fibroblast contractility above highly contractile basal 
levels. These data suggest that periostin effects on myofibroblast differentiation may not 
be specific to HTS fibroblasts but may be a common feature of fibrotic conditions of the 
skin. Periostin also induces myofibroblast differentiation of fibroblasts derived from 
Dupuytren’s disease, a fibrosis of the palmar fascia with similarities to scarring (91), 
suggesting that these findings may be extendible to other tissues. 
Since HTS fibroblasts express increased endogenous levels of periostin relative to NS 
cells and as exogenous periostin addition promoted increased myofibroblast 
differentiation in HTS-derived fibroblast, loss of function studies were performed to 
confirm these findings. Adenoviral transduction was chosen as an optimal method for 
shRNA delivery for several reasons. Transient transfection efficiency is typically low in 
primary fibroblasts and selection for stable transfection is impractical in primary 
fibroblasts that lose their in vivo characteristics after a limited number of passages. 
Previous studies in our laboratory have demonstrated that, unlike transient transfection, 
viral transduction efficiency approximates 100% in primary fibroblasts under optimal 
conditions. An adenoviral transduction system was used in preference to a lentiviral 
system because adenovirus remains episomal and does not integrate into the host 
genome, thereby limiting the potential for non-specific disruption of gene expression 
caused by viral DNA integration into the genome. 
In contrast to the gain-of-function studies where exogenous periostin significantly 
enhanced HTS myofibroblast differentiation, no significant effects of periostin depletion 
on myofibroblast differentiation were evident in the loss-of-function studies. As markers 
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of myofibroblast differentiation, a significant decrease in collagen lattice contraction, 
αSMA or OB cadherin levels would have provided independent support for the gain-of-
function studies. The lack of significant findings in these loss-of-function studies may be 
explained in part by inter-patient variability. Factors including age, gender and race may 
affect the sensitivity of periostin depletion between individual patients and make it 
difficult to identify consistent effects. Future analyses of additional patients may be 
required to overcome inter-patient variability and allow us to identify consistent effects in 
all, or even a majority of, patients assessed. It is also a possibility that a 60% reduction in 
endogenous periostin levels in HTS fibroblasts following POSTN shRNA treatment was 
insufficient to induce detectible effects on contraction and myofibroblast differentiation. 
Periostin is proposed to be a very stable protein with a long half-life that is difficult to 
deplete under conditions of high ECM tension (222). Therefore, depletion of intracellular 
periostin in HTS fibroblasts may not correlate with depletion of secreted and potentially 
very stable ECM-associated periostin. Another possibility is that, while periostin can 
modestly enhance myofibroblast differentiation above basal levels, its primary role is to 
maintain, rather than induce, myofibroblast differentiation. Therefore, increased matrix 
tension, such as that experienced by fibroblasts cultured in sFPCLs, may be sufficient to 
induce HTS myofibroblast differentiation and periostin may play a modestly stimulatory, 
but dispensable, role in this process. 
Interestingly, no evidence of periostin-induced myofibroblast contraction was observed in 
NS fibroblast cultured in sFPCLs. These findings suggest that periostin induces 
pathological, rather than normal, collagen lattice contraction, as the effects were specific 
to fibroblasts derived from abnormal scar tissue. It remains unclear if periostin-induced 
contraction is a component of normal cutaneous wound healing, as, due to ethical 
constraints, we were unable to obtain samples of normal human scar tissue from which to 
derive primary fibroblasts. The mechanisms that explain the differences in sensitivity to 
periostin between HTS and NS fibroblasts are currently unclear. It is feasible that NS 
fibroblasts may need to be “activated” in order to respond to periostin. This activation 
could include induction or activation of a receptor(s) not normally present in unwounded 
NS fibroblasts or exposure to fibrosis-associated growth factors and cytokines required 
for periostin signalling. 
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Preliminary western immunoblotting studies demonstrated that both HTS and NS 
fibroblasts express integrins αV, β3 and β5 subunits (data not shown) through which 
periostin has been shown to signal in other systems (127-129, 131-134). Although HTS 
and NS fibroblasts had similar expression profiles of individual integrin subunits, it is 
unclear if HTS and NS fibroblasts express different integrin heterodimers and the 
activation state of these dimers. 
The hypothesis that exposure to fibrosis-associated growth factors and cytokines are 
required to activate and induce periostin sensitivity in NS fibroblasts was also tested. 
During cutaneous wound healing, TGFβ-1 is released following injury to the dermis and 
plays a critical role in many processes essential to normal wound repair, including 
myofibroblast differentiation (8, 13, 40, 41, 174-177, 220). Therefore, TGFβ-1 signalling 
may be required to activate NS fibroblasts and induce periostin sensitivity in these cells. 
These studies indicated that priming NS fibroblasts with recombinant TGFβ-1 was only 
partially effective in inducing NS fibroblast sensitivity to periostin. It is likely that a 
combination of fibrosis-associated growth factors that are expressed at high levels by 
HTS fibroblasts (for example, CCN2 (223)), might be required to induce periostin 
sensitivity in NS fibroblasts.  
Since a large number of growth factors are secreted by fibroblasts during cutaneous 
wound healing (8), it is feasible that HTS fibroblasts might secrete factors that can 
activate NS fibroblasts. The data presented in this chapter supports this notion as 
periostin significantly enhanced NS fibroblast contractility when cultured in HTS-
conditioned media. As HTS-conditioned media had no discernible effect on NS fibroblast 
contractility in the absence of exogenous periostin, these data imply that periostin is 
interacting with a component in the conditioned media to enhance contraction of NS 
fibroblasts. Despite multiple optimization experiments, no periostin interacting molecules 
that were specific to HTS-conditioned media were identified by immunoprecipitation 
analyses. Future studies, beyond the scope of this thesis, will be required to identify the 
elusive molecular interactions that induce periostin sensitivity in NS fibroblasts. 
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The second component of this aim was to assess periostin effects on myofibroblast 
persistence. Normally, as cutaneous wounds heal and ECM stress is relieved, the 
myofibroblasts that promote wound closure undergo apoptosis (8, 12). However, in 
abnormal scarring conditions, myofibroblasts fail to undergo apoptosis and persist, and 
continue to remodel the ECM and increase dermal density to abnormal levels. Many 
factors, most notably TGFβ-1 (41), have been demonstrated to induce myofibroblast 
differentiation in combination with increased ECM tension (30, 38, 42). However, much 
less is known about the factors that maintain myofibroblasts in a differentiated state in 
hypertrophic scars that persist for month or years. Since periostin promotes myofibroblast 
differentiation in HTS fibroblasts and is abundant and persistent in the dermis of 
hypertrophic scars, it was hypothesized that periostin promotes myofibroblast persistence 
in hypertrophic scarring. 
To test this hypothesis, αSMA levels in HTS fibroblasts in sFPCLs cultured under 
mechanical tension (pre-release) and up to 48 hours after collagen lattice release were 
assessed. This model was designed to mimic the loss of ECM stress that induces 
apoptosis in normal scar myofibroblasts (8, 12). While the rapid loss of ECM tension 
induced by collagen lattice release in sFPCLs is much more abrupt than the physiological 
process it is designed to mimic (183), it does provide a reproducible assay system for 
myofibroblast persistence under rapidly diminishing ECM tension. These studies 
demonstrate that HTS fibroblasts are able to maintain αSMA levels at constant levels 
under conditions of decreasing ECM tension in the presence of endogenous periostin and 
that these levels are significantly increased and maintained by the addition of exogenous 
periostin. In contrast, αSMA levels were significantly decreased in periostin-depleted 
HTS fibroblasts under conditions of decreasing ECM tension relative to scrambled 
controls. It is unclear if this loss in αSMA levels following collagen lattice release was 
due to the onset of myofibroblast apoptosis, myofibroblasts dedifferentiation or a 
combination of both. These findings support the hypothesis that periostin maintains 
myofibroblast differentiation in HTS fibroblasts under conditions of decreasing ECM 
tension. 
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In summary, these studies demonstrated that periostin induces HTS fibroblast contraction 
and differentiation in 3D collagen lattices, a model that mimics the mechanical tension of 
granulation tissue during cutaneous wound healing. In addition, periostin maintained 
αSMA levels, a marker of myofibroblast differentiation, in sFPCL cultures exposed to 
reduced ECM tension, mimicking wound remodelling after closure. Together these data 
demonstrate novel roles for periostin in inducing and maintaining myofibroblast 
differentiation and persistence in HTS fibroblasts.  
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Chapter 5  
5 In vitro analysis of the mechanisms utilized by periostin 
to induce myofibroblast differentiation and persistence 
in hypertrophic scarring 
5.1 Rationale  
Periostin was shown to induce dermal fibroblasts derived from hypertrophic scar tissue to 
express α smooth muscle actin (αSMA) and differentiate into myofibroblasts in Chapter 
4.  However, the signalling pathway(s) and mechanisms activated by periostin to induce 
and/or maintain myofibroblast differentiation had not been elucidated.  Therefore, the 
focus of Chapter 5 is to identify these pathway(s).  Periostin has been previously reported 
to signal through integrins in other cell types (127-134), and integrins have well-
established roles in mediating signalling events that increase cellular attachment and 
contraction of the ECM (46).  The integrin-associated complexes that form between cells 
and the matrix are known as focal adhesions (30, 46, 156). Previous studies have shown 
that αSMA is only incorporated into the stress fibers of these cells when the mechanical 
tension in the surrounding ECM is sufficient to induce the “maturation” of focal 
adhesions (FAs) into “supermature” focal adhesions (suFAs, (30, 43)). As periostin 
induces αSMA production and HTS myofibroblast contractility, the hypothesis for this 
chapter was that periostin signals through integrins in HTS fibroblasts, activates integrin-
associated signalling pathways, enhances the formation of suFAs between HTS 
fibroblasts and the surrounding collagen matrix and promotes the incorporation of αSMA 
into stress fibres.  This hypothesis is illustrated in Figure 5.1.  
5.2 Immunoprecipitation analyses of receptor interactions 
with periostin in HTS fibroblasts.  
To determine if periostin interacts with integrins in HTS fibroblasts, immunoprecipitation 
analyses with a periostin-specific antibody were performed on total cell lysates derived 
from HTS fibroblasts cultured on plastic as described in 2.2.9. Using this approach, 
periostin immunoreactivity was evident in samples immunoprecipitated with a periostin-  
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Figure 5.1 Schematic representation of the proposed signalling pathway utilized by 
periostin to induce myofibroblast differentiation and persistence. The central 
hypothesis of Chapter 5 is that ECM-associated periostin signals through integrins 
(Chapter 5.2) in HTS fibroblasts to activate focal adhesion kinase (FAK, Chapter 5.3.1), a 
tyrosine kinase that localizes to focal adhesion complexes. FAK activation promotes 
myofibroblast differentiation and focal adhesion formation through RhoA-GTP and 
ROCK (Chapter 5.3.2) and its downstream effectors cofilin (Chapter 5.3.3) and myosin 
light chain (MLC, Chapter 5.3.4). Cofilin inhibition and MLC-mediated stress fiber 
contraction promotes stress fiber maintenance, increased ECM tension and integrin 
clustering resulting in the formation of supermature focal adhesions (suFA, Chapter 5.4), 
a prerequisite for αSMA incorporation into stress fibers of differentiated myofibroblasts.  
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specific antibody and absent in samples immunoprecipitated with a non-specific IgG 
control, demonstrating the specificity of the antibodies for periostin. Western 
immunoblotting analyses revealed interactions between periostin and integrins αv and α5 
however, these interactions were also consistently evident in samples immunoprecipitated 
with a non-specific IgG control. These data indicated that these interactions were not 
specific to periostin.  Several modifications of standard immunoprecipitation protocols 
were trialed including the use of nickel (Ni) coated magnetic beads that bind specifically 
to histidine-tagged human recombinant periostin, shorter incubation times and more 
stringent washing conditions (described in detail in 2.2.10) to enhance the specificity of 
interactions between periostin and integrin subunits. The approach of using Ni coated 
magnetic bead to specifically isolate recombinant periostin from total cell lysates of HTS 
fibroblasts exposed to treatment was successful (Figure 5.2a). However, interactions 
between periostin and integrins αv and α5 were evident in HTS cell lysates in both the 
presence and absence of recombinant periostin treatment, indicating a high background 
level of non-specific interactions (Figures 5.2b and c). In addition to western 
immunoblotting analyses, immunoprecipitated samples were stained with coomassie to 
identify bands of unique molecular weight in comparisons between treated and untreated 
samples, potentially indicating novel periostin interactors. Despite substantial method 
optimization and multiple mass spectrometry analyses, no novel periostin interactors 
were identified using this approach (data not shown). Therefore, this research effort was 
refocused onto the identification of integrin-associated signalling intermediates that were 
modified by periostin during myofibroblast differentiation. 
5.3 Assessment of the effects of periostin on integrin-
associated signalling molecules in HTS-derived 
fibroblasts 
The integrin-associated complexes that form between cells and the ECM are known as 
focal adhesions (30, 46, 156). Focal adhesion kinase (FAK) is a tyrosine phosphorylated 
protein that localizes to focal adhesions (224, 225) and its activation is required for 
adhesion-mediated myofibroblast differentiation (226) and suFA formation (43). FAK  
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Figure 5.2 Immunoprecipitation analyses of receptor interactions with periostin in 
HTS fibroblasts. Primary hypertrophic scar (HTS) fibroblasts were cultured to 85% 
confluency on tissue culture plastic trays and treated with 2 µg/ml periostin (PN) or 
vehicle (veh) in 2% FBS-αMEM overnight prior to formaldehyde fixation. 1 mg of total 
cell lysate was precipitated using nickel (Ni) coated magnetic beads to bind histidine-
tagged human recombinant periostin as described in 2.2.10.  Eluted precipitation 
complexes were subjected to SDS-PAGE and assessed for periostin, αv and α5 integrin 
immunoreactivity by western immunoblotting as described in 2.2.6. (a) Ni coated 
magnetic beads specifically precipitated recombinant periostin as demonstrated by the 
presence of a band at 90 kDa that is absent in the vehicle control lane. (b and c) Ni coated 
magnetic beads non-specifically precipitated integrins αv and α5 as demonstrated by the 
presence of  bands at (b) 140 kDa and (c) 150 kDa in both the periostin and vehicle 
treated samples. Representative immunoblots are shown. MW= molecular weight, 
WB=western immunoblot. 
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can promote myofibroblast differentiation and focal adhesion formation by modifying 
Rho Kinase (ROCK) activity and the activities of its downstream targets. These targets 
include cofilin and myosin light chain (MLC), which regulate stress fiber stabilization 
and stress fiber-mediated contraction, respectively. Therefore, it was hypothesized that 
periostin promotes myofibroblast differentiation and persistence through a FAK-ROCK 
dependent signalling pathway. 
5.3.1 Assessment of the effects of periostin on FAK activation in 
HTS fibroblasts cultured in sFPCLs  
To assess the contribution of FAK activation in periostin-induced HTS myofibroblast 
differentiation and persistence, phosphorylated FAK levels were assessed in sFPCL 
lysates immediately prior to release and up to 48 hours after release by western 
immunoblotting and densitometry. A significant interaction between periostin treatment 
and time was observed (p<0.01) and exogenous periostin treatment enhanced FAK 
phosphorylation following collagen lattice release relative to vehicle controls with a 
significant increase in FAK phosphorylation evident at 48 hours after lattice release 
(Figure 5.3a, p<0.05, N=3 patients, n=3). A significant overall treatment effect was also 
evident in periostin-depleted HTS fibroblasts (p<0.05) with periostin-depleted HTS 
fibroblasts displaying increased levels of phosphorylated FAK relative to scrambled 
shRNA controls. Significant increases in FAK phosphorylation were evident in periostin-
depleted HTS fibroblasts immediately prior to collagen lattice release and at 48 hours 
after release (Figure 5.3b, p<0.05, N=3 patients, n=3). Periostin addition or depletion had 
no discernible effects on total FAK levels (data not shown, N=3 patients, n=3). 
5.3.2 Assessment of the effects of ROCK inhibition on periostin-
induced HTS myofibroblast differentiation 
ROCK plays a central and essential role in activating and maintaining myofibroblast 
differentiation and contractility (30, 43, 51-53). To confirm that periostin signalling 
required ROCK activity to induce HTS myofibroblast-mediated collagen lattice 
contraction, a ROCK specific inhibitor, Y27632, was included in a subset of sFPCL 
cultures of HTS fibroblasts, with or without exogenous periostin treatment, and collagen  
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Figure 5.3 Periostin enhances focal adhesion kinase phosphorylation. Primary 
hypertrophic scar (HTS) fibroblasts were cultured in stressed fibroblast populated 
collagen lattices (sFPCLs) as described in 2.2.5 and total cell lysates were derived 
immediately prior to sFPCL release (72 hours after polymerization), 24 and 48 hours 
after release. Levels of phosphorylated focal adhesion kinase (pFAK, tyr397) were 
assessed in HTS lysates by western immunoblotting and densitometry as described in 
2.2.6. (a) Periostin significantly enhanced FAK phosphorylation in HTS fibroblasts 
cultured in conditions of decreasing ECM tension relative to vehicle controls. Values 
were normalized to vehicle controls immediately prior to lattice release (N=3 patients, 
n=3). (b) Periostin depletion by shRNA treatment significantly increased FAK 
phosphorylation in HTS fibroblasts in a model of decreasing ECM tension relative to 
scrambled shRNA controls. Values were normalized to scrambled shRNA controls 
immediately prior to lattice release (N=3 patients, n=3). β-actin immunoreactivity was 
assessed to ensure equal protein loading. Significant overall treatment effects are denoted 
by ^p<0.05 and significant treatment/time interactions are denoted by ##p<0.01 
(ANOVA of repeated measures). Significant treatment effects at individual time points 
are denoted as *p<0.05 (t-tests and simple main effect analyses). Data are presented by 
mean values and SEM. Representative immunoblots of the mean densitometry data are 
shown. AU=arbitrary units.  
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Figure 5.4 Rho kinase inhibition significantly attenuates hypertrophic scar 
fibroblast contraction of stressed fibroblast populated collagen lattices. To assess the 
effects of Rho kinase (ROCK) inhibition of hypertrophic scar (HTS) fibroblast 
contractility, primary HTS fibroblasts were seeded in stressed fibroblast populated 
collagen lattices containing periostin (PN) or vehicle (veh) as described in 2.2.5 and 
cultured in 2% FBS-αMEM supplemented with 10 µM ROCK inhibitor, Y27632 
(ROCKi), or vehicle control (water) for 72 hours. Collagen lattice contraction was 
assessed over 24 hours. ROCK inhibition significantly attenuated basal HTS fibroblast 
collagen lattice contraction at all time points assessed. The addition of exogenous PN was 
unable to rescue HTS fibroblast contraction in the presence of Y27632 (N=1 patient, 
n=3). Significant treatment/time interactions are denoted by #p<0.05 (ANOVA of 
repeated measures). Significant treatment effects at individual time points are denoted by 
*p<0.05, **p<0.01, ***p<0.001 (simple main effect analyses). Data are presented by 
mean values and SEM. 
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lattice contraction was assessed over 24 hours. A significant interaction between Y27632 
treatment and time was observed (p<0.01) and ROCK inhibition strongly attenuated HTS 
fibroblast contractility relative to vehicle controls with significant differences observed at 
all time points assessed (p<0.05). The addition of exogenous periostin did not rescue 
HTS fibroblast contraction in the presence of Y27632 (Figure 5.4, N=1 patient, n=3). 
5.3.3 Assessment of the effects of periostin on cofilin activation in 
HTS fibroblasts cultured in sFPCLs 
Cofilin is an actin-binding protein that is a downstream target of ROCK and promotes 
actin stress fiber depolymerization (227). ROCK activation leads to the phosphorylation 
and inhibition of cofilin activity, thereby preventing actin depolymerization (228). To 
assess the contribution of cofilin in periostin-induced HTS myofibroblast differentiation, 
phosphorylated cofilin levels were assessed in sFPCL lysates immediately prior to release 
and up to 48 hours after release by western immunoblotting and densitometry.  
Exogenous periostin treatment had no significant effect on cofilin phosphorylation 
relative to vehicle controls when HTS fibroblasts were assessed as a group (Figure 5.5a, 
N=3 patients, n=3). However, it was noted that periostin significantly increased cofilin 
phosphorylation at individual time points in two of the three individual patients assessed 
(Figure 5.5b, p<0.05).  
Periostin depletion by shRNA treatment had no significant effects on cofilin 
phosphorylation in HTS fibroblasts when assessed as a group (Figure 5.5c, N=3 patients, 
n=3). However, a significant treatment effect was observed (p<0.05) in one of the three 
patient-derived fibroblast lines assessed and phosphorylated cofilin levels were found to 
be significantly decreased in periostin-depleted HTS myofibroblasts relative to scrambled 
shRNA controls. In addition, phosphorylated cofilin levels were found to be significantly 
decreased at individual time points in the other two patient-derived fibroblast lines 
assessed (Figure 5d, p<0.05). Periostin addition or depletion had no discernible effects on 
total cofilin levels (data not shown, N=3 patients, n=3). 
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Figure 5.5 Periostin enhances cofilin phosphorylation in conditions of decreasing 
ECM tension in a subset of patients. Primary hypertrophic scar (HTS) fibroblasts were 
cultured in stressed fibroblast populated collagen lattices (sFPCLs) and total cell lysates 
were derived immediately prior to sFPCL release (72 hours after polymerization), 24 and 
48 hrs after release. Levels of phosphorylated cofilin (pCofilin, ser3) were assessed in 
HTS lysates by western immunoblotting and densitometry. (a) Periostin had no 
discernible effect on cofilin phosphorylation relative to vehicle controls when assessed as 
a group (N=3 patients, n=3 patient). (b) However, periostin significantly enhanced cofilin 
phosphorylation relative to vehicle controls in a subset of individual patients. Shown is a 
representative immunoblot and densitometry data for HTS patient #5.Values were 
normalized to vehicle controls immediately prior to lattice release. (c) Periostin depletion 
by shRNA treatment had no significant effects on cofilin phosphorylation relative to 
scrambled shRNA controls when assessed as a group (N=3 patients, n=3). (d) In contrast, 
periostin depletion by shRNA treatment significantly decreased cofilin phosphorylation 
relative to scrambled shRNA controls in a subset of individual patients. Shown is a 
representative immunoblot and densitometry data for HTS patient #5. Values were 
normalized to scrambled shRNA controls immediately prior to lattice release. β-actin 
immunoreactivity was assessed to ensure equal protein loading. Significant treatment 
effects at individual time points are denoted by *p<0.05 (t-tests). Data are presented by 
mean values and SEM. Representative immunoblots of the mean densitometry data are 
shown. AU=arbitrary units.  
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5.3.4 Assessment of the effects of periostin on MLC activation in 
HTS fibroblasts cultured in sFPCLs 
The contractile forces induced by myofibroblasts on their ECM are generated by 
contractile stress fibres composed of actin bundles, non-muscle myosin, and actin-
binding proteins and is regulated by the activity (phosphorylation) of MLC (30, 45-47). 
To assess the contribution of MLC in periostin-induced HTS myofibroblast 
differentiation, phosphorylated MLC levels were assessed in sFPCL lysates immediately 
prior to release and up to 48 hours after release by western immunoblotting and 
densitometry.  Exogenous periostin addition to sFPCL cultures had no significant effect 
on MLC phosphorylation in HTS fibroblasts cultured under mechanical tension or 
following the release of tension relative to vehicle controls (Figure 5.6a, N=3 patients, 
n=3). No significant changes in MLC phosphorylation were observed in periostin-
depleted HTS fibroblasts relative to scrambled shRNA controls cultured under 
mechanical tension and following the release of tension (Figure 5.6b, N=3 patients, n=3). 
However, a significant treatment effect was observed (p<0.05) in one of three patient-
derived fibroblast lines assessed with phosphorylated MLC levels being significantly 
lower in periostin-depleted HTS fibroblasts relative to vehicle controls (Figure 5.6c). 
Periostin addition or depletion had no discernible effects on total MLC levels (data not 
shown, N=3 patients, n=3). 
As described earlier in this chapter, FAK activity enhances suFA formation and 
myofibroblast differentiation through the activation of ROCK and its downstream targets 
cofilin and MLC. ROCK-mediated cofilin inhibition prevents stress fiber 
depolymerization, whereas MLC activation leads to myofibroblast contraction that 
increases the mechanical tension in the ECM and induces integrin clustering resulting in 
the formation of larger focal adhesion complexes. Although no consistent effects of 
periostin on cofilin inhibition and MLC activation could be discerned in HTS fibroblasts 
when assessed as a group, the significant effects noted in individual fibroblast lines were 
invariably consistent with periostin promoting suFA formation during myofibroblast 
differentiation. Therefore, the potential for periostin to enhance suFA formation was 
assessed in HTS fibroblasts as a group. 
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Figure 5.6 Periostin depletion reduces myosin light chain phosphorylation in HTS 
myofibroblasts cultured in sFPCLs in a subset of individuals.  Primary hypertrophic 
scar (HTS) fibroblasts were cultured in stressed fibroblast populated collagen lattices 
(sFPCLs) and total cell lysates were derived immediately prior to sFPCL release (72 
hours after polymerization), 24 and 48 hours after release. Levels of phosphorylated 
myosin light chain (pMLC, ser19) were assessed in HTS lysates by western 
immunoblotting and densitometry. (a) Periostin had no significant effect on MLC 
phosphorylation in HTS fibroblasts cultured in sFPCLs relative to vehicle controls. 
Values were normalized to vehicle controls immediately prior to collagen lattice release 
(N=3 patients, n=3). (b) Periostin depletion by shRNA treatment had no significant 
effects on MLC phosphorylation in HTS fibroblasts relative to scrambled shRNA 
controls when assessed as a group (N=3 patients, n=3). (c) While periostin treatment did 
not significantly affect MLC phosphorylation at any specific time point, an overall 
treatment effect indicating a significant decrease in MLC phosphorylation in periostin-
depleted HTS fibroblasts relative to scrambled shRNA controls was detected in a subset 
of individual patients. Shown is a representative immunoblot and densitometry data for 
HTS patient #9. Values were normalized to scrambled shRNA controls immediately prior 
to collagen lattice release. β-actin immunoreactivity was assessed to ensure equal protein 
loading. Significant overall treatment effects are denoted by ^p<0.05 (ANOVA of 
repeated measures). Data are presented by mean values and SEM. Representative 
immunoblots of the mean densitometry data are shown. AU=arbitrary units. 
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5.4 Supermature focal adhesions 
Focal adhesions are integrin-associated complexes that facilitate communication between 
cells and their surrounding ECM (30, 46, 156).  Fibroblasts typically exhibit a mixture of 
immature and mature focal adhesions (FAs, (229)) and, when they differentiate into 
myofibroblasts, the formation of suFAs corresponds with the incorporation of αSMA into 
stress fibres (43, 184, 230).  suFAs can be identified by the coexpression of αSMA with 
other proteins normally found in FAs including ED-A fibronectin, vinculin, paxillin and 
tensin (230). suFAs can also be distinguished by size, where suFAs are defined as FAs 
that are greater than 6 μm in length, mature focal adhesions are typically between 2 and 6 
μm in length, and immature FAs are typically less than 2 μm in length (43, 184, 230, 
231). The incorporation of αSMA in suFAs is essential to allow myofibroblasts to exert a 
greater (typically 2 to 4-fold) higher contractile force on the surrounding ECM thereby 
enhancing ECM tension and maintaining the myofibroblast phenotype (30, 43). 
5.4.1 Assessment of the effects of periostin on the formation of 
supermature focal adhesions 
To determine if periostin enhances suFA formation, a novel approach was developed to 
measure focal adhesion length in sFPCLs by immunofluorescence confocal microscopy 
based on modifications of protocols described in previous studies (184, 232).  In brief, 
“mini” sFPCL cultures were designed to be thin enough to allow confocal microscopy of 
the cells within a three-dimensional matrix and while under mechanical tension. These 
cultures of HTS fibroblasts were prepared in the presence or absence of matrix-associated 
periostin and, after a 72 hour incubation to induce myofibroblast differentiation, the mini 
sFPCLs were co-stained with αSMA to confirm myofibroblast differentiation, and 
vinculin, a focal adhesion protein found in all three focal adhesion classes (Figure 5.7, 
(184)). Focal adhesion length was measured in serial optical sections of individual cells 
cultured under 3D matrix tension in collagen using Image-Pro Plus 7.0 and the straight-
line tool in Image J as described in 2.2.12.3.  The total number of focal adhesions, their 
average length and their classification as immature (≤ 2 μm), mature (2-6 μm) and 
supermature (≥ 6 μm) FAs were determined in 30 cells per treatment in HTS fibroblasts 
derived from three patients.  
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As shown in Figure 5.8a, periostin treatment had no significant effects on the total 
number of focal adhesions present in HTS fibroblasts cultured in sFPCLs relative to 
vehicle controls (53.5 FAs  ± 10.8 vs 47 FAs ± 9.9, N=3 patients, n=30 cells per 
treatment). However, the average length of FAs were significantly increased in periostin 
treated HTS fibroblasts (4.55 μm ± 0.26 in length) compared to vehicle treated controls 
(4.02 μm ± 0.24 in length, Figure 5.8b, N=3 patients, n=30 cells per treatment). Vehicle 
treated HTS fibroblasts contained significantly more immature FAs (10.00 % ± 1.63 vs 
7.04 % ± 1.61) and mature FAs (76.95 % ± 1.32 vs 72.91% ± 1.28) than periostin treated 
fibroblasts. Conversely, periostin treated HTS fibroblasts contained a significantly higher 
percentage of suFAs than vehicle treated cells (20.04 % ± 2.53 vs 13.12 % ± 2.58) 
cultured under identical conditions (Figure 5.8c, N=3 patients, n=30 cells per treatment).  
5.5 Discussion 
The objectives of this chapter were to identify the signalling pathways utilized by 
periostin to induce myofibroblast differentiation in hypertrophic scarring and to identify 
the structural consequences of activating this pathway. The in vitro studies presented here 
demonstrate that periostin promotes/maintains myofibroblast differentiation through the 
formation of supermature focal adhesions by activating FAK-ROCK mediated 
pathway(s).  
The first objective of this chapter was to identify the receptor(s) utilized by periostin to 
induce myofibroblast differentiation.  Changes in mechanical tension within the ECM are 
transmitted between the ECM and cells through integrin-adhesion complexes (46). Since 
periostin has been reported to signal through integrins in other systems (127-134), it was 
hypothesized that periostin promotes myofibroblast differentiation and persistence 
through an integrin-mediated pathway. Immunoprecipitation experiments were performed 
to address this question. When performing immunoprecipitation experiments for 
receptors, disruption of the cell membrane with harsh detergents, denaturing buffers or 
mechanical lysing can lead to receptor deactivation and loss of receptor-ligand 
interaction, especially if the interaction is weak. To account for this, immunoprecipitation 
experiments were performed in non-denaturing lysis buffers with gentle detergents and a 
121 
 
 
Figure 5.7 Periostin enhances supermature focal adhesion formation in 
hypertrophic scar-derived fibroblasts. (a) Primary hypertrophic scar (HTS) fibroblasts 
were cultured in “mini” stressed fibroblast populated collagen lattices (sFPCLs) for 72 
hours in the presence or absence of periostin (PN, 2 µg/ml) as described in 2.2.12.1. 
Lattices were fixed and assessed for vinculin immunoreactivity (red), alpha smooth 
muscle actin (αSMA) immunoreactivity (green), co-stained with Hoescht (blue) to 
identify nuclei and imaged using immunofluorescence confocal microscopy as described 
in 2.2.12.2. Focal adhesion length was measured as described in 2.2.12.3 and 
supermature focal adhesions (<6 µm in length) are indicated by arrows. Representative 
photographs are shown. Scale bar = 20 µm. 
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Figure 5.8 Periostin enhances focal adhesion length and supermature focal adhesion 
formation in hypertrophic scar-derived fibroblasts. Primary hypertrophic scar (HTS)-
derived fibroblasts were cultured in mini stressed fibroblast populated collagen lattices 
for 72 hours and focal adhesion numbers and length were assessed by 
immunofluorescence confocal microscopy as described in 2.2.12. (a) Exogenous PN 
treatment had no discernible effects on the total number of focal adhesions present in 
HTS fibroblasts cultured under mechanical tension (N=3 patients, n=30 cells per 
treatment). (b) The average focal adhesion length was significantly greater in PN treated 
HTS fibroblasts relative to vehicle (veh) controls (N=3 patients, n=30 cells per 
treatment). (c) Vehicle treated HTS fibroblasts had significantly more immature and 
mature focal adhesions relative to PN treated fibroblasts. However, PN treated HTS 
fibroblasts had significantly more supermature focal adhesions relative to vehicle treated 
cells under these culture conditions (N=3 patients, n=30 cells per treatment). Significant 
treatment effects are denoted by *p<0.05 (t-tests). Data are presented by mean values and 
SEM. 
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subset of samples were formaldehyde fixed prior to lysis to stabilize potential interactions 
(233, 234). Optimization studies demonstrated that formaldehyde fixation prior to cell 
lysis had no discernible negative effects on the ability of the periostin antibody or nickel 
coated magnetic beads to bind periostin in the samples (data not shown). 
Multiple assay conditions were tested to optimize the detection of direct interactions 
between periostin and integrins. Initial immunoprecipitation studies were performed in 
sFPCLs to model 3D interactions in vivo, however neither endogenous nor recombinant 
periostin could be detected in the subsequent immunoprecipitation analyses. While the 
technical roadblocks that prevented periostin detection in these assays remains unclear, 
one possibility was that the abundance of collagen caused non-specific antibody binding 
and/or interfered with antibody-epitope binding. Therefore, despite being potentially less 
physiologically relevant, subsequent immunoprecipitation experiments were performed 
on HTS fibroblasts cultured on plastic dishes in the absence of a collagen substrate. 
While periostin and integrin subunits were consistently co-immunoprecipitated in these 
analyses, apparently non-specific, yet consistent, integrin binding was also observed in 
samples immunoprecipitated with non-antigen specific IgG controls, making it 
impossible to demonstrate that these interactions were specific to periostin. Optimization 
studies were undertaken with the aim of reducing non-specific integrin binding in the IgG 
immunoprecipitated samples. These included 1) the use of different IgG controls from 
different suppliers, 2) the use of Ni coated magnetic beads to bind histadine tags at the 
amino terminus of the recombinant periostin, 3) various combinations of incubation times 
and 4) more stringent binding and washing conditions.  None of these modifications 
proved to be effective for reducing non-specific binding between these integrin subunits 
and IgG controls.  
To our knowledge, there are currently no examples of immunoprecipitation experiments 
demonstrating interactions between periostin and integrins in the literature. Previous 
studies investigating periostin interactions with integrins have utilized blocking 
antibodies that are targeted against specific integrins in functional assays (128, 131, 134).  
Experiments designed to assess these interactions with HTS fibroblasts in sFPCLs using 
blocking antibodies against integrin αvβ3 and β1 induced very modest decreases in lattice 
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contractility that were indistinguishable to the effects induced by non-specific IgG 
controls (data not shown).  Co-localization experiments for periostin and integrins were 
also performed using immunofluorescence confocal microscopy.  However, HTS 
fibroblasts that were fixed and probed with a fluorescently labeled periostin antibody 
exhibited abundant and saturated staining throughout the collagen matrix, making it 
impractical to use this approach to identify specific areas of co-localization with integrins 
in these cultures (data not shown).  
In the event that periostin might interact with and signal through molecules other than 
integrins, multiple immunoprecipitation experiments were performed using a periostin-
specific antibody and coomassie staining to detect differential banding patterns between 
periostin and IgG immunoprecipitated samples.  No differential banding patterns were 
observed in these assays. Coomassie staining is insensitive relative to some other protein 
stains, such as silver nitrate, however these stains were incompatible with subsequent 
mass spectrometry analyses. In summary, no specific interactions between periostin and 
integrins or other molecules could be demonstrated. The development of substantially 
more sensitive and specific methodologies will be required for future studies assessing 
protein interactions with periostin in more physiologically relevant, 3D collagen matrices. 
The second objective of this chapter was to identify the signalling pathway(s) utilized by 
periostin to induce myofibroblast differentiation and persistence. The ROCK signalling 
pathway was an obvious focus for these studies, as ROCK activation plays a central and 
essential role in activating and maintaining myofibroblast differentiation and contractility 
(30, 51-53). ROCK inhibition was shown to significantly attenuate basal HTS fibroblast 
contractility, and this effect could not be rescued by exogenous periostin treatment. 
Inhibiting such a central and essential regulator of myofibroblast differentiation and 
contraction is unlikely to be helpful for distinguishing the specific effects of periostin 
from multiple signalling pathways that also induce differentiation and contraction in a 
ROCK dependent manner. Therefore, gain- and loss-of-function studies were performed 
to assess the effects of periostin addition or depletion on upstream and downstream 
effectors of ROCK-mediated myofibroblast differentiation and contraction. 
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Integrin-associated complexes known as focal adhesions (30, 46, 156) mediate 
communication between cells and the ECM. These complexes transmit external signals 
from the microenvironment to modulate cellular phenotypes (235). Focal adhesion kinase 
(FAK) has been shown to localize to focal adhesions (224, 225), regulate ROCK-
dependent stress fiber formation and maintenance (236), promote suFAs formation (43) 
and to be involved in adhesion-mediated myofibroblast differentiation (226).  Since 
periostin has been shown to enhance FAK phosphorylation in other systems (130, 133, 
134, 187, 237, 238), it was hypothesized that periostin promotes HTS myofibroblast 
differentiation and maintenance through a FAK-ROCK dependent signalling pathway. 
The findings presented in this chapter demonstrate that, when cultured under isometric 
tension, periostin had no significant additive effects on FAK phosphorylation in HTS 
fibroblasts. However, after the release of isometric tension, a significant increase in FAK 
phosphorylation was observed in periostin treated HTS fibroblasts for up to 48 hours 
relative to vehicle controls. While these results are not informative regarding FAK 
activation during myofibroblast differentiation, these data suggest that periostin enhances 
FAK activation in HTS fibroblasts under conditions of decreasing mechanical tension. 
Surprisingly, phosphorylated FAK levels were also significantly increased in periostin-
depleted HTS fibroblasts 48 hours after collagen lattice release relative to vector 
transduced controls. These findings may be explained in the context of previous studies 
demonstrating that FAK signalling can both promote and inhibit ROCK activation and 
stress fiber maintenance (236, 239-241).   
FAK signalling can promote stress fiber formation and contraction through the 
phosphorylation and activation of p190 RhoGEF (236, 241). p190 RhoGEF is a Rho 
specific guanine nucleotide exchange factor (GEF) that activates RhoA by promoting the 
dissociation of guanosine-5’-diphosphate (GDP) and the binding of GTP to RhoA  (242, 
243). RhoA-GTP binding to ROCK induces a conformational change in ROCK that 
activates the protein (244, 245). FAK signalling can also promote the phosphorylation 
and activation of p190 RhoGAP, a GTPase activating protein (GAP), which inhibits 
RhoA activity by promoting binding of GDP to RhoA (236, 246). Inhibition of RhoA 
prevents downstream activation of signalling intermediates involved in stress fiber 
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maintenance and contraction. It is possible that, following the release of mechanical 
tension in sFPCLs, periostin signalling is able to maintain positive FAK-ROCK 
activation and thereby promote myofibroblast persistence. 
This hypothesis could be tested by assessing the effects of periostin on the activity of 
RhoA and ROCK. The RhoA activity assays currently available utilize the Rho binding 
domain of the Rho effector protein, Rhotekin, to specifically bind RhoA-GTP. However, 
these analyses require the precipitation of Rhotekin-RhoA-GTP complexes using 
glutathione affinity beads. Unfortunately, the amount of total cell lysate required for this 
assay would be unattainable in practice for 3D collagen cultures. As ROCK is activated 
by a conformational change induced by RhoA-GTP binding, its activity cannot be 
assessed using western immunoblotting. Therefore, to gain additional insights into 
periostin effects on ROCK activation, the activation of downstream ROCK targets were 
assessed using gain- and loss-of-function studies. 
ROCK activation can promote stress fiber maintenance, focal adhesion formation and 
myofibroblast differentiation through two divergent pathways. Cofilin, a downstream 
target of ROCK, is an actin-binding protein that promotes actin stress fiber 
depolymerization (227). ROCK-mediated cofilin phosphorylation inhibits cofilin activity 
and actin depolymerization, thereby promoting stress fiber maintenance (228). ROCK 
activation also induces myofibroblast-mediated contraction through phosphorylation and 
activation of the regulatory MLC (51-53). In combination, these signalling events 
promote the formation and maintenance of stress fibers and increase ECM tension 
through myofibroblast contraction, resulting in integrin clustering, the formation of suFA 
complexes and myofibroblast differentiation and/or persistence (247).  
No significant changes in the phosphorylation states of cofilin or MLC were consistently 
detected in HTS myofibroblasts cultured under isometric tension or following the release 
of tension irrespective of treatment. It is likely that the lack of significant findings in 
these studies can be explained by inter-patient variability. Gender, age, scar location, scar 
maturity and additional co-morbidities may influence periostin sensitivity between 
individual patients and this variability can make it difficult to detect significant 
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differences when patients are assessed as a group. This was evident in several of these 
studies as statistically significant treatment effects were observed in a subset of individual 
patients but significance was lost when the patients were assessed as a group.  Future 
analyses of much larger numbers of patient-derived fibroblast lines may be required to 
overcome this inter-patient variability, and sub-group analyses of those that yield 
significant results may shed new light on the source(s) of variability. These findings also 
illustrate the importance of assessing treatment effects in primary fibroblast lines derived 
from multiple patients, as such variability might not be observed in an immortalized cell 
line derived from a single patient. 
Although inconclusive, these studies did not rule out the possibility that periostin 
signalled through these intermediates to enhance suFA formation, myofibroblast 
differentiation and/or persistence. Therefore, independent analyses of suFA formation 
were performed. As described previously in this chapter, αSMA is only incorporated into 
stress fibers of myofibroblasts when the mechanical tension in the ECM passes a critical 
threshold that allows for the formation of suFAs (30). The formation of suFAs and the de 
novo expression and incorporation of αSMA into stress fibers allows myofibroblasts to 
exert much greater contractile forces on the ECM (43), thereby contributing to the 
abnormal dermal density that characterizes scar formation. As periostin promotes 
myofibroblast differentiation and persistence in hypertrophic scarring (Chapter 4.4 and 
4.7), potentially by activating focal adhesion signalling molecules (Chapter 5.3), it was 
hypothesized that exogenous periostin treatment would enhance the formation of suFAs. 
To assess suFA formation, two markers of suFAs, αSMA and vinculin, were assessed by 
immunofluorescence confocal microscopy.  The combination of αSMA and vinculin was 
optimal for confirming the differentiated state of the myofibroblasts while simultaneously 
visualizing all three FA classes (184). The length of each FA was assessed along its 
longest axis regardless of orientation as described in previous studies (184). Using this 
approach, periostin treated HTS fibroblasts cultured under mechanical tension were 
shown to exhibit significantly larger focal adhesions and a higher percentage of suFAs (> 
6 μm in length) per cell relative to vehicle controls. A feedback mechanism between 
enhanced suFA formation and increased ECM tension above threshold levels promotes 
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myofibroblast differentiation and persistence (43, 44) leading to the excessive deposition 
and contracture of the ECM characteristically seen in hypertrophic scarring. These data 
suggest that periostin signalling may promote and maintain suFA formation and 
myofibroblast differentiation in patients prone to hypertrophic scarring. 
In summary, periostin was shown to promote myofibroblast differentiation by enhancing 
suFA formation in HTS myofibroblasts. Although the receptor(s) utilized by periostin to 
induce suFA formation are yet to be identified, these findings are consistent with 
periostin enhancing myofibroblast differentiation and persistence in hypertrophic scarring 
through a FAK-ROCK dependent pathway. This is the first study to link periostin 
activation of these signalling pathways to suFA formation in hypertrophic scarring. As 
hypertrophic scarring and related benign fibrotic conditions are characterized by 
enhanced myofibroblast differentiation and the persistence of these highly contractile 
cells within the dermis, periostin may have potential as a therapeutic target for novel 
therapies designed to induce myofibroblast de-differentiation and/or apoptosis and, 
thereby, enhance hypertrophic scar resolution. 
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Chapter 6  
6 Conclusion 
Hundreds of millions of patients in developed countries develop scars each year 
following surgical procedures, with the incidence rate for hypertrophic scar formation 
varying between 40-70% in many centers (66, 67, 248). Hypertrophic scars and other 
abnormal scarring conditions are the result of aberrant wound healing after an insult to 
the deep dermis. Scarring imposes morbidity that is difficult to quantify, but includes 
pain and loss of mobility, especially if the scar is associated with a joint (60). As well as 
imposing a financial burden, scars are often disfiguring and can adversely affect a 
patient’s quality of life, both physically and psychologically (60, 61). Unfortunately, 
there are few, if any, truly effective treatment options for abnormal scarring conditions 
(58, 60). Prevention of hypertrophic scarring is also difficult, as abnormal skin 
remodelling may not become evident until 4-8 weeks after wound closure (59). Current 
treatment strategies have therefore focused on improving hypertrophic and keloid scar 
resolution, rather than on prevention.  
The findings presented in this thesis suggest that increased and persistent levels of 
periostin in the dermis of human hypertrophic scar tissue contribute to excessive 
fibroblast proliferation and myofibroblast differentiation and persistence (Figure 6.1). 
Periostin depletion in the dermis of hypertrophic scars may therefore have utility as a 
therapeutic target for novel therapies designed to improve scar resolution by attenuating 
fibroblast proliferation and promoting myofibroblast apoptosis and/or dedifferentiation. 
In addition to hypertrophic scars, periostin is abnormally abundant in keloid scars and 
periostin may play a similar role in promoting and maintaining myofibroblast 
differentiation of keloid scar-derived fibroblasts. These data suggest that the effects of 
periostin described in this thesis may not be specific to HTS but may be a common 
feature of other benign fibroses. This concept is supported by findings that periostin 
promotes myofibroblast differentiation of primary fibroblasts derived from Dupuytren’s 
Disease, a benign fibrosis of the palmar fascia (91). Therefore, periostin may not only be  
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Figure 6.1 Schematic representation of the roles of periostin in hypertrophic 
scarring. Increased and persistent levels of ECM-associated periostin in the dermis of 
hypertrophic scar tissue contribute to hypertrophic scar formation by enhancing fibroblast 
proliferation and myofibroblast differentiation and persistence through a Rho kinase 
mediated pathway. Enhanced fibroblast proliferation and myofibroblast differentiation 
leads to excessive ECM deposition and remodelling leading to the formation of raised, 
dense collagenous scars.  
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an attractive therapeutic target to improve abnormal scar resolution but may have utility 
as a more universal target for treating a variety of benign fibrotic conditions.  
Non-healing chronic wounds are a less obvious but potentially relevant application of 
these findings. Chronic non-healing wounds do not progress beyond the inflammatory 
phase of wound healing (54), display decreased growth factor activity and increased 
fibroblast senescence relative to normal healing wounds (249). The prevalence of non-
healing wounds within the Canadian healthcare system is approximately 35% (250) and 
may result in amputation of the affected limb due to lack of effective treatment options 
(251). Since periostin expression is decreased in chronic non-healing wounds (97), 
exogenous periostin treatment may stimulate fibroblast proliferation and myofibroblast-
mediated ECM deposition and remodelling resulting in wound closure.  
In order to assess the role(s) of periostin in normal and abnormal cutaneous wound repair, 
an appropriate model system was required. Unfortunately, there is a lack of representative 
and physiological relevant in vivo animal models of hypertrophic scarring (59). 
Hypertrophic or any other forms of fibrotic dermal scarring do not normally occur in 
mice (163) as they can regenerate dermal wounds very efficiently (160). While several 
scarring-prone mouse models have been developed after genetic modifications or 
chemical treatments (165, 252), the physiological relevance of these models are unclear. 
There are significant anatomical differences between the inter-follicular area (161), 
epidermal thickness and turnover rate (159) and dermal thickness (160) of mouse and 
human skin, limiting our ability to translate findings between these species (253, 254).  
More recently, the red duroc pig has been utilized as a model for human cutaneous 
wound healing. Swine have a similar dermal and epidermal architecture (255-257) and 
heal wounds by re-epithelialization in a similar manner to humans (258). In contrast to 
mouse models, red duroc pigs readily form raised collagenous scars that are similar to 
hypertrophic scars following insult to the deep dermis (255, 259).  Nonetheless, the 
clinical relevance of these extremely expensive models (257) remains unclear. Very little 
is known about the complex array of single nucleotide polymorphisms or other genetic or 
epigenetic changes that predispose some patients to scarring, and these details will need 
to be elucidated before any truly representative animal models can be developed.  As it is 
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not ethically feasible to perform scarring experiments on humans, it can be argued that 
the best available models of hypertrophic scarring are the tissues or tissue-derived cells 
derived from surgical scar resection.  In this thesis, primary human dermal fibroblasts 
derived from hypertrophic scar, keloid scar and normal skin from multiple patients were 
chosen to assess periostin effects in in vitro models.  
While the clinical relevance of analyzing primary dermal fibroblasts obtained from 
normal and abnormal human tissue is obvious, these cells have inherent characteristics 
that can make them challenging to interpret. Scars are generally resected months or years 
after their initial formation, making it difficult or impossible to identify the earliest 
signalling events that promote abnormal scar formation (59).  The major challenge, 
however, is inter-patient variability. Differences in gender, race, age, scar location, and 
other co-morbidities may affect the sensitivity of individual patient-derived fibroblasts to 
treatment and can make it extremely difficult to identify consistent effects on fibroblast 
proliferation and/or myofibroblast differentiation in all, or even the majority, of patients. 
This was evident in several studies presented in this thesis, as significant treatment effects 
were evident in a subset of patients but absent in others. Additionally, variation can arise 
from selection between passages, as the fibroblasts derived from patient tissues are a 
heterogeneous population of cells. Therefore, there is the potential to select for different 
subsets of fibroblasts that have differing tolerances to in vitro culture with each passage. 
With inter-patient and inter-passage variability, it can be difficult to identify statistically 
significant effects when assessing the mean data derived from a mixed population. Thus, 
several trends have been identified in this thesis that may or may not represent real 
effects in a subset of patient-derived fibroblasts. Assessment of very large numbers of 
patients may be required to identify the source of this inter-patient variability and yield 
significant findings within pre-identified sub groups of patients. However, such 
variability may also be impossible to avoid in practice due to the very large number of 
variables between individuals.   
Another limitation of using primary cells is their limited replicative potential compared to 
immortalized cell lines. The pilot studies that led to this project in our laboratory 
demonstrated that HTS fibroblasts lose their initial characteristics after approximately 
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four passages.  Due to their short “shelf life,” it is difficult to genetically modify primary 
fibroblasts by conventional transfection techniques and obtain meaningful results in four 
passages or less.  It could be argued that an immortalized human HTS fibroblast cell line, 
which currently does not exist to our knowledge, would be beneficial in reducing 
experimental variability in these assays and in identifying and characterizing periostin-
induced specific signalling pathways in more detail. However, the “trade off” with such a 
cell line is that it would be even more difficult to translate the findings in these 
immortalized cells to a clinical setting. A single cell line could only provide a detailed 
assessment of periostin effects in a single patient that may, or may not, be representative 
of the broad and variable population of individuals affected by abnormal scarring. Thus, 
despite their inherent limitations, this thesis focused on in vitro analyses of primary 
fibroblasts derived from surgically resected scar tissue of multiple patients, and on 
identifying and characterizing the signalling pathways that were activated by periostin in 
most or all of these patients. With further development, the approach of using primary 
cell “banks” derived directly from patients may have great potential for providing 
clinically relevant information about the cellular processes that cause the abnormal 
persistence of scars.  
The molecular focus of this thesis was periostin, a TGFβ-1-inducible secreted ECM 
protein (101) that is transiently expressed during normal cutaneous wound repair (98, 
151, 152), and is abnormally abundant and persistent in abnormal scars and other benign 
fibroses (91, 97-99, 148, 150, 179, 260-263). This protein is often described as a 
“matricellular” molecule, a term originally coined by Bornstein (90, 124) to describe 
extracellular proteins that do not contribute directly to the structure of the ECM but 
instead serve to modulate cell-matrix interactions and cell function.  Periostin has been 
demonstrated to enhance fibroblast proliferation and myofibroblast differentiation in 
other models of variable physiological relevance to humans (91, 132, 133, 152, 178-180). 
To assess the functional consequences of enhancing or depleting any matricellular 
protein, it is essential that an appropriate 3D cell culture system be in place to assess 
signalling effects from the ECM that may or may not occur in the absence of a 
physiologically relevant ECM as a culture substrate. Previous studies have demonstrated 
that culturing fibroblasts on rigid tissue culture plastic dishes results in spontaneous 
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proto- and myofibroblast differentiation (31) and that substrate-induced effects can 
overshadow treatment effects on cellular phenotypes (133). Our laboratory is one of 
many that have shown that variations in substrate stiffness can modify gene expression 
and protein levels in primary human fibroblasts (171). Others have shown that, when 
cultured on tissue culture plastic, cells can adopt very different structures to in vivo and 
fail to respond to appropriate stimuli. However, if the same cells are cultured on 
substrates that mimic the in vivo microenvironment, they adopt in vivo-like structures and 
function (264-266). The effectiveness of therapeutic treatments has also been shown to 
differ between cells cultured on plastic and on in vivo-like matrices (267-269). Taken 
together, these studies highlight the importance of the microenvironment in regulating 
cellular phenotype in in vitro cultures, particularly in the context of matricellular 
signalling.  
For these reasons, the primary human fibroblasts examined in this thesis were cultured on 
two- and three-dimensional type I collagen substrates, the most abundant collagen in the 
skin and mature scars (8), to more closely mimic the microenvironment and substrate 
stiffness experienced by these fibroblasts in vivo. Although the dermal ECM is much 
more complex than polymerized type I collagen, the use of collagen substrates allows for 
the incorporation of periostin within a collagenous ECM matrix, mimicking its 
localization in vivo, and provides a simple and reproducible physiological relevant in 
vitro culture system for assessing the effects of periostin on hypertrophic scar formation. 
To gain additional insight into the roles of periostin in promoting abnormal scar 
formation, future in vitro studies should focus on culturing fibroblasts directly on 
decellularized hypertrophic scar and normal skin tissue to achieve even better models of 
the microenvironments in normal and abnormal conditions. Alternatively, much more 
complex mixtures of purified collagens and other ECM molecules, or co-culture 
experiments with other cell types involved in cutaneous wound repair such as 
keratinocytes, may be used for in vitro analyses to enhance the physiological relevance of 
the cellular environment. 
Despite the methodological challenges in achieving such complex culture systems, there 
is a clear and urgent need for better in vitro models that are physiologically relevant to 
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humans and representative of a genetically diverse population. Recent high profile reports 
(270) have described how the majority of peer reviewed medical research publications 
describing novel drug targets and similar findings cannot be independently reproduced.  
Amongst many other contributing factors, a lack of physiologically relevant and 
representative models is likely to have contributed significantly to this problem.  We 
should not be surprised that novel drug targets identified in immortalized human cells 
derived from a single individual, and then “verified” in animal models with significant 
physiological differences to humans and with much less individual variability, fail to 
progress in clinical trials on human populations.   
The identification of molecules that promote aberrant wound healing signals will improve 
our current understanding of the processes involved in abnormal scar formation. The 
findings presented in this thesis indicate that periostin enhances fibroblast proliferation in 
compliant collagen cultures, a model designed to mimic the low mechanical tension of 
the provisional matrix in the early stages of wound healing, through an Akt and ROCK 
dependent pathway. When subjected to isometric tension in sFPCLs, a model that mimics 
aspects of wound closure in vivo, periostin induces myofibroblast differentiation, as 
evidenced by an increase in αSMA levels, collagen lattice contraction and supermature 
focal adhesion formation. Additionally, periostin signalling maintained αSMA levels in 
myofibroblasts in an environment of decreasing ECM stress, indicating a role for 
periostin in myofibroblast persistence, potentially through a FAK-ROCK dependent 
pathway. Since periostin had no discernible effects on NS-derived fibroblast proliferation 
or differentiation, these data support the central hypothesis that periostin promotes 
pathological effects leading to abnormal scar formation.  
The function of an organ, including the skin, is dependent on the numerous cell types that 
make up the organ and the organization of the surrounding extracellular matrix (235). 
Interactions between the cells and the surrounding ECM through integrins and cell-cell 
interactions through adherens junctions determine the gene expression and phenotype of 
the resident cells without altering the genotype (235, 271). Therefore, the 
microenvironment provides necessary signalling to maintain tissue homeostasis and 
suppress malignant or abnormal phenotypes. However, aberrant signalling from the 
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microenvironment can lead to loss of tissue homeostasis and promote abnormal or 
malignant behaviours in the resident cells (271).  
Wounding events have been shown to be an effective stimulus for promoting malignancy 
(272). Stromal fibroblasts are responsible for the production, deposition and remodelling 
of the ECM (271) and increased stromal density (changing tissue microenvironment) has 
been correlated with an increase risk of cancer progression (273, 274). Increased 
myofibroblast differentiation within the stroma has been correlated with increased risk of 
cancer development and the induction of an inflammatory response by an established 
tumour can further promote a fibrotic stroma (271). Studies in mouse models of epithelial 
cancer progression have demonstrated that increased stromal density enhanced epithelial 
cell proliferation, tumourgenesis, tumour growth, migration and invasion (275-277), 
some of which may be induced by FAK and Rho signalling within epithelial cells (278-
280).  
These finding may be relevant to this thesis because, in addition to being an upregulated 
component of benign fibroses, periostin expression is also increased in malignant 
diseases. Periostin is upregulated in a variety of tumours and associated stroma and its 
increased expression is correlated with malignancy (108, 128, 129, 141, 180, 281). 
Periostin can interact with several integrins to induce tumour cell migration, growth, 
EMT and survival (128-131, 142). Over expression of periostin in colon cancer cells 
increased the size and number of metastatic colonies at secondary sites (129). A recent 
study by Malanchi et al., (281) demonstrated that metastatic colonies required periostin 
expression by stromal fibroblasts in order to successfully colonize at those locations. As 
periostin enhanced fibroblast proliferation and myofibroblast differentiation in fibroblasts 
derived from hypertrophic scar tissue, the findings in this thesis may enhance our 
understanding of periostin’s roles in tissue remodelling in metastatic conditions. 
Increased levels of periostin in the stroma of metastatic diseases may promote excessive 
fibroblast proliferation and myofibroblast differentiation, causing abnormal stromal 
density and enhanced tumour formation, growth and invasion. A normal 
microenvironment can induce some malignant cells to regain a normal phenotype in vitro 
(235, 282) stressing the importance of the microenvironment in tissue homeostasis and 
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disease progression. Therefore, periostin depletion in the stroma surrounding malignant 
cells may be an attractive therapeutic target for novel therapies designed to reduce 
stromal density. 
It has become increasingly evident that achieving normal tissue homeostasis is the 
ultimate treatment outcome and that targeting the microenvironment may have profound 
clinical benefits (271). The findings presented in this thesis demonstrate that increased 
levels of periostin in the wound microenvironment of hypertrophic scar tissue results in 
excessive fibroblast proliferation and myofibroblast differentiation. Even in conditions of 
decreasing ECM tension, abundant and persistent levels of periostin in the 
microenvironment “shield” HTS myofibroblasts from the mechanotransduction signalling 
events associated with changes in ECM tension, thereby allowing these cells to maintain 
a differentiated state. Identification of the molecular components and mechanisms 
involved in periostin regulation and degradation may have profound clinical benefits for 
improving scar resolution in patients affected by abnormal scarring. 
Periostin levels are increased and persistent in the ECM of benign fibrotic conditions 
such as hypertrophic scarring. It is plausible that the pathways that normally regulate 
periostin levels in the ECM are atypical in these conditions and that their identification 
may reveal attractive therapeutic agents for depleting periostin levels in the 
microenvironment of hypertrophic scar tissue. Periostin expression is reported to be 
regulated by a number of factors essential for normal cutaneous wound healing such as 
TGFβ-1, platelet derived growth factor, interleukins, fibroblast growth factor and 
mechanical tension (101, 103, 104, 283) and these would be difficult to target in a clinical 
setting. The factors that regulate periostin depletion in normal cutaneous wound healing 
are unclear. As periostin is proposed to be a very stable protein with a long half-life, and 
to be difficult to deplete under conditions of high ECM tension (222), active degradation 
of periostin in the dermis may be responsible for decreased periostin levels in the dermis 
during the remodelling phase of normal cutaneous wound healing. 
Unfortunately, nothing is known about periostin degradation. Previous studies have 
shown that matricellular proteins thrombospondin-1, SPARC and CCN1 are targets of 
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several proteases including plasmin, MMP-1 and MMP-9 (284-286). As levels of 
plasmin, MMP-1 and MMP-9 are decreased in hypertrophic and keloid scarring (287-
289), these or similar proteases may have roles in the degradation of the matricellular 
protein periostin in hypertrophic scarring. This hypothesis should be assessed initially in 
a cell free system to determine if individual proteases degrade periostin in solution, and 
then verified in 3D restrained collagen in vitro model systems like those described in this 
thesis. If periostin levels were significantly reduced following protease treatment relative 
to controls, addition of these proteases to sFPCL cultures should inhibit periostin-induced 
HTS myofibroblast differentiation and promote myofibroblast apoptosis and/or 
dedifferentiation in conditions of decreasing ECM tension.  
Another intriguing possibility is that dermal periostin levels may be regulated by 
receptor-mediated endocytosis and lysosomal degradation. The matricellular protein 
SPARC has been shown to be regulated by interacting with stabilin-1 (290), a scavenger 
receptor involved in receptor-mediated endocytosis expressed in macrophages and 
endothelial cells (291). Periostin and stabilin-1 both belong to the fasciclin family of 
proteins characterized by the presence of FAS-1 domains involved in cell adhesion and 
protein-protein interactions (108). Therefore, it is possible that interactions between 
periostin and stabilin-1 may regulate periostin levels in normal and abnormal wound 
healing.  
Identification of proteases and/or mechanisms involved in periostin degradation may 
have profound benefits as therapeutic treatments designed promote myofibroblast 
apoptosis and reduce dermal density in patients affected by hypertrophic scarring. 
Conversion of the disease microenvironment to a more homeostatic state should improve 
scar resolution and eliminate the need for costly surgical and therapeutic interventions. It 
is hoped that these studies will encourage research in the area of periostin regulation in 
excessive cutaneous wound repair with the goal of uncovering new therapeutic 
approaches for disease resolution. 
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